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PREFACE 
 
The present PhD dissertation summarizes the research findings of the research group 
of prof. Dr. Thomas R. Ward from the period of September 2013 to December 2017. 
The main goal of the Ward group is the development and optimization of artificial 
metalloenzymes for their use in asymmetric catalysis. These hybrid catalysts, resulting from 
an incorporation of a metal–containing cofactor within a protein or DNA scaffold, can be 
optimized by either chemical or genetic means.  
The present work aims at the genetic optimization of the protein scaffold and 
exploration of the use of the resulting hybrid catalysts in nano–applications. Apart from a 
general introduction section, this dissertation is divided into two chapters. Each chapter 
represents research performed in context of several projects, which were published or will 
be submitted to peer-reviewed journals. These chapters contain a brief introduction into the 
topic, followed by the corresponding publications, and author contributions. The electronic 
supplementary information for each publication can be found in the Appendices chapter. 
The first chapter describes our efforts in genetic optimization of artificial 
metalloenzymes, design of a screening library and directed evolution of the resulting 
mutants. The second chapter illustrates two possibilities of applying artificial 
metalloenzymes in nano-applications, specifically the immobilization on silica nanoparticles 
or encapsulation in a ferritin protein cage. 
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CHAPTER I:  
INTRODUCTION 
1.1 ASYMMETRIC CATALYSIS 
In nature, biomolecules such as nucleotides, DNA, RNA, amino acids, proteins, or 
sugars are present in an enantiopure form. The homochirality of biological molecules 
represents a challenge for the development of novel drug substances, flavors and fragrances, 
as two enantiomers of a compound will display different biological effects (Table 1).1 In 
addition, stereoselective synthesis is of great importance in polymer industry (offering a 
higher degree of crystallinity or non-linear behavior) and materials (such as liquid 
crystals),2,3 pesticides and herbicides.4 
Table 1 Differences in the biological effects of enantiomers. 
Compound Enantiomer Biological effect  
Thalidomide (R)-(+)-thalidomide teratogenic
5 (eutomer) 
(S)-(−)-thalidomide sedative 
Ethambutol (S,S)-ethambutol tuberculostatic (R,R)-ethambutol blindness6 (eutomer) 
Tetramisole (S)-tetramisole (levamisole) nematocide (R)-tetramisole causing numerous side-effects7 (eutomer)
Warfarin (S)-warfarin anticoagulant (R)-warfarin 5 -6 times less potent8 (eutomer) 
Propranolol (S)-(−)-propranolol β-blocker (R)-(+)-propranolol 100 times less potent9 (eutomer) 
Approximately 50 % of all pharmaceuticals currently in use are chiral.10 The 
proportion of single-enantiomer drugs introduced into the market has been growing over the 
years and currently represents approximately 70 % of new molecular entity drugs.11 The 
demand for the synthesis of enantioenriched or enantiopure compounds is therefore immense 
and is likely to increase. 
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The production of enantiopure drugs can be performed by multiple ways, such as the 
chiral pool strategy,12 or separation of racemates.13 Both of these strategies come with 
disadvantages, either due to the requirement of enantiomerically pure starting material, or 
by maximum 50 % yield of the desired enantiomer. Asymmetric catalysis,14 i.e. the selective 
formation of a single stereoisomer of a given compound, represents an alternative method to 
the chiral pool and racemate separation. This field has experienced a rapid growth over the 
last few years and nowadays represents a fundamental synthetic method in pharma industry 
and drug discovery.15 The efficiency of this process profits from the high turnover number 
(TON), meaning that even small amounts of a chiral catalyst produces large quantities of 
products. 
Homogeneous asymmetric catalysis based on transition metal complexes represents 
a well-established method with advantages of high catalytic activity, high enantioselectivity 
for either of the enantiomers, good atom economy, and tolerance towards organic solvents 
and harsh reaction conditions (extreme temperature, high pressure). Moreover, transition 
metal complexes can easily tolerate high substrate concentrations and possess a large 
substrate scope. However, it was not until recently ago that enantiomeric excess of >99 % 
was achieved with a synthetic catalyst.16  
1.2 BIOCATALYSIS 
Enantiomerically pure compounds are produced in nature by means of transferring 
the chiral information from enzymes. Although their substrate scope and operational stability 
might be limited in some cases, enzymes can produce valuable products selectively and with 
high turnover numbers (TONs) and turnover frequencies (TOF).17 Their implementation in 
organic synthesis brings a benefit of mild reaction conditions, and biorthogonality with great 
advantages such as eco-friendliness, renewability and sustainability.18 In contrast to non-
catalyzed processes, the reaction rate of an enzyme-catalyzed process can be enhanced by a 
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factor of 1010 - 1017.19 A process, which would require 300 to 3 billion years in the absence 
of enzymes can be, upon utilization of enzymatic catalysis, performed in one second. Such 
control over the reaction rate makes enzymatic catalysis a very attractive alternative method 
to traditional homogeneous catalysis.  
The high efficiency of enzymatic catalysis lies in the stabilization of the reaction’s 
transition state within the active site.20-24 The catalytic elements within the active site, i.e. 
the amino acid residues, are precisely positioned and allow for formation of van der Waals 
and electrostatic interactions, hydrogen bonding, steric and differential solvation effects, 
leading to conformational changes.25,26 Upon substrate binding, the effective concentration 
is increased,24 and the “tightness” of the reaction transition state changes, i.e. circumvents 
the loss of translational or rotational entropy in the transition state compared to catalysis in 
solution.27,28 This entropy advantage lowers the free energy barriers29-31 of chemical 
reactions and gets compensated in formation of the enzyme-substrate complex (the Circe 
effect).32 The degree of contribution of the entropic effects is, however, still under 
discussion.33,34 
As a result of the recent advances35 in bioinformatics, directed evolution, protein 
engineering, and high throughput screening techniques, new properties can be now encoded 
into the protein scaffolds. Enzymes can be enhanced to accept non-natural substrates,36 
tolerate organic solvents,37 or to increase their robustness under operating conditions.38   
On the other hand, enzymes have been evolving over millions of generations to perform 
under physiological conditions. Their window of activity has therefore its limitations,39 such 
as low substrate concentrations, ambient temperature and pressure, requirement of aqueous 
media and mild pH and relatively narrow substrate scope. Another limitation of enzymatic 
catalysis is the level of expression, stability, refolding and solubility in the reaction medium, 
the time-consuming purification, requirement of expensive cofactors, or the specificity of 
used enzymes. 
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1.3 ARTIFICIAL METALLOENZYMES 
Historically, homogeneous and enzymatic catalysis have been operating on 
independent grounds. However, these two systems are complementary in multiple aspects 
(Table 2).  
Table 2. Features of homogeneous and enzymatic catalysis.40  
Feature Homogeneous catalysis Enzymatic catalysis 
Reaction medium Organic solvents Aqueous medium 
Reaction repertoire Large Small 
Substrate scope Large Limited 
Selectivity Both enantiomers Single enantiomer 
TON Small Large 
Optimization Chemical Genetic 
In the past fifteen years, the field of biocatalysis has been enhanced by introduction 
of artificial metalloenzymes (ArMs), resulting from an incorporation of a catalytically active 
metal cofactor within a bioscaffold.41-45 These combine the broad reaction scope of metal 
catalysts with high selectivity and turnovers of enzymatic catalysis, thus bridging the gap 
between the two.  
The basic concept for ArMs was first established by Kaiser and Yamamura in 197646 
and Wilson and Whitesides in 1978.47 Since the new millennium, the field of ArMs has 
experienced rapid growth.48 The metal (usually a transition metal) is surrounded by its first 
coordination sphere represented by an endogeneous ligand. Upon embedding within the 
biomolecular scaffold, the resulting second coordination sphere around the metal interacts 
with the metal and its ligand, but also substrates, intermediates and products. 
1.3.1 ANCHORING STRATEGIES 
To avoid random localization and to stabilize the catalytic moiety within the 
biomolecular scaffold, various anchoring strategies have been developed (Figure 1): 
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a) The covalent anchoring strategy relies on an irreversible reaction between a 
reactive amino acid side chain residue of the protein with a functional group of the 
cofactor. Typical examples include introduction of cysteine,49-552 lysine53,54 and 
serine  modifications,55 or the introduction of an unnatural amino acid residue.56-60  
(b) The supramolecular anchoring strategy (also known as non-covalent) relies on 
the formation of weak interactions between host bioscaffolds and small molecules 
resulting from the self-assembly of the resulting ArM.47,60-67 Since a strong 
interaction is necessary to avoid catalysis taking place outside of the biomolecular 
host, natural cofactors are often covalently modified and linked to the catalyst. One 
of the advantages of this approach is avoiding post-biosynthetic modification or 
purification. 
(c) Dative anchoring strategy uses the amino acid residue (cysteine, histidine, 
aspartate, serine, etc.) of the biomolecule as a ligand for a coordinately unsaturated 
metal center.46,63,64 This approach is often combined with covalent or supramolecular 
strategy.  
(d) Metal substitution uses the possibility to exchange a metal center in a natural 
metalloenzyme by a non-native metal.65-70 This strategy allows for introducing new-
to-nature reactivity.  
 
Figure 1. Anchoring strategies for localizing metal cofactors within a biomolecule.41 
- 6 - 
 
All of these strategies lead to new enzymatic activities, providing that they are 
implemented using purified proteins. Operating in complex cellular media or in vivo is not 
likely with all of the methods71 (Table 3), especially if we take into account the possibility 
of off-target binding and high amount of cofactor required for successful loading.  
Table 3. Characteristics of anchoring strategies72  
Anchoring Coupling mechanism 
Coupling 
efficiency
Off-
target 
binding 
Bond 
stability 
In vivo 
coupling 
Covalent Reactive Low Likely High Challenging 
Supramolecular Spontaneous High Unlikely Variable Straightforward
Dative Spontaneous High Moderate Intermediate Possible 
Metal substitution Spontaneous High Unlikely Variable Possible 
1.3.2 SAV-BIOT TECHNOLOGY 
In the context of overcoming the anchoring challenges for ArMs creation, the 
supramolecular approach of streptavidin-biotin (Sav-biot) technology has been proven 
particularly versatile.72,73 Streptavidin (Sav) is a homotetrameric protein representing a 
bacterial equivalent to avidin. Its high affinity towards biotin (KD < 10-13 M) and its analogs 
represents one of the strongest non-covalent interactions known to nature.74-79 Additionally, 
the biotin dissociation rate can be further decreased by introducing mutations S52G and 
R53D.80 This technology therefore allows for quantitative and specific loading of 
biotinylated probes even at sub-nanomolar concentration of both Sav and biot.  
Because of the versatility of this anchoring strategy, the Sav-biot technology has 
found numerous applications across a wide range of technologies and methods.81 These 
include: cell biology, proteomics, immobilization, protein purification, detection, labelling, 
drug delivery, and diagnostic applications etc.82-84   
The tight biotin anchoring relies on a hydrogen bonding network arising from the 
S27, Y43 and N23 interactions with the carboxyl oxygen of biotin, interactions of D128 and 
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S45 and the ureido nitrogens, T90 and the sulfur of the thiolane moiety, and N49 and S88 
interactions with the carboxyl group of the valeric acid moiety. Moreover, the three 
tryptophan residues W79, W92 and W108 (and W120 from the adjacent Sav monomer) 
create additional hydrophobic interactions (Figure 2).88-88 
 
Figure 2. Interactions between the biotin moiety and the amino acid residues present in streptavidin’s 
biotin binding pocket.88 
Streptavidin represents a remarkably robust protein capable of withstanding very 
harsh conditions such as elevated temperature, extreme pH, presence of organic solvents and 
denaturing agents, or sonication,89-91 which makes it an ideal selection for the creation of 
ArMs. Relying on a non-covalent incorporation of a biotinylated metal catalyst, the resulting 
hybrid catalyst takes advantage of the secondary coordination sphere formed by the Sav 
amino acid residues and catalyzes the formation of chiral products from prochiral substrates 
(Scheme 1).  
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Following the initial report of an ArM derived from the biotin-avidin technology,47 
numerous catalytic systems implementing the Sav-biot technology have been reported. 
These include hydrogenation47,92,93 and transfer hydrogenation,94-103 C-H activation,104 
dihydroxylation,105 alcohol oxidation,106 sulfoxidation,107,108 allylic activation,109 Suzuki 
cross-coupling110 and metathesis.111,112 Some of these transformation do not take place in 
natural biological systems, which highlight the ability of ArMs to catalyze new-to-nature 
reactions that are absent from the (natural) biocatalysis repertoire.113-117 
 
Scheme 1. Creation of an ArM based on the Sav-biot technology. If catalyzing a prochiral substrate, 
the resulting hybrid catalysts can use the interactions of the second coordination sphere as a source 
for enantioselectivity. 
1.4 ARTIFICIAL IMINE REDUCTASE 
Enantiopure amines represent important intermediates for the synthesis of 
biologically active compounds, flavors and fragrances and agrochemicals. Their relevance 
is underlined by the fact that approximately 40 % of all pharmaceuticals contain at least one 
enantiopure amine moiety.118 There are multiple strategies for their production such as 
organic synthesis and homogeneous catalysis,119-121 biocatalysis,122-129 and resolution of 
racemates.130 Enzymatic synthesis of chiral amines has been achieved with amine 
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dehydrogenases,131-133 transaminases,134-138 phenylalanine ammonia lyases139-141 and imine 
reductases,142-147 or by dynamic kinetic resolution of amines by relying on monoamine 
oxidases147-152 or lipases.153-156  
Since their first report in 2010,142 imine reductases have gained importance in 
biocatalysis and synthesis. However, their industrial usage remains limited for the following 
reasons: i) their non-competitive price, ii) restricted number of available enzymes iii) limited 
substrate scope and iv) instability of their substrates in water. These limitations call for the 
development of an alternative approach. 
One of the options for biocatalytic reduction of imines is to use an artificial transfer 
hydrogenase (ATHase). The path of their development started in 1996, when Noyori showed 
that the [(η6-arene)Ru((S,S)-TsDPEN))Cl] catalyst reduces imines in various aprotic polar 
organic solvents using azeotropic mixtures with trimethylamine and formic acid, achieving 
97 % ee in the reduction of various isoquinolines157. The possibility to perform this type of 
reaction in aqueous solutions95, 158-161 opened exciting new opportunities, which ultimately 
led to the development of an ATHase of ketones and imines, i.e. an artificial imine reductase 
(IRED) (Scheme 2). 
 
Scheme 2. An artificial IRED is created by a combination of a biotinylated three-legged pianostool 
iridium catalyst 3 with Sav. Its activity has been utilized in ketone and imine reduction. 
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In the initial screening, the iridium-containing complex [Cp*Ir(biot-p-L)Cl] 
outperformed95 ruthenium and rhodium containing complexes [Cp*Rh(biot-p-L)Cl] and [(p-
cymene)Ru(biot-p-L)Cl], when incorporated in Sav WT, representing contrasting results to 
ATH of ketones.94  Screening with a library S112X, K121X and double mutants thereof 
revealed several mutants with improved activity. Catalyst [Cp*Ir(biot-p-L)Cl] ꞏ S112A Sav 
reduced 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 1a to salsolidine 2a in full 
conversion and 91 % ee (R), whereas [Cp*Ir(biot-p-L)Cl] ꞏ S112K Sav displayed opposite 
enantioselectivity and produced salsolidine in 78 % ee (S). A subsequent study identified 
that a double mutant [Cp*Ir(biot-p-L)Cl] ꞏ S112A-K121A Sav display improved catalytic 
efficiency for the reduction of 1-methyl-3,4-dihydroisoquinoline 1b.162 
 
Scheme 3. Initial screening with various ruthenium, rhodium and iridium pianostool complexes for the transfer 
hydrogenation of salsolidine precursor 1a.95   
X-Ray structure analysis of crystals of S112A Sav soaked with an excess of the 
iridium cofactor suggested that the configuration at Ir is (S)-[Cp*Ir(Biot-p-L)Cl], which 
corresponds to (R)-[Cp*Ir(Biot-p-L)H]) for the catalytically active hydride form.162 
Regarding the mechanism, a non-concerted transition state allowing CH⋅⋅⋅π interaction 
between the Cp* moiety and the aromatic moiety of the substrate has been suggested 
suggested.94,163  
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Figure 3. Postulated transition states for the d6 pianostool-catalyzed asymmetric transfer 
hydrogenation of 1a showcasing the CH⋅⋅⋅π interaction along with the cation⋅⋅⋅π interaction with 
K121 (b).95 
Furthermore, the ratio between the Sav tetramer and [Cp*Ir(Biot-p-L)Cl] has a strong 
influence on the performance of the resulting artificial IREDs.164 In the case of  [Cp*Ir(biot-
p-L)Cl] ꞏ S112A Sav, increasing the Ir:Sav ratio from 1:1 (i.e. on average one biotin binding 
site occupied per tetramer) to 1:4 (all biotin binding sites occupied) decreased the 
enantioselectivity in the reduction of 1a from 69 to 45 % along with the catalytic efficiency 
from kcat/KM = 0.22 min−1mM−1 to 0.011 min−1mM−1. In contrast to S112A mutant, the 
enantioselectivity of [Cp*Ir(biot-p-L)Cl] ꞏ S112K remained almost constant across all tested 
ratios, while the activity decreases only by 1.5 fold. This observation suggested that the 
catalyst moieties within Sav operate independently. This hypothesis was confirmed by the 
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X-ray analysis of the obtained crystal; the four cofactors are able to occupy the binding sites 
without any steric clashes between them. 
The development of artificial IREDs was recently further advanced by 
implementation of a dual anchoring strategy. This approach relies on using a biotinylated 
iridium cofactor with three available coordination sites, which can be used for coordination 
with amino acids present in the binding site.64 Introducing histidines (either K121H or 
S112H) in close proximity of the rhodium metal center affected the enantioselectivity for the 
reduction of salsolidine precursor compared to the use of WT Sav. A similar approach 
utilizing the free coordination sites around the metal was used for screening a bidentate 
library of 34 diamines, amino acids and amino amides for the reduction of 1-phenyl-3,4-
dihydroisoquinoline 1c.165 Promising ligands were identified, [Ir(biot-en-η5-Cp*)(L-
ThrNH2)Cl)] ꞏ WT Sav produced the (S)-product in 63 % ee and 190 TON. 
 Scheme 4. An artificial IRED was integrated in a four-enzyme cascade to produce enantioenriched 
2b.102 
- 13 - 
 
The versatility of artificial IREDs extends to the creation of enzyme cascades. The 
initial effort aimed at the dynamic kinetic resolution of amines using an artificial IRED, 
monoamine oxidase (MAO) and a catalase.97 The process successfully produced (R)-amines, 
taking advantage of the (S)-selectivity of MAO.   
Additionally, an artificial IRED can be also used for the regeneration of NAD(P)H 
and NADH mimics,97,99,100 although NADH can be also implemented as a hydride source.102 
The four-enzyme cascade consisting of an NADPH-dependent artificial IRED, glucose 
dehydrogenase, MAO and a catalase produced (R)-product thanks to the dynamic kinetic 
resolution power of MAO (Scheme 4). 
The activity of an ATHase can be cross-regulated, similar to the enzymatic activity 
in living organisms (Scheme 5). This approach uses a protease cleaving an SGF tripeptide 
attached to Sav at its C-terminus. Upon releasing the tripeptide, an active catalyst [Ir(biot-
en-η5-Cp*)(SGF)L]·S112A-K121A Sav afforded 1956 TON in the reduction of 1b and 741 
TON in the reduction of salsolidine precursor 1a.166,167 
 
Scheme 5. The development of an artificial zymogen based on the biotin-streptavidin technology.167 
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1.5 GOALS OF THE THESIS 
An ATHase results from a non-covalent incorporation of a biotinylated pianostool 
metal complex into Sav. In this context, the Ward group has developed an Ar-IRED during 
the last seven years. In this respect, the aims and goals of the presented thesis are: 
(i)  To develop a high-throughput genetic screening protocol for ArMs by 
streamlining a glutathione-scavenger approach. 
(ii)    To genetically optimize the artificial IRED by means of directed evolution. 
(iii)  To optimize the operational stability and reaction rates of ArMs by 
immobilization on nanoparticles and encapsulation within a protective 
organosilane layer. 
(iv) To further expand the potential of influencing the catalysis by implementing 
a third coordination sphere around the metal catalyst. 
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CHAPTER II:  
GENETIC OPTIMIZATION OF ARMS 
2.1 INTRODUCTION 
The immense diversity of natural biocatalysts originates from the activity of ancestral 
enzymes, whose performance has been optimized by natural evolution over the course of 
millions of years.168 Consisting of recursive cycles of mutagenesis and selection followed 
by amplification of the “fittest”, evolution represents the driving force of nature and ensures 
that organisms can adapt over generations to the ever-changing conditions of their 
environment. 
To mimic natural evolution on a much shorter time scale and in a laboratory set-up, 
a step-wise procedure of directed evolution169-177 can be implemented for accelerated 
enzyme discovery. This Darwinian method relies on repeated cycles of mutagenesis 
combined with high throughput screening (HTS) techniques for activity and selectivity 
evaluation.  
As a starting point, a protein with a pre-existing activity is often used, although the 
activity can be also implemented into an existing active site or by de novo design.178,179 As 
an alternative to install a non-natural reactivity, utilization of a low promiscuous activity of 
a given enzyme is also possible.180  
The gene encoding the starting protein is subjected to mutagenesis and the resulting 
DNA library is translated into corresponding mutant variants. After the first round of 
mutagenesis, the genetically modified gene of the best mutant, i.e. displaying the best 
attributes that were screened for, is subjected to another round of mutation and screening 
(Figure 4). This process is repeated until the desired degree of stability (thermal181, 
oxidative182,183 or general robustness38), solubility,184,185 organic solvent170 and alkaline 
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tolerance,186 activity or selectivity is achieved and allows for either altering already existing 
features, or for engineering new functions.187-191 
 
Figure 4. Strategy for directed evolution of enzymes. 
In principle, no structural information of the protein is required for directed 
evolution. Alternatively, relying on rational design creates informed libraries of mutant 
protein variants, which contain targeted mutations emerging from the X-ray structure of the 
starting protein, phylogenetics, reaction mechanism, or computational modelling. This 
structure-guided192,193 approach to directed evolution, i.e. designed evolution,194 helps to 
overcome the searchable-size library limitation. 
The genetic diversity can be generated by various methods (Figure 5):176 
(i) Focused libraries target specific enzyme sites that are expected to have an impact 
on the catalytic activity, protein folding, or stabilization.195,196 This method widens 
the possibility that the produced mutant library will contain improved variants. 
Since simultaneous saturation of multiple positions requires excessive screening, a 
defined selection of amino acid residues to be introduced as mutations can be 
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implemented.197 Another popular semi-rational design is consensus protein design, 
which introduces consensus mutations identified from phylogenetic analyses.198  
(ii) Random mutagenesis199-203 targets the entire gene, allowing for introducing 
mutations distant from the active site. These changes in the protein structure might 
influence the protein dynamics, allosteric binding or the catalytic activity. The first 
error prone polymerase chains reaction (epPCR) was first described in 1989.202 The 
technique relies on the low fidelity of DNA polymerases. Under certain conditions, 
single-point mutations can be introduced into the gene of interest. Moreover, 
increasing the manganese concentration reduces the base-pair fidelity and allows 
for mutation rate acceleration to 10−4-10−3 per replicated base.203 
(iii) DNA shuffling, originally described in 1994,204 utilizes diversification by 
homologous recombination of DNA fragments. This promising method creates 
large libraries of variants with swapped genetic information and is performed by 
means of PCR without primers.205, 206 
 
Figure 5. Decision-tree for selecting the diversification strategy.176 
2.2 DIRECTED EVOLUTION OF ARMS 
Since ArMs comprise of an organometallic catalyst and a biomolecule, they bear the 
potential to be optimized by genetic means, either by using random mutagenesis207-211 or 
rational design.67,194, 210-212 Structure-guided directed evolution is based on the structure of 
the apo-bioscaffold. Introducing mutations within the secondary coordination sphere has 
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been shown to have a striking impact on the activity, selectivity, and robustness of the 
resulting hybrid catalysts. Moreover, the mutated variants have the potential to achieve 
efficiencies close to those of naturally evolved enzymes.213, 214 
 One of the limitations of directed evolution of enzymes is that with an increasing 
library size, the screening step becomes excessive. Multiple high-throughput assays exist,215 
but their applicability remains limited. In an ideal case, the expressed library of mutant 
enzyme variants could be screened directly in vivo in a high-throughput fashion, i.e. 
bypassing the time-consuming protein-purification step. In the case of an enantioselective 
ArM, the product of the reaction could ideally be analyzed by means of GC or LC with a 
chiral stationary phase. 
2.3 CELLULAR MATRIX LIMITATION 
The introduction of a synthetic cofactor containing a transition metal complicates the 
directed evolution of the resulting hybrid catalysts by multiple ways. First, the activity 
arising from the presence of the free cofactor should be minimized. This can be achieved 
either by a time-consuming protein purification, or by measuring the concentration of the 
free cofactor binding sites. In the case of ArMs based on the biot-Sav technology, a simple 
spectrophotometric assay using the large decrease in extinction coefficient of biotin-4-
fluorescein (B4F) after binding to Sav.216 
Secondly, the activity of the corresponding metal cofactor has to be retained even in 
the context of synthetic biology. For the directed evolution of a transition metal containing 
ArM, this represents a major bottleneck, as the activity of the metal cofactor is hindered by 
the cellular constitution of the expression model (Table 4).217 
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Table 4. Selection of intracellular metabolite concentrations in exponentially growing E. coli fed 
with glucose.217 
Metabolite Concentration [mM] Metabolite 
Concentration  
[mM] 
Glutamate 96 UTP 8.3 
Glutathione 17 GTP 4.9 
Fructose-1.6-bisphosphate 15 dTTP 4.6 
ATP 9.6 Aspartate 4.2 
UDP-N-acetylglucosamine 9.2 NAD+ 2.6 
Hexose  8.8 Glutathione disulfide 2.4 
Glutathione (GSH) is a tripeptide consisting of glutamic acid, cysteine, and glycine 
(γ-glutamyl-cysteinyl-glycine). This most abundant cytosolic thiol217 acts as a single 
electron donor capable of scavenging a wide variety of free radicals, thereby playing a role 
in cell signaling and non-enzymatic antioxidant protection (i.e. redox buffer).218 In the 
context of performing catalysis with soft transition metals, GSH represents a detrimental 
agent, as it easily coordinates to both soft metal ions.218,219 
 
Catalysis in a cellular matrix can be achieved by using purified proteins, by 
mechanically shielding the catalyst in a protective layer,101 by performing catalysis in the 
periplasm of E.coli,211 or by utilizing various GSH neutralizing agents.220 As the presence of 
GHS, but not glutathione disulfide (GSSG) inhibits the activity of the [Cp*Ir(biot-p-L)Cl] 
and the resulting ATHases, a pre-incubation step with a GSH-oxidizing agent or a Micheal 
acceptor is necessary, should the catalysis be performed in the presence of cellular debris. 
As can be appreciated from the data summarized in Figure 6, pre-incubation of E. coli cell 
free extracts (CFE) or cell lysates with 1,1'-azobis(N, N-dimethylformamide) (diamide) 
proved to be most efficient both in terms of activity and selectivity.220 Treatment with CuII  
also proved to be efficient. 221 
  
26
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 Figure 6. Bubble-chart representation of the activity of ATHase in the presence of various GSH 
neutralizing agents.220 
Given the fact that expression of Sav in Escherichia coli (E. coli) can be performed 
in small quantities of medium222 without the need of manual induction of Sav expression,223 
the ease of parallelization enabled the use of diamide for the implementation of a directed 
evolution strategy of ATHases. 
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2.4 LIBRARY DESIGN AND SCREENING PROTOCOL FOR ARTIFICIAL 
METALLOENZYMES BASED ON THE BIOTIN-STREPTAVIDIN 
TECHNOLOGY 
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2.4.1 ABSTRACT 
ArMs based on the incorporation of a biotinylated metal cofactor within Sav combine 
attractive features of both homogeneous and enzymatic catalysts. To speed up their 
optimization, we present a streamlined protocol for the design, expression, partial 
purification and screening of Sav libraries. Twenty-eight positions have been subjected to 
mutagenesis to yield 335 Sav isoforms, which can be expressed in 24-deep-well plates using 
autoinduction medium. The resulting CFEs typically contain >1 mg of soluble Sav. Two 
straightforward alternatives are presented, which allow the screening of ArMs using CFEs 
containing Sav. To produce an artificial transfer hydrogenase, Sav is coupled to a 
biotinylated three-legged iridium pianostool complex Cp*Ir(Biot-p-L)Cl (the cofactor). To 
screen Sav variants for this application, you would determine the number of free binding 
sites, treat them with diamide, incubate them with the cofactor and then perform the reaction 
with your test compound (the example used in this protocol is 1-phenyl-3,4-
dihydroisoquinoline). This process takes 20 d. If you want to perform metathesis reactions, 
Sav is coupled to a biotinylated second-generation Grubbs-Hoveyda catalyst. In this 
application, it is best to first immobilize Sav on Sepharose-iminobiotin beads and then 
perform washing steps. Elution from the beads is achieved in an acidic reaction buffer before 
incubation with the cofactor. Catalysis using your test compound (in this protocol, 2-(4-
(N,N-diallylsulfamoyl)phenyl)-N,N,N-trimethylethan-1-aminium iodide) is performed using 
the formed metalloenzyme. Screening using this approach takes 19 d. 
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2.4.2 INTRODUCTION 
In recent years, artificial metalloenzymes have attracted increasing attention as an 
alternative to homogenous catalysts (such as Rh-based hydrogenation- or Os-based 
dihydroxylation catalysts) and naturally occurring enzymes (including variants produced by 
standard mutations).226, 48 Such hybrid catalysts result from the incorporation of an artificial 
cofactor within a host protein and combine attractive features of both systems. Several 
anchoring strategies have been pursued to ensure localization of the metal moiety within a 
well-defined protein environment: dative, covalent and supramolecular.43 
In this context, the biot-Sav system has proven particularly versatile for the creation 
of ArMs.72 Indeed, the hemispheric biotin-binding vestibule, which consists of loops 
between sheets β3,4, β4,5, β5,6 and β7,8, is ideally sized to harbor a biotinylated cofactor and 
its substrate. Inspired by a visionary publication by Wilson and Whitesides,47 eight catalytic 
transformations have been implemented relying on ArMs derived from the biotin-
(strept)avidin technology which include hydrogenation,47, 227, 93, 228 transfer-hydrogenation 
(of ketones, imines and enones),96 allylic alkylation,109 C–H activation,104 metathesis,111 
sulfoxidation,107, 108 dihydroxylation105 and alcohol oxidation.106 Although initial studies 
have relied on avidin as a host protein,47,227 Sav is preferred in most cases thanks to its 
straightforward expression in E. coli. To minimize laborious steps, mature Sav is preferred 
over core Sav as the latter is expressed as inclusion bodies.229, 230 The biotin-streptavidin 
technology has proven to be a versatile tool for the implementation of ArMs, offering the 
possibility to implement abiotic reactions within a biological environment. In this context, 
olefin metathesis (Metathesase) is particularly attractive as it is a bio-orthogonal reaction231 
which has no equivalent in nature. Recently, it was shown that an ATHase based on the 
biotin-streptavidin technology could be combined with enzymes in cascades by preventing 
mutual inactivation.97 Compared to other abiotic cofactor anchoring strategies,43 
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supramolecular anchoring allows faster screening as the ArMs are generated quantitatively 
and thus require no additional reagents, coupling steps or purification. 
Sav is a highly versatile protein often referred to as “molecular velcro”. In the past 
40 years, it has found numerous applications in a variety of fields including protein 
purification, immobilization, interaction studies and diagnostic applications.37, 82-84 The 
protocol described herein may be applicable to any application of the biotin-streptavidin 
technology requiring fine-tuning of Sav properties. 
A chemogenetic optimization strategy opens up the possibility to rapidly improve the 
catalytic performance of ArMs based on the biotin-streptavidin technology (Scheme 6).  
 
Scheme 6. Model reactions and structures of the ATHase cofactor [Cp*Ir(biot-p-L)Cl] 3 and the 
metathesase cofactor 6 (for a synthesis overview see Appendix A Schemes A2 and A3). Upon 
incorporation of the biotinylated cofactor within Sav, an artificial transfer hydrogenase (see Step 
28A) and an artificial metathesase (see Step 28B) are formed. The reaction conditions for the 
hydrogenation of 1c and for the ring-closing metathesis reaction of 2-(4-(N,N-
diallylsulfamoyl)phenyl)-N,N,N-trimethylethan-1-aminium iodide 4 are displayed. MR buffer, 
metathesase reaction buffer; cat., catalyst. 
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Systematic variation of the biotinylated spacer–ligand moiety can be combined with 
genetic modification of Sav to afford ArMs with improved characteristics (kinetics, stability, 
TON and selectivity). In view of the requirement of purified Sav samples to ensure activity 
of the abiotic metal cofactor, optimization efforts thus far have been limited to large scale 
expression and purified Sav mutant libraries.37, 95 Thus far, mostly close lying amino acid 
residues have been subjected to saturation mutagenesis. An attractive feature of this strategy 
is the possibility to exploit the same Sav libraries for a variety of ArMs.  
To fully capitalize on the potential of ArMs based on the biotin-streptavidin 
technology, a streamlined screening protocol relying on CFE or partially purified Sav is 
highly desirable (Figure 7). Indeed, thus far, screening has been performed on purified Sav 
samples, thus seriously limiting the number of mutants accessible. The protocol described 
herein allows to screen hundreds of Sav mutants within a reasonable time frame using CFE. 
With this goal in mind, we selected a twenty-four well-plate based screening assay to 
streamline the entire screening process, thus significantly increasing the throughput. 
2.4.3 EXPERIMENTAL DESIGN 
2.4.3.1 OVERVIEW 
Herein, we detail a protocol for the creation of Sav isoforms, their functional 
overexpression, the generation of ArMs and two complementary screening methods (Figure 
7). The protocol is broken down in the following sections: (i) Basic primer design for 
QuikChange mutagenesis and generation of the Sav library (mutagenesis section); (ii) 
recombinant protein expression in 24 deep well plate format from the glycerol stock culture 
to the final CFE containing the overexpressed soluble Sav (library expression section); (iii) 
the determination of the free biotin binding sites present in the CFE using B4F (Fig. 7, Step 
28A); and (iv) the optimization of the performance of ArMs for an artificial ATHase (Step 
28A) and a metathesase (Step 28B) using CFE relying on two partial Sav purification 
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schemes. For the ATHase, a diamide treatment is used to neutralize the deleterious GSH,222 
and for the metathesase a reversible immobilization on a Sepharose-iminobiotin resin is 
performed (Fig. 7, Step 28B).111, 232 
2.4.3.2 LIBRARY DESIGN 
Precise primers are designed for each mutation. In the present context, this strategy 
offers several advantages: (i) the introduced amino acid can be chosen freely (i.e., not 
dictated by the choice of degenerate primers),233 (ii) the screening effort is reduced as no 
oversampling is required, and (iii) as each well contains a defined Sav mutant, structure-
activity relationships can be obtained for each experiment. For this purpose, a protocol for 
using site-directed mutagenesis234 in 96 well format is implemented. Based on previous 
screening efforts with a variety of artificial metalloenzymes, mature Sav229 bearing an 
alanine mutation at position 121 as starting isoform for the library generation is selected. 
The sequence of pET-24a SavK121A is codon optimized to reduce the G/C content from 68 
%229 to 52 %. This significantly improves mutagenesis success rate without influencing Sav 
expression levels.  
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Figure 7. Workflow used in this protocol. Mutagenesis, expression and screening for the 
identification of genetically engineered ArMs variants based on the biotin-Sav technology. Step 
numbers are listed according to the PROCEDURE. 
The positions for mutagenesis are selected by identifying residues that lie within a 
15 Å radius around the averaged position of the biotinylated metal moiety bound to Sav 
(Protein Data Bank (PDB) codes: 2QCB, 2WPU, 3PK2, 4GJS, 4GJV).95, 232, 235, 64 This lead 
to the identification of 21 amino acid positions, namely G48, A50, A65, D67, S69, R84, 
N85, A86, H87, L110, T111, S112, G113, T114, T115, A117, N118, A119, S122, T123, 
L124. By examination of the X-ray structures, four further amino acid positions (R53, P64, 
G68, E116) lying close to mutated areas, one (G98) within the backbone of loops between 
sheets β5,6 and β7,8 and two (K144, N150) within the non-resolved, flexible C-termini from 
mature Sav are selected. In total, 28 positions are subjected to mutagenesis (Figure 8).  
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Unique primers are designed for each Sav mutant according to the guidelines 
summarized in Box 1.236 The following amino acids are substituted at the above positions in 
the template Sav K121A sequence (Figure 9): A, V, L, D, E, Q, K, H, M, Y, S, P (or N if 
one of the targeted mutation is present at this position). It should be noted that the primer 
library used for the first round of mutagenesis may be used for the second round. However, 
this requires that the position to be mutated is distant enough from the mutation position 
from the previous round (typically six amino acids). If this is not the case, new primers need 
to be designed for use in the second round of mutagenesis. For the library production and 
the Sav expression, the E. coli strains TOP10 and BL21 (DE3) are used respectively. The 
TOP10 strain is versatile for the site-directed mutagenesis steps, whereas the BL21 (DE3) 
strain is very efficient for the production of soluble Sav.229 
2.4.3.3 EXPRESSION OF SAV MUTANTS IN 24 WELL DEEP PLATES  
To maximize the amounts of soluble Sav in small scale expression (i.e., > 1 mg Sav, 
corresponding to 61 nmol free binding sites (Sav FBS) or 15 nmol tetrameric Sav in 6 ml 
medium), a simple and robust protocol based on the Lac-operon induction system is applied. 
For this purpose, the ZYP-5052 medium is used. It contains defined amounts of glucose and 
lactose in the culture medium.223 Upon using this medium, the recombinant protein’s 
expression is induced by lactose in the exponential growth phase once glucose is consumed, 
thus requiring no manual induction by IPTG. The protein production is automatically turned 
on in each well at nearly the same optical density (OD). Relying on this simple and 
reproducible procedure, good yields of soluble and functional Sav are obtained within 24 h. 
Typically, final ODs of 6 – 7 are reached for each culture. A slight modification of the ZYP-
5052 media is required for a 24 h expression: compared to the original recipe, the amount of 
carbohydrates (lactose and glucose) and the MgSO4 concentration are doubled. To improve 
aeration within the wells, a pipette tip (0.1 to 10 µl) is added. This leads to an increase in 
OD and Sav yields. Following this procedure, Sav yields > 1 mg (61 nmol Sav FBS) per 
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well are consistently obtained. This is sufficient to perform one to two ArM screening 
experiments. Slightly higher Sav yields can be achieved if the expression time is increased 
to 48 h using the same culture volume. In this case, the original ZYP-5052 media and no 
pipette tip are required. 
 
Figure 8. Close-up view of the X-ray structure of an artificial transfer hydrogenase based on the 
biotin-Sav technology. For clarity, only one cofactor [Cp*Ir(Biot-p-L)Cl] (compound 3) is displayed 
(as stick), and Sav (mutant S112A, displayed as surface/cartoon representation). The positions 
selected for mutagenesis are highlighted in orange and residue K121 is highlighted in cyan (PDB 
code: 3PK2). 
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A technical issue concerns the necessary laboratory equipment. Although the 
protocol described herein may be adapted to culture tubes, we strongly favor a 24-well plate 
format. For this purpose, we recommend shaking-flask incubators that are equipped with 
sticky pads. In our experience, the 24-well plates can be conveniently fixed and are held 
securely up to at least 250-rpm shaking speed. This enables the cultivation of many plates in 
parallel in a single incubator. To save time, a plate centrifuge is recommended to harvest and 
to clarify the supernatants. In our experience, adapting this protocol to culture tubes is less 
efficient and unpractical. Indeed, we routinely observe lower cell densities, leading to higher 
deviations in catalysis. Additionally, the handling of tubes versus 24-well plates is more time 
consuming. 
Gratifyingly, upon cultivating ninety replicates in four 24-well expression plates, an 
11% (Step 28A) and a 9% (Step 28B) s.d. in conversion for the ArM-catalyzed reaction is 
obtained, highlighting the excellent reproducibility of the protein expression protocol using 
this format.  
2.4.3.4 DETERMINATION OF SAV FREE BINDING SITES IN CFE 
Previous experience suggests that the concentration of the biotinylated cofactor (50 
µM) should not exceed half of the Sav FBS (100 µM). Although each ArM behaves 
differently, it has been found that saturating all the biotin-binding sites with a metal cofactor 
may lead to significant erosion of an ATHase’s performance.164 To determine the Sav FBS 
concentration within the CFE, a modified assay using B4F is implemented.237, 216 Gruber and 
colleagues237 and Mascotti and Waner216 demonstrated that B4F can be used for the Sav FBS 
determination in CFE using either fluorescence (excitation 485 nm; emission 520 nm) or 
absorbance at 493 nm. We adapted this assay to a 96-well-plate format measuring 
simultaneously the drop in absorption and in fluorescence of B4F in the presence of the Sav 
CFE. With this assay, multiple samples can be handled in parallel. The biotinylated 
fluorophore B4F (40 µM) is added to each Sav-containing well and the resulting decrease in 
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absorbance and fluorescence are determined. Depending on the expression levels, 30 – 60 
µl CFE is required to determine the Sav FBS concentration in triplicate. The single point 
determination yields a 10 – 20 % error margin. However, when evaluating Sav FBS < 10 
µM the error increases substantially. Importantly, the pET-24a empty vector CFE 
background must be subtracted from both the absorbance and fluorescence determinations. 
 
Figure 9. Summary of designed mutants. Matrix of Sav isoforms designed and produced for 
screening purposes. As template for mutagenesis, the mutant Sav K121A is used. (a) amino acids (b) 
position in Sav template. 
2.4.3.5 ARTIFICIAL TRANSFER HYDROGENASE FOR THE REDUCTION OF CYCLIC IMINES  
Prochiral cyclic imines are versatile substrates for the production of enantioenriched 
amines. We have previously demonstrated that artificial transfer hydrogenases resulting 
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from the incorporation of a biotinylated pianostool complex within Sav are promising hybrid 
catalysts for this transformation (Scheme 6, Route A). The biotinylated three-legged iridium 
pianostool complex 3 was synthesized according to a published procedure238 and added to 
Sav isoforms to afford an ATHase. Unfortunately, the recombinant Sav isoforms 
overexpressed in E. coli need to be purified by affinity chromatography as traces of 
glutathione, present in cellular debris,217 irreversibly poison the precious metal cofactor. To 
circumvent this severe bottleneck, we recently identified that diamide neutralizes the 
dendrimental effect of GSH on Compound 3 by oxidizing it to GSSG.222 This finding allows 
us to screen samples of Sav contained in E. coli CFEs and cell lysates. 
2.4.3.6 CATALYSIS WITH IMMOBILIZED SAV-MUTANTS USING IMINOBIOTIN-SEPHAROSE 
BEADS 
As a model reaction with Sav using iminobiotin-sepharose beads as a rapid 
purification tool,232 the ring closing metathesis of olefins was selected (Scheme 6, Route B). 
An artificial metathesase based on the biotin-streptavidin technology was previously 
reported by us.111 As the ring-closing reaction using diallylsulfonamides works best at pH 4, 
an acetate buffer is selected as reaction medium. At this low pH, iminobiotin is protonated 
and the immobilized Sav is released from the iminobiotin-sepharose beads. As the metathesis 
cofactor 6239 bears a biotin anchor, it binds tightly to Sav at this pH and catalyzes the ring-
closing metathesis of substrate 4 to form product 5.  
2.4.3.7 LIMITATIONS  
The main limitation of this protocol is the marked decrease in activity and 
reproducibility of ArMS when the Sav FBS concentration is low. For both reactions 
presented herein, cell cultures, with Sav FBS > 100 µM should be targeted. Indeed, past 
experience with ATHase of cyclic imines reveals that highly reproducible results require 3 
M sodium formate in 0.6 M MOPS at pH 6 and > 50 µM Sav FBS. The limited solubility of 
both formate and MOPS does not allow preparation of more than 2x concentrated stock 
buffer solutions. In contrast, the metathesase performs well down to 10 µM FBS Sav on 
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purified Sav samples. However, the immobilization protocol requires > 100 µM Sav FBS. 
Indeed, Sav FBS in the CFE must be present in excess compared to the loading capacity of 
the iminobiotin-sepharose beads.  
As illustrated by the ATHase and metathesase, each ArM behaves differently and 
exploratory screens should be performed to identify the most suitable screening strategy. For 
example, diamide treatment is not suitable for the metathesase as the ruthenium cofactor is 
inactivated by this reagent. Instead, iminobiotin sepharose beads are highly versatile for the 
metathesase as the Sav is released from the beads at pH 4 allowing to perform catalysis in 
solution. In our experience, the iminobiotin beads immobilization (Route B) is more versatile 
than diamide treatment (Route A). However, for reactions requiring neutral or basic 
conditions, an additional buffer-exchange step is necessary. For this purpose, the eluted 
fraction containing Sav at pH 4 can be back-titrated to the desired pH by the addition of 
concentrated base or a high molarity reaction buffer. 
Concerning evolution strategies, a combination of synergistic mutations may be 
envisaged.233 In order to be able to re-use the initial design primer library, it is important to 
ensure that the fixed mutation (first mutation) does not overlap with the primer pair used for 
the mutation to be introduced (second mutation). For this purpose, the second mutation 
should be more than six amino acids away from first mutation. If this is not the case, a new 
set of primers for the second mutation needs to be designed and used. 
2.4.4  TROUBLESHOOTING 
Troubleshooting advice can be found in Table 5. For mutagenesis, Sav expression 
and Sav FBS, the following guidance applies: 
After preparation of a fresh stock of the template plasmid it is recommended to 
validate it for the right Sav sequence by sequencing prior to mutagenesis. Prepare a positive 
control of the PCR by using a primer pair (Appendix A Table 1) which will give you a 
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specific amplification. If, after site directed mutagenesis, no amplified vector is visible on 
the gel, reduce the annealing temperature. If several amplified fragments are visible and no 
mutant is obtained, increase the annealing temperature. The transformation efficiency of 
competent cells can decrease during storage due to their low viability. It is thus suggested to 
always use a positive-control transformation using the pUC19 vector. Due to the lower 
transformation efficiency of the BL21 (DE3), the transformation into this strain is less 
effective in 24 deep well plates. If no colonies are obtained, a transformation in 1.5 ml tubes 
can lead to fewer colony-forming units (cfu).  
This Sav expression protocol is highly robust, but reduced Sav yields can exceptionally be 
obtained with no apparent reason. When this is the case, it is recommended to perform a new 
transformation into BL21 (DE3) and to prepare a new glycerol stock resulting from an 
overnight culture inoculated by a single colony. During expression of the Sav library, it is 
recommended to include controls on each 24 deep well plate to validate the screening for 
hits and background. For this purpose, wild-type Sav, SavK121A and pET-24a empty vector 
should be included in each 24 deep well plate.  
The B4F-absorption-fluorescence assay has a limited precision window ranging from 10 to 
40 µM Sav FBS. It is thus recommend to re-determine data for samples with Sav FBS < 10 
µM or Sav FBS > 35 µM after having adapted the concentration. It is important to subtract 
the background spectrum for the pET-24a empty vector (both for the absorbance and 
fluorescence determination). As residual biotin and biotinylated E. coli proteins may be 
present in cell lysates, the B4F assay may underestimate the [Sav]: it is, however highly 
reliable for the Sav FBS determination, which is the relevant concentration for catalysis with 
ArMs. 
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Table 5. Troubleshooting table. 
Step Problem Possible reason Possible solution 
 
5 
 
No colonies  
 
 
 
Transformation failed 
 
Positive control with no colonies: prepare 
new competent cells (Box 2) 
 
Positive control with colonies: band on 
gel: repeat transformation of mutant, plate 
all, perform transformation in +1.5-ml 
tubes (especially for E. coli BL21 (DE3) 
because of the naturally lower 
transformation efficiency of the strain 
compared with E. coli TOP10) 
 
14 
 
No band present 
on agarose gel  
 
 
 
 
There are 
multiple 
nonspecific 
bands on 
agarose gel 
 
 
Composition of PCR 
mixture is wrong 
 
Primers are annealing 
during PCR  
 
 
Primer binds 
nonspecifically 
 
Include a positive control using a gene-
specific primer (Supplementary table 1)  
 
Test a lower annealing temperature (>50 
°C)  
 
Vary the DMSO content  
 
Re-design primers (Box 1)  
 
Proceed with transformation; often 
colonies carry the right mutation if one of 
the fragments has the right vector size  
 
Perform PCR at higher annealing 
temperatures (up to 65 °C)  
 
Re-design primers (Box 1) 
 
17 
 
Plasmid 
preparation has 
low yield  
 
Low OD in overnight 
culture; pH of LB is not 
adjusted (important for 
kanamycin resistance) 
 
Check the pH of LB medium (>7.25) and 
increase the culture time  
 
Elute in 2 x 15 µl of elution buffer  
 
Prepare 6 ml of overnight culture in a 2-
deep-well plate 
 
18 
 
Wild-type 
background  
 
DpnI digestion 
failed/inefficient 
 
Use fresh DpnI and increase the digestion 
by 1 h  
 
Reduce the template amount in PCR to 0.1 
ng µl-1 
 
27 
 
Reduced Sav 
yield  
 
Viability of glycerol 
stock reduced 
 
New transformation into E.coli BL21 
(DE3) and new glycerol stock 
 
Avoid thawing the glycerol stock solution; 
keep it on dry ice  
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28A 
(xiv) 
Possible 
formation of 
gel-like 
emulsion during 
work-up  
 
Protein layer 
during phase 
separation 
Protein denaturation due 
to organic solvent, high 
protein content  
 
Sav precipitates due to 
organic solvent 
Spin down the emulsion in a small 
centrifuge before separating the phases  
 
 
Spin down the emulsion in a small 
centrifuge before separating the phases 
(Route A: Step xiv.) 
 
 
28B 
(i) 
 
Beads cannot be 
taken up by 
Eppendorf 
pipette 
 
Suspension is too thick 
 
Make sure that the total volume of the 
bead suspension is 2x the volume of 
settled beads. Thoroughly shake 
suspension before adding the beads 
 
Use pipette tips with wider opening  
 
28B 
(iv)  
 
Catalyst stock 
solution turns 
brown  
 
Catalyst slowly 
decomposes in pure 
DMSO 
 
Directly use the catalyst after dissolving 
the aliquot in DMSO  
  
2.4.5 ANTICIPATED RESULTS 
Upon sequencing a single colony for each mutagenesis reaction, a coverage of 80-
90% of the targeted Sav mutants was achieved following PCR and transformation in E. coli 
TOP10. This value is achieved by sequencing one colony for each mutant. If amplification 
is visible on the analytical agarose gel, sequencing an additional one or two colonies from 
the transformation plate leads to nearly complete coverage of all targeted Sav mutants. 
Following this protocol, 335 Sav mutants from the targeted 336 Sav mutants are obtained.  
Comparable ODs and Sav yields are obtained for each well when using the ZYP-
media expression protocol in 24 deep well plates. Routinely, ≥ 1 mg Sav (corresponding to 
15 nmol tetrameric Sav or 240 µM Sav FBS in 250 µl) is obtained per well after 24 h using 
the modified ZYP and adding a pipette tip. Following this procedure, 250 µl CFE can be 
obtained. This is sufficient to determine the Sav FBS and to perform two catalytic runs either 
for the ATHase or the metathesase reaction (100 µM Sav FBS required). Upon increasing 
the expression time to 48 h, the Sav FBS typically increases by 40 %. For this purpose, no 
pipette tip should be added to the well and the standard ZYP media is recommended. 
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Both the absorption and the fluorescence Sav FBS single point determinations afford 
10 to 20 % errors. This is perfectly acceptable for the screening procedure as catalysis is 
performed using twice the Sav FBS concentration vs. the biotinylated catalyst, thus ensuring 
quantitative binding of the latter to Sav. The standard curves either for absorbance or 
fluorescence display high linearity with a R² = 0.95 – 0.99 (Appendix A, Figure A7). Using 
this dilution, the CFE samples typically yield Sav FBS = 20 – 30 µM. For CFE of the empty 
pET-vector, the background absorption or fluorescence corresponds to 1 – 5 µM Sav FBS.  
Because of the high affinity of biotinylated probes for Sav, the ATHase or 
Metathesase are immediately formed upon addition of the biotinylated catalyst to Sav 
isoforms. The success rate for catalysis depends on factors including activity, stability and 
expression level of the specific mutants. The excellent reproducibility of the protocol may 
allow to evaluate NNK libraries, as hits of different screening plates can be compared. The 
success rate for catalysis is improved thanks to the normalization of the FBS present in each 
sample prior to catalysis: Route A is normalized by the FBS determination and Route B by 
the specific binding capacity of the applied beads if Sav is present in excess in the CFE. 
2.4.5.1 ARTIFICIAL TRANSFER HYDROGENASE (OPTION A) 
The protocol allows highly reproducible preparation of cell lysates and 
corresponding CFEs containing the overexpressed Sav isoforms. Sav is produced in high 
concentrations, which allows to set up two catalysis experiments (200 μl final volume) from 
a 6 ml cell culture (corresponds to approx. 0.25 ml of cell lysate). 
Preincubation of either cell lysates or CFEs for 2 h with 5 mM diamide, before 
addition of the transition metal catalyst, leads to the partial restoration of the activity of 
artificial metalloenzymes performed in the presence of purified Sav samples. Screening 
results from ATHase in the [Cp*Ir(biot-p-L)Cl] 3  K121A Sav are summarized in Table 6. 
As can be appreciated, upon addition of diamide, the catalytic activity is partially restored 
for samples containing either cell lysates or CFEs. 
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Table 6. Expected results for the transfer hydrogenase (Step 28A). 
 ATHase 
Sav source ee [% (R)] conv. [%] TON 
 No protein rac. 58 116 
 K121A purified protein 71 91 183 
K121A CFE untreated 0 0 0 
K121A CFE + DiAm 59 21 42 
K121A cell lysatea untreated 0 0 0 
K121A cell lysatea + DiAm 42 19 39 
Empty vector CFE untreated 0 0 0 
Empty vector CFE + DiAm rac. 3 6 
Empty vector cell lysatea untreated 0 0 0 
Empty vector cell lysatea +DiAm 0 2 4 
a The use of cell lysates alleviates an additional clarification step. Nevertheless, CFE (clarified 
supernatants) are preferred because the number of background contaminants is significantly reduced. 
2.4.5.2 RING-CLOSING OLEFIN METATHESIS (OPTION B) 
CFEs and cell lysates contain unidentified catalyst poisons that inhibit ring closing 
metathesis on substrate 4. Upon immobilization of Sav from CFEs on the iminobiotin-
sepharose beads, impurities from the CFEs can be washed away, thus partially restoring 
metathesase activity. Duplicate measurements performed without protein, with Sav K121A 
mutant and pET-24a empty vector CFE typically yield the following results (Table 7). 
Table 7. Expected results for the metathesis (Step 28B). 
 Metathesasea 
Sav source conv. [%] TON 
No protein 19 ± 0.5 38 ± 0 
K121A purified protein 33 ± 0.5 66 ± 1 
Empty vector CFE untreated 0 ± 0 0 ± 0 
Empty vector CFE bead-treated 5 ± 0.5 10 ± 1 
SavK121A CFE untreated 0 ± 0 0 ± 0 
SavK121A CFE  bead-treated 9 ± 0.5 18 ± 1 
a average of duplicate measurements 
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2.5.1 ABSTRACT 
 
Artificial metalloenzymes, resulting from incorporation of a metal cofactor within a host 
protein, have received increasing attention in the last decade. Herein, we report on the 
directed evolution of an ATHase based on the biotin-streptavidin technology using a 
straightforward optimized protocol allowing screening in cell free extracts. Our efforts 
yielded two streptavidin isoforms with improved catalytic activity and selectivity for the 
reduction of cyclic imines. Gratifyingly, the evolved ATHases proved stable under biphasic 
catalytic conditions. The X-ray structure analysis reveals that introducing bulky residues 
within the active site results in flexibility changes of the cofactor, thus increasing exposure 
of the metal to the protein surface and leading to a reversal of enantioselectivity. This 
hypothesis was confirmed by a multiscale approach based mostly on molecular dynamics 
and protein-ligand dockings. 
TOC:
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2.5.2 INTRODUCTION 
Biocatalysis offers an attractive means to produce high-added value products.35,190,247 
Its limitations in reaction repertoire, substrate scope and operational stability can be 
overcome using directed evolution or encapsulation techniques.248-250 
Enantiopure amines, representing important intermediates for synthesis of 
biologically active compounds, agrochemicals, and flavors, are gaining increasing 
importance in both academic and industrial sectors. Indeed, approximately 40 % of all 
pharmaceuticals contain at least one enantiopure amine moiety.118 There is thus a high 
demand for versatile tools to produce these. Current strategies include: homogeneous 
catalysis and organic synthesis,119-121 resolution of racemates130 or biocatalysis.122,125,126,129, 
251 Amine dehydrogenases,131-133 phenylalanine ammonia lyases,139-141 transaminases134-137 
and imine reductases142-146 have been reported for the synthesis of enantiopure amines. The 
dynamic kinetic resolution of amines can be achieved using monoamine oxidases148, 150, 151 
or lipases153-156. Following the first reports by Mitsukura in 2010,142 imine reductases have 
gained significant interest from the synthetic community. The limited number of available 
imine reductases calls for alternative biocatalytic approaches.146 
In the past fifteen years, biocatalysis has been complemented with ArMs. These 
combine attractive features of enzymatic catalysis with the vast reaction repertoire of 
organometallic catalysis.41,42,47,104,227,252-254 In this context, the biotin-streptavidin 
technology73,96,255 has proven versatile, allowing the development of numerous ArMs that 
have been optimized to catalyze new-to-nature transformations.67,114,116 
In order to fine-tune the performance of enzymes, directed evolution has proven 
extremely powerful.173,176258,259 Consisting of iterative cycles of (random) mutagenesis, 
protein overexpression and screening, this versatile technique allows to incrementally 
improve a targeted feature of an enzyme: activity, selectivity, stability etc. As ArMs consist 
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of an abiotic cofactor and a genetically-encoded host protein, directed evolution can also be 
applied to the optimization of such hybrid catalysts.69,112,189,208,260,261 
To speed-up the directed evolution of ArMs, we set out to perform catalysis using E. 
coli CFE rather than purified protein samples. Previously, we identified GSH as a main 
contaminant,217,222 leading to the irreversible poisoning of the precious metal cofactor when 
catalysis is performed in CFE. Addition of diamide to CFE containing Sav prior to the 
addition of the cofactor significantly restores the catalytic performance of ArMs.222 To test 
the usefulness of this screening protocol, we set out to optimize the performance of an 
artificial imine reductase based on the biot-Sav technology by directed evolution. 
In this work, we present the implementation of a streamlined optimization 
protocol,222 which allows us to screen protein variants using CFE pre-incubated with DiAm. 
Upon screening 300 variants contained in CFE, which corresponds to four weeks of 
mutagenesis and expression, four weeks of protein purification, and 200 hours of analytical 
measurements, two mutants with an increased catalytic activity and opposite 
enantioselectivity for the reduction of cyclic imines were identified. 
2.5.3 RESULTS AND DISCUSSION 
To improve the catalytic performance of the ATHase, we selected a volume of 10 Å 
around the iridium center anchored within Sav and subjected the corresponding amino acids 
to iterative saturation mutagenesis (Figure 10). As starting point for the screen, we selected 
Sav K121A. For the first generation of the directed evolution, a reduced library of amino 
acids was included. At positions T111, S112, G113, T114, A116, N118, S122, T123 and 
L124, the following residues were introduced relying on precise primers: A, V, L, D, E, Q, 
K, H, M, Y, S, P (or N if one of the targeted mutation is present at this position). For the 
following generations, all canonical amino acids were individually introduced.  
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Figure 10. Close-up view of the active site of an artificial imine reductase. The protein is displayed 
as solvent accessible surface and the biotinylated cofactor as color-coded stick. Positions selected for 
mutagenesis are highlighted (PDB 3PK2). 
Mutants were overexpressed in E. coli in 96 deep-well plates, and the cells were 
lysed, incubated with DiAm for 15 minutes, supplemented with [Cp*Ir(biot-p-L)Cl] and 
screened for the transfer hydrogenation of cyclic imines 1a, 1c and 1d (Scheme 7, See 
Appendix B for details). After identification of improved variants using CFE, the 
corresponding mutants were overexpressed in 1 L autoinduction medium,223 purified by 
iminobiotin-sepharose affinity chromatography and lyophilized. The pure Sav mutants were 
then tested for their ATHase activity. 
In the first generation, positions S112 and N118 were screened, yielding (S)- and (R)-
selective mutants K121A-S112R and K121A-N118P (Table 8, entry 4 and 5; Figure 11). 
Next, K121A-N118P was subjected to focused saturation mutagenesis at position S112. 
Mutant K121A-N118P-S112A yielded (R)-2c with 86 % ee (entry 6). Position S122 was 
mutated next. Substituting the polar serine to a methionine further improved the 
enantioselectivity for the reduction of 1c, yielding (R)-2c in 92 % ee and full conversion 
(conv., entry 7). 
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Scheme 7. Reduction of cyclic imines 1a, 1c and 1d using ATHase based on the biot-Sav technology 
We hypothesized that mutating alanine to bulky arginine at position 112 would afford the 
opposite enantiomer of 2c. To our delight, the resulting Sav variant produced (S)-2c in 63 % 
ee and with improved conv. (entry 9). The (S)-selectivity was further improved by 
introducing tyrosine instead of lysine at position 124, which yielded (S)-2c with 78 % ee and 
full conv. (entry 10). Because of the low solubility of 1c in water, we performed experiments 
under a biphasic set-up262 with 100 mM 1c dissolved in ethyl acetate. To our delight, 
improved enantioselectivity was observed for both (R)- and (S)-selective ATHases (entry 8 
and 12). In stark contrast, [Cp*Ir(biot-p-L)Cl] ꞏ K121A proved less active under biphasic 
conditions (entry 3). Preparative-scale experiments (>120 mg of 1c) resulted in >99 % HPLC 
yield (70 % isolated yield) and 91 % ee (R) for S112A-N118P-K121A-S122M and >75 % 
HPLC yield (55 % isolated yield) and 71 % ee (S) for S112R-N118P-K121A-S122M-L124Y 
(Table 8, entry 9 and 13). 
- 51 - 
 
 Figure 11. Summary of the directed evolution path to afford both an (R)- and an (S)-selective 
ATHase for the reduction of 1c. 
Table 8. Selected results for the reduction of cyclic imine 1c using purified proteins.[a] 
Entry Sav ee (%)[d] conv. (%)[d] TON 
1 [Cp*Ir(biot-p-L)Cl] 0 17 35 
2 K121A 54 99 198 
3 K121A [b] 31 5 100 
4 N118P-K121A 59 96 193 
5 S112R-K121A -27 36 72 
6 S112A-N118P-K121A 86 100 200 
7 S112A-N118P-K121A-S122M 92 100 200 
8 S112A-N118P-K121A-S122M[b] 95 19 380 
9 S112R-N118P-K121A-S122M[c] 91 99 (70e) 198 
10 S112R-N118P-K121A-S122M -63 90 179 
11 S112R-N118P-K121A-S122M-L124Y -78 99 198 
12 S112R-N118P-K121A-S122M-L124Y[b] -85 11 220 
13 S112R-N118P-K121A-S122M-L124Y[c] -72 75 (55e) 150 
[a] The reactions were performed with 10 mM substrate at 37°C for 48 h (see SI). [b] Reactions were 
performed in a biphasic system with 100 mM substrate at RT for 4 days. [c] Preparative-scale reaction, 
124 mg of 1c were added to the reaction mixture (60 ml). [d] Enantiomeric excess and conv. were 
determined by HPLC. Positive ee values correspond to (R)-product and negative ee values 
correspond to (S)-product. [e] Isolated yield. 
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The resulting Sav library was tested for the reduction of the bulky isoquinoline 1a as 
well as cyclic imine 1d (Table S3). For the reduction of 1a, an (S)-selective ATHase was 
identified; S112T-N118K-K121A-S122K affords (S)-2a in 50% ee and 75 % conv. 
(Appendix B, Table B3, entry 8). The highest (S)-selectivity for the reduction of 1d was 
obtained with S112R-N118P-K121A-S122M-L124Y, yielding (S)-2d in 55 % ee and 86 % 
conv. (Table B3, entry 22). 
Next, the saturation kinetic behavior of the bare cofactor and the best performing 
ATHases was determined (Scheme 8; Table B4). Variant K121A displays an 8-fold 
increased kcat value for the reduction of 1a compared to the bare cofactor. Moreover, both 
mutants S112A-N118P-K121A-S122M and S112R-N118P-K121A-S122M-L124Y display 
improved reaction rates for the reduction of 1a compared to the bare cofactor. Introducing a 
bulky tyrosine residue at position 124 has a dramatic effect on KM, increasing its value to 50 
mM from 7.4 mM for the bare cofactor. Both tested ATHases display very similar KM values, 
while their kcat differ significantly. This suggests that introducing a second bulky substituent 
contributes to stabilization of the reaction transition state, thus improving the reaction rate 
for the (S)-selective ATHase. Substrate inhibition is encountered for mutants K121A and 
S112R-N118P-K121A-S122M-L124Y, whereas the free cofactor and mutant S112A-
N118P-K121A-S122M display classical Michaelis–Menten kinetics. Unlike the results 
obtained with 1a, the reduction of 1c by ATHases revealed that none of the mutants could 
reach substrate inhibition due to limited solubility of 1c. Compared to the bare cofactor, all 
mutants display slightly higher kcat coupled with lower KM values. 
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Scheme 8. Saturation kinetic data for selected ATHases based on incorporation of [Cp*Ir(biot-p-
L)Cl] 3 (2 eq.) in various Sav isoforms (1 eq.) for the reduction of imine 1a or 1c. Error bars represent 
± standard deviation. 
To gain structural insight into the best performing ATHases, crystals of the most 
evolved variants were soaked with an excess of [Cp*Ir(biot-p-L)Cl] 3. Inspection of the X-
ray structure of [Cp*Ir(biot-p-L)Cl] ꞏ S112A-N118P-K121A-S122M (Figure 12a) highlights 
the structural similarities to the structure of [Cp*Ir(biot-p-L)Cl] ꞏ S112A.95,164 The overall 
ATHase structure and the position and absolute configuration of the piano stool moiety are 
virtually identical (RMSD of all C = 0.693). Due to potential steric clashes between two 
symmetry-related cofactors, the chloride ligand was not modeled. However, the crystal 
structure suggests the preferred formation of an (S)-configuration at the metal for 
[Cp*Ir(biot-p-L)Cl] (i.e. (R)-configuration for the catalytically active hydride [Cp*Ir(biot-
p-L)H]) (Figure B6a). The piano stool localization is stabilized by an H-bond between the 
A121 backbone carbonyl oxygen and the piano stool amine nitrogen. As the cationic lysine 
at position 121 is substituted by an apolar alanine, it prevents a possible interaction with the 
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imine nitrogen of the substrate. The non-concerted transition state allowing CH⋅⋅⋅π 
interaction between the Cp* moiety and the phenyl of 1c allows for the formation of (R)-2c. 
The X-ray structure of [Cp*Ir(biot-p-L)Cl] ꞏ S112R-N118P-K121A-S122M-L124Y (Figure 
3b) reveals that introducing bulky residues S112R and L124Y within the Sav monomer-
monomer interface results in a nearly 180° rotation of the piano stool moiety around the 
Cbenzene-Ssulfonamide bond. The position of the pianostool is stabilized by an H-bond between 
the Y124 hydroxyl and the cofactor amino group (Figure B7b,c). Unfortunately, no electron 
density was present to model the {Cp*IrCl} moiety. We speculate that is may be due to 
increased flexibility of the surface-exposed complex or partial dissociation of the {Cp*IrCl}. 
Increased cofactor exposure presumably leads to increased solvent exposure of the substrate 
(Figure S7b), reminiscent to the structure of [Cp*Ir(biot-p-L)Cl] ꞏ S112K (PDB 4OKA).95,164 
Importantly, both crystal structures of the evolved ATHases reveal increased atomic B-
factors within the loop-7,8 and the surface-exposed terminus of the cofactor when compared 
to published ATHases S112A and S112K (PDB 3PK2 and 4OKA) (Figure B10, Table 
B5).217,222 In the latter structures, the loop-7,8 is conformationally rigidified by an H-bonding 
network including i) the N118 side chain amide, ii) a water molecule and iii) the T115 
backbone amide. Mutation N118P results in elimination of this H-bonding network (Figure 
B11a). Additional flexibility is produced in loop 7,8 through mutation S122M that induces 
breaking of H-bonds in a Sav monomer-monomer interface (Figure B11b). These 
observations are reminiscent of the elevated atomic B-factors found in the crystal structure 
of a Sav-based metathase.112 
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 Figure 12. Close-up view of the crystal structure of [(Cp*)Ir(Biot-p-L)Cl] ꞏ S112A-N118P-K121A-
S122M (PDB 6ESS) (A) and [(Cp*)Ir(Biot-p-L)Cl] ꞏ S112R-N118P-K121A-S122M-L124Y (PDB 
6ESU) (B). The protein is displayed as transparent surface and cartoon model with mutations 
highlighted in red. For clarity, one cofactor per Sav tetramer is displayed. The cofactor is contoured 
with electron density from a 2FoFc map in marine (1.0 ) and an anomalous dispersion density map 
in red (4.0 ). Magenta atoms are not resolved in the electron density. 
Crystal structures were determined assuming saturation of Sav monomers by the 
cofactor. However, catalysis was performed under a 1:2 ratio of cofactor per Sav monomer. 
To structurally characterize the assemblies under catalytic conditions, Molecular Dynamics 
(MD) simulations were performed using an implicit solvent approach and applying 
metadynamics to initially boost the exploration of conformational space (see Appendix B). 
The achiral planar [Ir(III)] 16e- two-legged pianostool was considered. Conformations from 
the MD trajectories were grouped (clustered) based on the cofactor position in the vestibule. 
The number of configurations in each group (cluster) is displayed in Figure B13a,b together 
with an estimate of the interaction energy between the [Ir] complex excluding the biotin 
fragment and the protein (Figure B13c,d). Variant S112R-N118P-K121A-S122M-L124Y 
was computed to bind the cofactor more tightly than variant S112A-N118P-K121A-S122M. 
This observation may be explained based on the polarity of the residues in the vestibule, 
A B 
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which is more hydrophobic for S112A-N118P-K121A-S122M. Accordingly, the MD 
trajectory of S112R-N118P-K121A-S122M-L124Y shows reduced mobility of the cofactor 
compared to S112A-N118P-K121A-S122M. The conformation of the cofactor in the most 
populated cluster in the trajectory of S112A-N118P-K121A-S122M is very similar to the X-
ray determination (Figure B14a). However, further conformations are accessible to the 
cofactor via rotation around the S–N bond (Figure B14b). Similarly, the cofactor 
conformation in the most populated cluster in the trajectory of S112R-N118P-K121A-
S122M-L124Y is consistent with the X-ray structure (Figure B12c). 
Next, we used this structural insight to rationalize the opposite enantioselectivity 
resulting from the most evolved ATHases towards substrate 1c. For this purpose, we docked 
the protonated form of 1c to the representative structures of selected clusters. The resulting 
structures were energy-minimized, and the substrate binding energy estimated. We did not 
attempt to estimate reaction energies (i.e. with QM/MM methods). In the most populated 
cluster from the MD trajectory of S112R-N118P-K121A-S122M-L124Y, [Cp*Ir(biot-p-
L)H] leads to the formation of (R)-2c. The best docking solutions for the pro-R and pro-S 
faces of 1c project the phenyl substituent in a pocket formed by residues R112 and Y124 
from both monomers and P118 of the adjacent monomer. The difference between the two 
binding poses consists in the orientation of the imine plane: the NH group points towards 
the hydroxyl of tyrosine Y124 in the pro-S structure (Figure 13a), whereas it is rotated by 
180 degrees and does not display interactions in the pro-R structure (Figure 13b). From a 
docking point of view, the pro-R binding mode is slightly favored over the pro-S one. 
However, MD simulations starting from these structures reveal that the pro-R binding mode 
is not stable, whereas the pro-S displays a longer lifetime (i.e. about 200 ps). During this 
time, the NH group reorients to form an H-bond to the backbone carbonyl of A121. 
Therefore, we conclude that [Cp*Ir(biot-p-L)H] ꞏ S112R-N118P-K121A-S122M-L124Y 
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should preferentially reduce the pro-S face of 1c, an observation in agreement with the 
experiments. 
 
Figure 13. Substrate 1c docked to the most populated cluster from MD simulations of variants 
S112R-N118P-K121A-S122M-L124Y (panel a and b) and S112A-N118P-K121A-S122M (c). The 
cofactor is shown in blue stick, with the Cp* group in cyan and the Ir-H atoms as balls; the substrate 
is shown as sticks; the protein surface is shown in gray, with the residues within 4 Å colored by type: 
white for hydrophobic residues, green for polar, blue for positively charged. 
Concerning mutant S112A-N118P-K121A-S122M, docking of 1c to the representative 
structure of the most populated cluster (which would form the (R)-configuration of the metal-
hydride) results in a binding mode with no clear preference for the reduction of either the 
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pro-R or the pro-S faces of the substrate 1c. In this binding mode, 1c sits on the hydrophobic 
surface formed by residues L110, A112, T114, P118, A121, L124 (Figure 13c). We also 
considered binding of 1c to representative structures of other clusters. In all cases, binding 
was weaker than for the most populated. The MD simulations started from these bound 
structures did not reveal any alternative long-lived binding mode. It seems then that the ee 
observed experimentally for this mutant cannot be easily rationalized from a pure binding 
process and further aspects including the calculation of reaction barriers may be required. 
2.5.4 CONCLUSION 
In summary, introduction of [Cp*Ir(Biot-p-L)Cl] 3 within Sav isoforms affords ATHases. 
These can be optimized by directed evolution protocols using unpurified CFE, thus 
dramatically improving the throughput of the effort. Two mutants with increased reaction 
rates and enantioselectivities were identified for the reduction of cyclic imine 1c, allowing 
for the formation of both (R)-2c (95 % ee) and (S)-2c (86 % ee). The possibility of 
performing catalysis in a biphasic medium paves the way for greater scope of applications 
of such hybrid catalysts. 
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2.6.1 ABSTRACT 
ArMs based on the incorporation of a biotinylated metal cofactor within Sav combine 
attractive features of both enzymatic and homogeneous catalysis. To speed up their 
optimization, we present a directed evolution of an ATHase based on a streamlined and 
optimized protocol for the design, overexpression and screening of Sav isoforms. Ten 
positions have been subjected to mutagenesis to yield two variants with improved catalytic 
activity and selectivity for the reduction of cyclic imines, along with higher stability in a 
biphasic medium.  
2.6.2 INTRODUCTION 
Catalysis represents an essential technique in synthetic organic chemistry. Thanks to 
its extraordinary value, various synthetic systems, including organocatalysts, heterogeneous 
solids, enzymes and metal complexes, have been developed.263 Biocatalytic use of enzymes, 
either in the whole cell format, contained in cell lysates or as purified proteins, has proved 
useful in multiple industries, such as fine and bulk chemicals, cosmetics, textile, pulp and 
paper, food and pharmaceuticals.190,247,264-267 
Chiral amines serve as important intermediates in synthesis of fragrances and flavors, 
agrochemicals and biologically active compounds. Since approximately 40 % of all 
pharmaceuticals contain at least one chiral amine building block,118 the demand for their 
enantioselective synthesis is immense and multiple methods are available. Current strategies 
to produce enantiopure amines include resolution of racemates,130 organic synthesis119,121 or 
biocatalysis.122,126,251 Biocatalytic production of chiral amines can be achieved by direct 
enzymatic synthesis using phenylalanine ammonia lyases,139,268,269 
transaminases,134,135,270,271 imine reductases,142-145,272 and amine dehydrogenases,131,133 or by 
dynamic kinetic resolution by implementing lipases,153,155,156 or monoamine oxidases.148-
150,152 Industrial use of imine reductases represents a challenge, which is predominantly 
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caused by the restricted amount of available enzyme types, their price, finite substrate scope 
and low stability of their substrates in water or buffer. Development of novel imine 
reductases and optimization of their catalytic performance is therefore highly desirable. 
ArMs are created by incorporating a synthetic metal cofactor within a protein or a 
DNA scaffold.41,42,47227,525-254 Multiple anchoring strategies are available:43,44,65,272-274 
covalent, non-covalent, dative, and metal substitution. Since ArMs comprise of a biological 
and synthetic part, the performance of both components can be optimized independently. 
The selection of the macromolecular protein or DNA scaffold determines the anchoring 
strategy and the methods for its genetic optimization, whereas the rationally designed 
synthetic cofactor determines which type of reaction could be performed.104,224,225,273,274 The 
(strept)avidin-biotin (Sav-biot) technology[16] has been established as a very versatile 
anchoring strategy for the preparation of ArMs. Following the initial reports of ArMs by 
Wilson and Whitesides in 1978,47 multiple catalytic systems have been realized. These 
include allylic alkylation,109 C-H activation,104 metathesis,111,112 dihydroxylation,105 alcohol 
oxidation,106 sulfoxidation,107,108 hydrogenation,93,227,228 and transfer hydrogenation.95-103,221 
Noteworthy, some of these reactions do not exist in biological systems, ArMs have therefore 
brought new-to-nature chemical transformations into enzymatic catalysis.114,116,117,191,210 
ATHase has received an increased amount of attention, which resulted in their application 
in reduction of enones and ketones, and, more recently, of imines, NAD(P)+ and its analogs. 
To mimic the natural process of enzyme evolution, directed 
evolution67,113,169,176,189,204,210,259 was established by Arnold, Chen169 and Stemmer204 almost 
two decades ago. Since then, this powerful method has been used to fine-tune the selective 
formation of enantiomers, broaden the substrate acceptance of enzymes or to improve their 
stability in a targeted manner. This versatile methodology, comprising iterative cycles of 
mutagenesis followed by protein expression and their screening, can also be applied in the 
evolution of hybrid catalysts, allowing for their Darwinistic progression (Figure 14).176 
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Figure 14. Workflow for directed evolution of ArMs. Mutagenesis based on precise primers is 
followed by expression in E. coli. The lysed cells are treated with DiAm prior to the addition of a 
biotinylated cofactor, which leads to the constitution of an active artificial metalloenzyme with an 
ATHase activity. After screening and identification of a “hit”, the mutation of interest is used as a 
template for another round of mutagenesis. 
The development of high-throughput screening methods for evolution of ArMs has 
a bottleneck; the E. coli cellular environment contains millimolar concentrations of GSH and 
other metabolites capable of poisoning the soft metal containing catalyst.216,220 Screening 
utilizing protein purification is therefore often necessary. Since the workload increases 
exponentially with the increasing library size, a system circumventing the protein 
purification stage is highly desirable. Our group has recently described a streamlined 
optimization protocol222 that allows parallel in vivo expression of Sav in E. coli in a 24-deep 
well plate format. The cells are grown in an autoinduction medium based on low amount of 
glucose and high amounts of lactose. Upon consuming glucose, the expression of the 
recombinant protein is induced by lactose during the exponential growth phase, which allows 
for automated protein production without the need of manual induction. After cell harvest 
and lysis, the resulting CFE are treated with diamide. This GSH scavenger capable of 
oxidizing GSH to GSSG notably recovers the catalytic performance222 when applied to CFE 
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prior to the addition of the metal cofactor. Building upon this technique, we selected an area 
of 10 Å around the iridium center of the biotinylated cofactor anchored within the Sav active 
site and subjected the corresponding amino acids to targeted mutation. Our efforts in directed 
evolution of the ATHase resulted in four generations of mutant variants, which showed 
improved activity in transfer hydrogenation of various cyclic imine substrates.103 
2.6.3 DISCUSSION 
Based on our previous screening results, mature Sav with alanine at position 121 was 
selected for the library generation. In the first round of directed evolution, a reduced library 
of amino acids constituting of A, V, L, D, E, Q, K, H, M, Y, S, P, and N was introduced at 
positions T111, S112, G113, T114, A116, N118, S122, T123 and L124. In the following 
generations, all canonical amino acids were individually introduced relying on precise 
primers. The resulting mutants were overexpressed in E. coli using an autoinduction medium 
in 24-deep well plates. The harvested cells were lysed and the concentration of the biotin 
free binding sites in the resulting CFE was determined by means of a biotin-4-fluorescein 
absorption-fluorescence assay.222,237 The extracts were consequently treated with DiAm 
followed by the addition of [Cp*Ir(biot-p-L)Cl] 3 and screened for their ATHase activity a 
cyclic imine substrate (Scheme 9). After identification of a successful “hit”, the results were 
reproduced, the corresponding mutant overexpressed in 1L shaking flasks, purified using an 
iminobiotin affinity chromatography column and confirmed by screening in MOPS buffer 
using sodium formate as the hydride source. In these experiments, the ratio between Sav and 
[Cp*Ir(biot-p-L)Cl] was fixed to 2:1 to ensure optimal reaction rate and the selectivity.164 
The first generation screening revealed two mutants with an improved activity. In the 
reduction of 1c, an (S)-selective mutant S112R-K121A (Table 9, entry 5) was identified 
along with and an (R)-selective mutant N118P-K121A (entry 4), which was subjected to 
saturation mutagenesis at position S112. In the resulting second generation, mutant S112A-
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N118P-K121A yielded (R)-2c in 86 % ee and full conversion (entry 6). Introducing an 
additional substitution of serine to methionine at position 122 in the third generation further 
improved the selectivity and yielded (R)-2c in 92 % ee (entry 7).  
 
Scheme 9. Directed evolution of ATHase. (A) Structure of the biotinylated pianostool Cp*Ir cofactor 
3. (B) ATHase is created upon incorporation of the biotinylated cofactor within Sav. (C) Directed 
evolution tree of ATHase of a model cyclic imine 1c. 
The (S)-selective route was evolved starting from the arginine-containing mutant S112R-
K121A. Upon introducing proline at position 118 and methionine at position 122, the 
selectivity for (S)-2c was increased to 63 % ee (entry 10). 
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Table 9. Reduction of substrate 1c catalyzed by various ATHases using purified proteins.[a] 
Entry ATHase conv. (%) TON ee (%) 
1 [Cp*Ir(biot-p-L)Cl] 17 35 - 
2 K121A 99 198 54 (R) 
3 K121A [c] 5 100 31 (R) 
4 N118P-K121A 96 193 59 (R) 
5 S112R-K121A 36 72 -27 (S) 
6 S112A-N118P-K121A 100 200 86 (R) 
7 S112A-N118P-K121A-S122M 100 200 92 (R) 
8 S112A-N118P-K121A-S122M[b] 100 (70[d]) 200 91 (R) 
9 S112A-N118P-K121A-S122M[c] 19 380 95 (R) 
10 S112R-N118P-K121A-S122M 90 179 -63 (S) 
11 S112R-N118P-K121A-S122M-L124Y 100 200 -78 (S) 
12 S112R-N118P-K121A-S122M-L124Y[b] 75 (55[d]) 150 -72 (S) 
13 S112R-N118P-K121A-S122M-L124Y[c] 11 220 -85 (S) 
[a] Reactions were carried out with 10 mM substrate, 100 µM biotin binding sites and 50 µM 
[Cp*Ir(biot-p-L)Cl] at 37 °C for 48 h in 0.6 M MOPS and 3 M sodium formate at pH 6. [b] Reactions 
were carried out on a preparative scale (>120 mg of 1c) in 60 ml. [c] Reactions were carried out using 
a biphasic set-up with 100 mM substrate at RT for 4 days. [d] Isolated yield. 
In the last generation, the introduction of tyrosine at position 124 as a second bulky 
residue within the Sav active site further improved the (S)-selectivity and the mutant S112R-
N118P-K121A-S122M-L124Y yielded (S)-2c in 78 % ee and full conversion (entry 11). 
Preparative scale experiments, performed in degassed buffer and with >120 mg of 
substrate, resulted in full conversion (GC; 70 % after purification) and 91 % ee (R) for 
S112A-N118P-K121A-S122M Sav (entry 8) and 75 % conversion (GC; 55 % after 
purification) and 72 % ee (S) for S112R-N118P-K121A-S122M-L124Y Sav (entry 12). Due 
to the low water solubility of the cyclic imine selected for screening, experiments in a 
biphasic set up using 100 mM of substrate were performed. Both most evolved Sav variants 
performed better in the terms of enantioselectivity and TON (entries 9 and 13) compared to 
mutant K121A, representing the starting point of our directed evolution (entry 3). 
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Analysis of the obtained X-ray structure of [Cp*Ir(biot-p-L)Cl] ꞏ S112A-N118P-
K121A-S122M suggests formation of the catalytically active hydride form of Cp*Ir cofactor 
in (R)-configuration. The non-concerted transition state grants a formation of a CH⋅⋅⋅π 
interaction between the substrate and the Cp* moiety of the catalyst, thus predominantly 
producing the (R)-enantiomer of 2c. The crystal structure of [Cp*Ir(biot-p-L)Cl] ꞏ S112R-
N118P-K121A-S122M-L124Y revealed that the introduction of two bulky amino acid 
residues at positions 112 and 124 within the Sav active site resulted in an approximately 
180° rotation of the pianostool moiety around the Cbenzene-Ssulfonamide bond. The cofactor 
becomes more surface-exposed, which may lead to increased solvent exposure of the 
substrate. 103 
2.6.4 CONCLUSION  
In conclusion, introduction of a biotinylated pianostool Cp*Ir catalyst within Sav variants 
produces ATHases. Directed evolution of such hybrid catalysts using the streamlined 
optimization protocol for Sav production allows for screening hundreds of Sav variants 
contained in CFE, hence notably improving the throughput of the process. After only four 
rounds of directed evolution, two mutants with an improved activity and selectivity on the 
model cyclic imine substrate were identified. These mutants perform well on a preparative 
scale and under biphasic reaction conditions, thus implying a wide range of application 
possibilities. 
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CHAPTER III:  
ENCAPSULATION OF ARMS 
3.1 INTRODUCTION 
The design of ArMs represents an essential and far-reaching area of chemical biology 
and bioinorganic chemistry. Over the years, the main area of interest has shifted from 
understanding fundamental principles and mechanisms to providing potential utilization in 
nanoscience and biotechnology with possible industrial relevance. 
However, the potential of enzyme utilization is hindered by aging, fragility, 
operational instability under non-physiological conditions and susceptibility to protease 
digestion. To allow the implementation of biocatalysis in biotechnology and material 
science, the reusability and stability issues must be thoroughly scrutinized and addressed. 
Besides directed evolution and protein engineering, enzyme stability and 
performance can be improved by means of immobilization.275-279 This approach brings 
several advantages: i) possibility to modulate the catalytic properties, ii) increase in the 
catalytic turnover,101 iii) repeated or continuous use of catalyst, iv) easy separation from the 
reaction mixture, v) prevention from product contamination by the protein or catalyst, vi) 
enhanced protein stability,280, 281 and vii) possibility to develop efficient multi-enzyme 
cascades.282-286 
In spite of limitations279 such as limited mass transfer due to the diffusion effects and 
physical hindrance of the enzyme, rarely quantitative protein binding, high cost of the 
carrier, low weight of the protein compared to the carrier, significantly reduced catalytic 
activity / weight ratio of the final material, enzyme immobilization represents a successful 
method with applications ranging from diagnostics, food and chemicals to pharmaceutical 
industry.286-289  
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The most widespread strategies290-295 for enzyme immobilization include: i) physical 
adsorption on solid support,296, 297 ii) covalent attachment on solid support, iii) protein 
entrapment or iv) encapsulation in inorganic or organic polymer matrices and cages,298, 299 
or v) cross-linking (Figure 15).300, 301 
 
Figure 15. Techniques for the enzyme immobilization: a) covalent attachment to solid support b) 
physical adsorption c) entrapment and encapsulation d) cross-linking. 
The first three methods rely on the implementation of solid support, which either acts 
as a solid carrier or provides a mechanical compartment. The last option involves linking of 
the enzymes without the need of an additional support matrix. Each of the methods presented 
includes various advantages and disadvantages originating in the selection of the support 
and the physical or chemical process of attachment, which impact the protein stability, 
tertiary and quaternary structure and microenvironment (Table 10).292 
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Table 10. Advantages and disadvantages of immobilization strategies. 
Method Advantage Disadvantage 
Covalent 
Wide selection of supports 
Wide selection of linkers 
Tight binding 
Control of enzyme loading 
Compatible with harsh conditions 
(organic solvent, elevated temperature) 
Chemical modification of the 
protein 
Low activity / carrier weight 
Limited mass transfer 
Adsorption 
Reversible 
Inexpensive 
No chemical modification of the 
protein 
Weak binding 
Leaching 
Low protein stabilization 
Non-specific binding 
Limited mass transfer 
Entrapment and 
encapsulation 
No chemical modification of the 
protein 
Possible for whole cells 
Low protein stabilization 
Leaching 
Limited mass transfer 
Cross-linking 
High activity / carrier weight 
Compatible with harsh conditions 
(organic solvent, elevated temperature) 
Tight binding 
Possible for whole cells 
No carrier, lower price 
Chemical modification of the 
protein 
Limited mass transfer 
Low size control 
Often required crystallization 
 
3.2 IMMOBILIZATION ON NANOPARTICLES 
Immobilizing enzymes by covalent attachment to a solid support requires formation 
of a covalent bond between a reactive group present on the support and an amino acid side 
chain residue of the protein, such as thiol (cysteine), hydroxyl (serine, tyrosine, threonine), 
amine (histidine, lysine, guanidine group of arginine, N-terminus), or carboxylate (C-
terminus, glutamic and aspartic acid). Activation of carboxylic side chains relies on 
carbodiimide (RN=C=NR) activation, whereas amine-containing side chains can be cross-
linked to the surface using glutaraldehyde.302  
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 The selection of the solid support for enzyme immobilization is of crucial 
importance, as the characteristics of the matrix will have an impact on the performance of 
the enzyme. Ideal support characteristics include ease of derivatization, biocompatibility, 
resistance towards protease digestion, physical resistance to friction and compression, 
chemical resistance and low price. The options for support selection are wide, including: i) 
multiple natural polymers (starch, chitosan, sepharose, pectin, alginate, collagen, cellulose), 
ii) synthetic polymers and iii) inorganic materials (zeolites, silica, alumina, glass etc.).291  
 Silica-based carriers represent one of the most suitable supports for both industrial 
and research applications.303, 304 Nanoparticles305, 306 are an efficient carrier material, mainly 
due to their effective enzyme loading, the ease of catalyst separation, large and specific 
surface area, tunable size and the ability to minimize diffusional limitations. It has been 
demonstrated that immobilizing enzymes on nanoparticles reduces their denaturation and 
positively influences their stability and catalytic activity.307 Further embedment in a 
protective layer acts as a shield, which in turn affects the turnover rate of the immobilized 
enzyme.101, 308  
3.3 ENZYME ENTRAPMENT IN A PROTEIN CAGE 
 
Implementation of a tertiary coordination sphere around the catalyst,309 for instance 
by encapsulating the artificial metalloenzyme within a cage, could allow protection of the 
hybrid catalyst and further influence the catalytic activity. Moreover, the physical 
compartmentalization of molecular species allows for control of matter distribution.310-313 
Encapsulation in protein cages311, 314-316 offers an elegant implementation of molecular 
containers as reaction vessels, delivery vehicles or templates for controlled synthesis of 
nanomaterials and nanodevices.317-320 
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Ferritins are natural nanocages serving as iron-storing containers almost ubiquitously 
distributed321 among all life forms. Their spherical protein shell consists of 24 subunits of 
different ratios between the light (L-) and heavy (H-) ferritin subunits; horse spleen ferritin, 
often implemented for research purposes due to its low cost, contains approx. 90 % of L-
subunits.322, 323 The inner cavity of ferritin with outer and inner diameters of 12-13 and 7-8 
nm respectively, can accomodate up to 4500 Fe-atoms. Removal of the iron cluster produces 
apoferritin,324 a remarkably stable protein cage capable of withstanding extreme conditions, 
such as elevated temperature (up to 70°C), a wide pH range (2.0 – 10.0) and the presence of  
chemical denaturants (Figure 16a).325, 326 
 Figure 16. a) Structure of an octahedral ferritin (PDB 1BFR).341 The helixes in the bundle are colored 
orange (A helix), yellow (B helix), blue (C helix), green (D helix), red (E helix) and cyan (BC 
loop).342 b) pH-dependent structures of apoferritin. The intact spherical apoferritin is stable within 
the pH range 10.1 – 3.40. Below this range, apoferritin undergoes a step-wise disassociation that was 
found to be only pseudo-reversible.343 
Its spherical inner cavity, representing a convenient biotemplate in nanotechnology, 
has attracted widespread attention, as it allows encapsulation and delivery of drugs, nutrients, 
quantum dots, and imaging agents.327-339 Moreover, the apoferritin hollow can be utilized for 
nanoparticle synthesis and as a reaction vessel, allowing cellular uptake of its cargo.340 In 
the case of implementing Archaeoglobus fulgidus apoferritin, which contains large pores, 
proteins can be incorporated using electrostatic interactions with its negatively charged 
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cavity.332 Encapsulation of neutral proteins within the cavity of apoferritin should be 
possible, providing that the selected protein would retain its structure and activity under 
harsh reassociation conditions. Given its remarkable robustness,90, 91 Sav represents an ideal 
selection. 
A disassociation and reassociation route relying on the pH change can reversibly 
assemble the three-dimensional structure of apoferritin.344 This process has been shown to 
be pseudo-reversible, e.g. the reassembled apoferritin cage contains hole defects, which can 
be attributed to disassembly of several monomeric subunits (Figure 16b).343 However, these 
additional holes could theoretically be utilized for improving the transport of material during 
catalysis. 
By virtue of its unique properties and robustness, ferritin and apoferritin found 
numerous applications in various research fields such as biomedical applications, materials, 
electronic devices, biosensors and catalysis.333 So far, the apoferritin shell was utilized for 
encapsulation of ions,345-347 small molecules348-354 and catalysts338, 339, 355, 356 and size- 
controlled synthesis of nanoparticles.357-3360 Encapsulating enzymes within confined 
environments of protein cages such as apoferritin might pose interesting means to develop 
new biohybrid materials with potential in vivo delivery. 
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3.4 IMMOBILIZATION OF AN ARTIFICIAL IMINE REDUCTASE WITHIN 
SILICA NANOPARTICLES IMPROVES ITS PERFORMANCE 
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3.4.1 ABSTRACT 
Silica nanoparticles equipped with an artificial imine reductase display remarkable activity 
towards cyclic imine- and NAD+ reduction. The method, based on immobilization and 
protection of streptavidin on silica nanoparticles, shields the biotinylated metal cofactor 
against deactivation yielding over 46 000 turnovers in pure samples and 4000 turnovers in 
crude cellular extracts 
 
TOC 
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3.4.2 INTRODUCTION 
Catalysis plays a crucial role in a variety of scientific fields including synthetic 
organic chemistry. Given this importance, a wide range of synthetic systems, including 
heterogeneous solids, organocatalysts, metal complexes and enzymes, have been developed 
in the past century.263 Transition metal catalysts and enzymes possess complementary 
properties, which can be exploited in the synthesis of various enantiopure compounds.361 
The industrial use of enzymes is partially limited by their operational instability and, 
in some cases, high price.248 Therefore, significant efforts have been invested in developing 
immobilization strategies that may contribute to stabilize enzymes, while allowing their 
recycling.262 
An ArM results from the incorporation of a synthetic metal complex cofactor within 
a host protein.96 The biotin–streptavidin technology has been widely exploited to ensure the 
localization of a biotinylated cofactor within the host protein.72 As ArMs often bear a soft 
metal, cellular metabolites, including organosulfur compounds present in the E. coli cellular 
debris, frequently deactivate the metal.220 Such hybrid catalysts can be viewed as 
complementary to both homogeneous catalysts and enzymes.43,47,114,226,361,363-365 
d6-piano stool complexes have shown great potential for in vivo catalysis as they 
display promising stability in biological environments.366 With the aim of improving its 
catalytic performance, we set out to shield an ATHase in a protective organosilica layer on 
silica nanoparticles (SNPs) and evaluate its catalytic performance towards the reduction of 
imines and the regeneration of NAD+.95  Working on the development of nanomaterials 
endowed with virus recognition properties,367,368 we have designed a chemical strategy that 
allows embedding enzymes in a biomimetic and soft organosilica layer.369,370 
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3.4.3 RESULTS AND DISCUSSION 
In the present work, we have expanded this shielding strategy to artificial 
metalloenzymes and tested the resulting nanocatalysts for the reduction of cyclic imine 1a 
in the presence of various cellular extracts. As shown previously with soluble ArMs, 
embedding the biotinylated pianostool iridium complex [Cp*Ir(biot-p-L)Cl] 3 within 
various Sav mutants allows to access either (R)- and (S)-salsolidine 2a (Scheme 10), 
depending on the Sav mutant (Table 11). This observation ensures that the biotinylated 
cofactor [Cp*Ir(biot-p-L)Cl] is indeed incorporated within Sav, as the bare cofactor yields 
(rac)-2a. 
 Scheme 10. (a) Immobilization and protection of ATHase in a protective organosilica layer yielding 
active and protected nanoparticles. The ATHase is covalently anchored (1) on the surface of SNPs 
(dark grey), followed by self-assembly and polycondensation of silanes (2), which eventually build 
a protective layer (3). (b) ATHase of cyclic imine and structure of the iridium cofactors 3 and 22. 
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Table 11. Reactions performed using purified proteins. 
entry Sav mutant eea,b (%) Conv.a (%) TON 
1 Cp*Ir(biot-p-L)Cl]ꞏSav WT 38 70 140 
2 Cp*Ir(biot-p-L)Cl]ꞏS112A 87 89 178 
3 Cp*Ir(biot-p-L)Cl]ꞏS112K -70 86 173 
4 Cp*Ir(biot-p-L)Cl]ꞏK121A -35 99 198 
5 Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 79 98 196 
6 Cp*Ir(biot-p-L)Cl]ꞏR84A-S112A-K121A 68 99 198 
Reactions were performed in 200 µl of reaction mixture. [a] Enantiomeric excess and conversion were 
determined by HPLC analysis on a Chiracel-IC column. [b] Positive ee values correspond to (R)-2a 
and negative ee values correspond to (S)-2a. 
Single mutants [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav and [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav 
were selected for immobilization and protection. These ArMs afford opposite enantiomers 
of amine 2. Additionally, the double mutant [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav was 
selected for immobilization in view of its remarkable activity as purified ArM.161 
Native SNPs (240 nm in diameter) were prepared by the Stöber method.371 Next, in 
order to covalently anchor Sav on the surface of the nanoparticles, the SNPs were amino-
modified by incubation with (3-aminopropyl)-triethoxysilane (APTES) and further reacted 
with glutaraldehyde. Sav isoforms preincubated with the iridium cofactor, [Cp*Ir(biot-p-
L)Cl]ꞏS112A Sav, [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav and [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 
Sav, were immobilized at the surface of SNPs by reacting with the free aldehyde functions 
present at the surface of the SNPs. The synthesis of a protective organosilica layer was 
achieved by incubating the SNPs with tetraethyl orthosilicate and APTES for one- and four 
hours respectively, yielding protected SNPs (prot-SNPs, Figure 17). 
SNPs were imaged using a field emission scanning electron microscope (FESEM). 
The micrographs revealed monodisperse and well-defined nanoparticles with an average 
diameter of 260 nm. As illustrated in Figure 2, the SNPs equipped with the additional 
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protective silica layer (prot-SNPs) display a homogeneous size distribution with a diameter 
increase of approx. 10 nm upon protection. 
 Figure 17. Scanning electron micrographs of the SNPs; A: native amino-modified SNPs,  B: 
[Cp*Ir(biot-p-L)Cl]ꞏS112A@prot-SNP, C: [Cp*Ir(biot-p-L)Cl]ꞏS112K@prot-SNP and D: 
[Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@prot-SNP. The scale bar corresponds to 200 nm. 
Gratifyingly, immobilization and additional protection of the ATHase on the SNPs 
to yield [Cp*Ir(biot-p-L)Cl]ꞏSav@SNP and [Cp*Ir(biot-p-L)Cl]ꞏSav@prot-SNP 
respectively only led to a modest variation of the enantioselectivity of the hybrid catalyst 
towards the reduction of imine 1a (Table 11, entries 6 and 10). The activity (i.e. TON) of 
the SNPs was established based on the iridium concentration. This latter was determined by 
inductively coupled plasma mass spectrometry (ICP-MS) for each SNP batch. Dried SNPs 
contain approximately 0.04 ng Ir per mg SNPs. Salsolidine reduction using [Cp*Ir(biot-p-
L)Cl]ꞏS112A Sav SNPs yielded total TON of 4294 after 2 days (Table 12, entry 1). 
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Table 12. Asymmetric imine reduction yielding 2a using silica nanoparticles equipped with an 
artificial transfer hydrogenase. 
Entry Sav sourcea Ir conc.
b 
 µM 
eec,d  
(%) 
Conv.c  
(%) TON 
1 [Cp*Ir(biot-p-L)Cl]ꞏS112A@prot-SNP 2.6 90 56 4294 
2 [Cp*Ir(biot-p-L)Cl]ꞏS112A@prot-SNP ♳ 2.6 83 28 2172 
3 [Cp*Ir(biot-p-L)Cl]ꞏS112A@prot-SNP ♴ 2.6 80 24 1863 
4 [Cp*Ir(biot-p-L)Cl]ꞏS112A@prot-SNPe 2.6 88 22 16990 
5 [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav Purified proteinf 2.6 79 15 1154 
6 [Cp*Ir(biot-p-L)Cl]ꞏS112K@prot-SNP 1.2 -56 22 3775 
7 [Cp*Ir(biot-p-L)Cl]ꞏS112K@prot-SNP ♳ 1.2 -53 12 2000 
8 [Cp*Ir(biot-p-L)Cl]ꞏS112K@prot-SNP ♴ 1.2 -58 9 1580 
9 [Cp*Ir(biot-p-L)Cl]ꞏS112K@prot-SNP e 1.2 -48 10 16667 
10 [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav Purified proteinf 1.2 -66 5 833 
11 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@prot-SNP 1.5 70 97 12885 
12 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@prot-SNP ♳ 1.5 68 56 7294 
13 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@prot-SNP ♴ 1.5 67 50 6570 
14 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@prot-SNPe 1.5 76 36 46747 
15 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav Purified proteinf 1.5 89 19 2513 
16 native SNPs 0 0 0 0 
17 empty  prot-SNPs 0 0 0 0 
18 [Cp*Ir(biot-p-L)Cl] freeg 2.6 0 8 444 
19 [Cp*Ir(4C-L)Cl] freeg 80 0 42 104 
20 [Cp*Ir(4C-L)Cl]@prot-SNPs 80 0 26 66 
[a]Reactions performed in a reaction buffer using 1 mg of SNPs in 100 µl reaction mixture with 20 
mM substrate concentration for 48 hours, [b] Determined by means of ICP-MS, [c] The enantiomeric 
excess and conversion were determined by HPLC (see Appendix C). [d] Positive ee values correspond 
to (R)-2a and negative ee values correspond to (S)-2a, [e] Reactions performed with 200 mM 
substrate. [f] Reactions were performed with free purified enzymes with the same iridium 
concentration as use with SNPs, [g] Reactions performed without the presence of Sav using the 
iridium ligand 22 [Cp*Ir(4C-L)Cl] in reaction buffer.   
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In line with the performance of the soluble ArM, the immobilized [Cp*Ir(biot-p-
L)Cl]ꞏS112A-K121A Sav@prot-SNP yielded the best results, with TON of 12’885 and 
almost full conversion (entry 11). Upon increasing the substrate concentration (200 mM), a 
TON of 46’747 was obtained using SNPs with [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 
Sav@prot-SNP (entry 14). Compared to the homogeneous ArMs (entries 5, 10 and 15 
respectively), the TONs are significantly increased, at the cost of slight erosion in selectivity. 
We hypothesize that the increased TON rates result from the protective effect of 
organosilane layer and, partly, by the hydrophobicity around the enzyme within the layer. 
The preferential formation of enantioenriched salsolidine 1a, depending on the Sav mutant, 
unambiguously demonstrates that the SNPs indeed contain the intact ArMs with preserved 
quaternary structure.  Importantly, the SNPs can be recycled at least twice (♳ and ♴), at 
the cost of an erosion in conversion (entries 2, 3, 7, 8, 12 and 13), yet with virtually the same 
enantiomeric excess. 
Control experiments with native SNPs or SNPs without the presence of Sav (e.g. 
empty SNPs) did not show any activity towards NAD+ or imine reduction (entries 16 and 
17). To address the synergistic effect of the silica layer and the streptavidin host on the 
catalytic performance of the iridium cofactor, a non-biotinylated [Cp*Ir(4C-L)Cl] analog 22 
was synthesized, immobilized and protected within SNPs ([Cp*Ir(4C-L)Cl]@prot-SNP). In 
contrast to the ArM, upon immobilization, the activity of ([Cp*Ir(4C-L)Cl]@prot-SNP 
decreases upon mineralization within SNPs, (Table 12, entries 19-20). 
We have also demonstrated the stability of enantioselectivity over time (see 
Appendix C). The time-point assay showed only a slight erosion of enantioselectivity over 
the course of 7 days (decrease of 11 %), which could be explained by disruption of the 
protective layer and leakage of the catalyst caused by friction in solution.370 However, the 
ICP-MS measurements of the reaction medium after the reaction showed only traces of 
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leaked iridium. We thus argue that the decrease of activity is predominantly caused by loss 
of material during centrifugation and wash cycles.  
With biomedical applications372 in mind, we evaluated the regeneration of NAD+ by 
[Cp*Ir(biot-p-L)Cl]ꞏS112A Sav@prot-SNP. For this purpose, the formation of NADH was 
monitored by absorbance spectroscopy at 340 nm (Appendix C). The results confirm that 
the immobilization does not significantly affect the catalytic properties of the hybrid 
catalysts towards the NAD+ reduction. The protected catalyst [Cp*Ir(biot-p-
L)Cl]ꞏSav@prot-SNP has an initial lower reaction rate, but overall slightly improved TONs 
compared to [Cp*Ir(biot-p-L)Cl]ꞏSav. 
In order to test the compatibility of SNPs with complex cellular media, we performed 
experiments in the presence of E. coli cell lysates. In stark contrast to the homogenous ArMs, 
which lose most of their activity in the presence of cellular debris solution, the SNPs partially 
maintained their catalytic activity. Up to 80 TONs were achieved with [Cp*Ir(biot-p-
L)Cl]ꞏS112A Sav@prot-SNPs and 171 TONs with [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav@prot-
SNPs (for detailed data see Supporting Information). Other complex media were evaluated 
with [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav @prot-SNPs (Table 13). 
Up to 4’500 TONs were obtained upon performing the imine reduction in urine. 
SNPs maintain their catalytic activity also in the presence of methanol (4’000 TONs, 
accompanied by an erosion in ee), which results in protein denaturation without the presence 
of protective organosilane layer and a complete loss of activity (Table 13, entries 9 and 10). 
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Table 13. Asymmetric imine reduction yielding 2a using [Cp*Ir(biot-p-L)Cl]·S112A-K121A 
Sav@prot-SNP. 
Entry SNP Cellular  debrisa 
ee 
(%)b,c 
Conv. 
(%)b TON
1 
[Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 
Sav@prot-SNP 
milk 41 24 2569
2 yeast extract 37 1 158 
3 urine pH 6 25 11 4554
4 blood pH 7 35 1 392 
5 blood serum 27 6 862 
6 empty vector CFE 89 3 1873
7 empty vector CL 33 1 132 
8 GSH 5 mM 30 0.15 20 
9 MeOH 50 % 14 30 4024
10 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav Purified proteind MeOH 50 % 0 0 0 
Reactions were performed in a reaction buffer using 1 mg of SNPs in 100 µl reaction mixture with 
20 mM substrate concentration at RT for 48 h; [a] Reaction mixture contained 48 µl of crude cellular 
extract, organic solvent or stock solution of glutathione, [b] Enantiomeric excess and conversion were 
determined by HPLC analysis on a Chiracel-IC column. [c] Positive ee values correspond to (R)-2a 
and negative ee values correspond to (S)-2a, [d] Reaction performed with purified protein without any 
protection against the organic solvent. 
The catalytic experiments reported herein reveal several noteworthy features: 
(i) Immobilization of Sav isoforms on silica nanoparticles and their protection with 
organosilane layer yields catalysts with higher turnover number rates compared 
to the use of purified proteins. 
(ii) Such nanoparticles can be recycled up to three times with only a slight erosion 
in selectivity. Protected catalysts can withstand the presence of cellular debris 
without the need of diamide pretreatment220. 
(iii) The protective layer also prevents the protein denaturation in the presence of 
chaotropic agents. 
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3.4.4. CONCLUSION 
In summary, we have successfully developed an artificial biocatalyst consisting of a 
pianostool iridium cofactor within Sav immobilized in SNPs. These nanoparticles display 
remarkable catalytic activity with TON ˃ 46'000 using aqueous solutions and TON ˃ 4'000 
in the presence of cellular debris. Presented SNPs offer interesting perspectives towards 
green chemistry as they operate under nearly physiological conditions and can be recycled 
with only a slight erosion of reactivity. Immobilization and protection of artificial 
metalloenzymes on silica nanoparticles represents a promising technique for activity 
enhancement of such hybrid catalysts. The next steps will include cellular uptake and 
engineering enzyme cascades incorporating natural and artificial metalloenzymes within 
SNPs. 
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3.5.1 ABSTRACT 
Ferritin, a naturally occuring iron-storage protein, plays an important role in 
nanoengineering and biomedical applications. Upon iron removal, apoferritin was shown to 
allow the encapsulation of an artificial transfer hydrogenase (ATHase) based on the 
streptavidin-biotin technology. The third coordination sphere, provided by ferritin, 
significantly influences the catalytic activity of an ATHase for the reduction of cyclic imines.  
TOC 
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3.5.2 INTRODUCTION 
Biocatalysis is an attractive means to prepare high-added value products under 
environmentally benign conditions. Over the past few decades, the use of biocatalysis has 
expanded significantly and is now widely applied for the synthesis of chemicals, 
pharmaceuticals, fragrances etc.35, 247, 364-366, 373 To expand the rather limited biocatalytic 
repertoire, ArMs have attracted increasing attention.114, 361  
ArMs, that result from the incorporation of an organometallic moiety within a protein 
or DNA scaffold, combine attractive features of both enzymatic and homogeneous transition 
metal catalysis.41, 42, 47, 103, 116,207, 227, 253, 254 To ensure the localization of the cofactor within 
the scaffold, the biot-Sav technology has found widespread use.73, 81, 96, 255 The protein 
scaffold provides a well-defined second coordination sphere around the metal moiety, and 
interacts with the cofactor, the substrates and intermediates. Accordingly, it significantly 
affects the selectivity and reaction rate of the ArM.207, 43, 374-378 
Inspection of the X-ray structures of various ArM based on the biot-Sav technology 
reveal that the biotinylated cofactor is partially solvent-exposed.103, 95, 164, 211 Efforts to 
genetically engineer the biotin-binding vestibule by introduction of various extended loops 
has shown promise.379 Building on our experience with mineralizing ArMs within silica 
nanoparticles,101 we reasoned that one could fully encapsulate an ATHase within a hallow 
protein shell. This additional protein environment, which provides the tertiary coordination 
sphere to the ArM309 was anticipated to influence the catalytic activity, both in terms of 
activity and selectivity.  
Inspection of the size of homotetrameric Sav (4.5 nm ꞏ 5.5 nm ꞏ 5.1 nm) led us to 
hypothesize that ferritin (from horse spleen, inner diameter 7-8 nm) may offer and ideal 
capsule to host an ArM (Figure 18). Herein, we report on our efforts to compartmentalize an 
ATHase based on the biotin-streptavidin technology within apoferritin.  
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Figure 18. Apoferritin (indigo cartoon display, PDB code: 5c6f) offers a commensurate hollow to 
encapsulate an artificial metalloenzyme based on the biotin-streptavidin technology (Sav, magenta 
cartoon display, the [Cp*Ir(biot-p-L)Cl] cofactor, blue, is displayed as space-filling; PDB code: 
3pk2). The model was generated by manually docking the ATHase within apoferritin. 
3.5.3 RESULTS AND DISCUSSION 
Building on our experience with ATHase relying on the [Cp*Ir(biot-p-L)Cl] cofactor, we set 
out to encapsulate the preassembled ArM [Cp*Ir(biot-p-L)Cl]ꞏSav within the cavity of horse 
spleen apoferritin. The following Sav mutants pre-assembled with the biotinylated iridium 
catalyst were selected for encapsulation: [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav (an (R)-selective 
imine reductase), [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav (an (S)-selective imine reductase) and 
[Cp*Ir(biot-p-L)Cl]ꞏK121A-S112A Sav (the most active imine reductase based on the biot-
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Sav complex).101,162 The ATHase was encapsulated within ferritin (ATHase@ferritin) by 
disassembling apoferritin upon decreasing the pH < 2. Upon increasing the pH to 8, the 
quaternary structure of ferritin is restored, thus allowing to encapsulate cargoes that are 
commensurate with the interior diameter of apoferritin. This strategy has been used to 
encapsulate various small molecules, nanoparticles, nanocrystals etc.328-336 To the best of our 
knowledge however, this approach has not been used to encapsulate proteins within 
apoferritin. 
To highlight the encapsulation of Sav upon reassembly of the ferritin cage, we 
selected Sav equipped with one equivalent of a fluorescent biotinylated probe per four free 
biotin binding sites (fbs) of Sav. Accordingly, Sav S112A (tetramer, containing four fbs) 
was preincubated with one equivalent of biotin-4-fluorescein (B4F hereafter) and added to 
apoferritin at pH = 2 (i.e. disassembled apoferritin). Upon increasing the pH to 8, B4FꞏSav 
S112A is encapsulated within ferritin (B4FꞏSav S112A@ferritin hereafter). To remove the 
unspecifically adsorbed B4FꞏSav S112A from the outer-surface of apoferritin, the solution 
was treated at pH = 8 with iminobiotin-sepharose beads and washed extensively. The 
iminobiotin moiety binds to free biotin-binding sites present in B4FꞏSav S112A, thus 
allowing to remove B4FꞏSav S112A that is not encapsulated within apoferritin by means of 
centrifugation and filtration. The solution that contains B4FꞏSav S112A@ferritin was then 
subjected to preparative size-exclusion chromatography (SEC). 
Fluorescence analysis of the ferritin band unambiguously revealed the presence of 
B4F. As no fluorescence was detected upon adding B4F (instead of B4FꞏSav) by means of 
size-exclusion chromatography (See Appendix D, Figure D1), we hypothesize that B4FꞏSav 
S112A@ferritin is formed (Figure 19). 
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Figure 19. Preparative size-exclusion chromatogram of B4FꞏS112A-K121A Sav@ferritin. The blue 
line indicates absorbance at 280 nm. The absorbance at 495 nm (red trace) shows that B4F co-elutes 
with the apoferritin cage at 65 mL (run in 50 mM Tris-HCl, 100 mM NaCl, pH 8.0). 
Having highlighted the formation of B4FꞏSav S112A@ferritin by fluorescence, we 
proceeded to encapsulate various ATHases in apoferritin following the same protocol. The 
resulting ATHases [Cp*Ir(biot-p-L)Cl]ꞏS112A@ferritin, [Cp*Ir(biot-p-
L)Cl]ꞏS112K@ferritin and [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@ferritin were purified by 
preparative SEC (Figure D2).  
The presence of iridium in the purified Sav@ferritin samples was confirmed by 
means of ICP-MS. Upon sample digestion, the samples were diluted and directly analyzed. 
Dynamic light scattering (DLS) measurements of the combined fractions containing 
the assembled ferritin shells revealed an increase in particle diameter of approx. 20% (Table 
D1). This observation suggests that the ATHase is indeed located within ferritin. 
The presence of the ATHase within the ferritin cage [Cp*Ir(biot-p-
L)Cl]ꞏSav@ferritin was further confirmed by comparison of the SDS- and native PAGE 
analysis. Under native conditions, the samples containing [Cp*Ir(biot-p-L)Cl]ꞏSav@ferritin 
revealed no band attributable to Sav (Figure D3). In contrast, under denaturing conditions, 
the Sav was released from the denatured ferritin cage and could be visualized by B4F on the 
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SDS PAGE, as it contained two available fbs sites. Due to the remarkable stability of 
homotetrameric Sav, Sav maintained its tetrameric structure and biotin-binding activity, 
even under denaturing SDS PAGE conditions (Figure D4). In stark contrast, native PAGE 
analysis of a 1:1 mixture of [Cp*Ir(biot-p-L)Cl]ꞏSav and apoferritin revealed two bands 
(Figure D4, lane 5). This demonstrates that [Cp*Ir(biot-p-L)Cl]ꞏSav is encapsulated within 
ferritin, rather than unspecifically adsorbed on the outer-surface of ferritin, thus confirming 
the DLS observations. 
Next, the encapsulated ATHases were tested for the reduction of cyclic imines 1a 
and 1c (Scheme 11). To determine the turnover number of the encapsulated ATHases (TON), 
ICP-MS analysis of samples containing Ir as [Cp*Ir(biot-p-L)Cl]ꞏSav@ferritin was carried 
out. The catalytic performance of the ATHases [Cp*Ir(biot-p-L)Cl]ꞏSav@ferritin was 
compared to the corresponding "free" ATHases: [Cp*Ir(biot-p-L)Cl]ꞏSav. 
 
 
Scheme 11. Reduction of cyclic imines 1a and 1c using the ATHase. 
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Since the isoquinoline substrates are protonated under the reaction conditions,95 they 
can penetrate through the ferritin 3-fold channels. In line with this assumption, we observed 
catalysis with all encapsulated ATHases. 
All tested [Cp*Ir(biot-p-L)Cl]ꞏSav@ferritin, afforded preferentially (S)-2a. This 
contrasts with [Cp*Ir(biot-p-L)Cl]ꞏSav, which affords either (R)-2a or (S)-2a, depending on 
the Sav mutant: i) [Cp*Ir(biot-p-L)Cl]ꞏSav S112A affords 2a in 75 % ee (R) and 35 % 
conversion (Table 14, entry 3) and [Cp*Ir(biot-p-L)Cl]ꞏSav S112K affords 2a in 41 % ee 
(S) and 20 % conversion (Table 14, entry 5). Reduction of imine 1a in the presence of the 
encapsulated [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav@ferritin affords (S)- 2a in 46 % ee (S) (Table 
14, entry 11). 
Similarly, catalysis with [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav yields 2a in 60 % 
ee (R) and 90 % conversion (Table 14, entry 7), while the encapsulated [Cp*Ir(biot-p-
L)Cl]ꞏS112A-K121A Sav@ferritin affords (S)-2a in 44 % ee (Table 14, entry 15). Control 
experiments with [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav at 1 µM catalyst loading afforded 
56 % ee (R)-2a and 72 TON. 
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Table 14. Results obtained from the reduction of cyclic imine 1a or 1c. The reactions were performed 
using 20 mM substrate concentration at 37°C for 48 h (See Appendix D for experimental details). 
Entry Catalyst [Ir] (µM)a Sub.
ee (%)b, 
c  
conv. 
(%)b TON
d 
1 [Cp*Ir(biot-p-L)Cl]  50 1a rac. 16 65 
2 [Cp*Ir(biot-p-L)Cl]  50 1c rac. 18 71 
3 [Cp*Ir(biot-p-L)Cl]ꞏS112A 50 1a 75 35 142 
4 [Cp*Ir(biot-p-L)Cl]ꞏS112A 50 1c 43 39 154 
5 [Cp*Ir(biot-p-L)Cl]ꞏS112K 50 1a -41 25 20 
6 [Cp*Ir(biot-p-L)Cl]ꞏS112K 50 1c 57 6 24 
7 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 50 1a 59 90 358 
8 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 50 1c 69 72 289 
9 [Cp*Ir(biot-p-L)Cl]@ferritin 1.24d 1a 0 0.08 13 
10 [Cp*Ir(biot-p-L)Cl]@ferritin 1.24d 1b 0 5 853 
11 [Cp*Ir(biot-p-L)Cl]ꞏS112A@ferritin 0.42d 1a -46 0.16 74 
12 [Cp*Ir(biot-p-L)Cl]ꞏS112A@ferritin 0.42d 1c 24 5.58 2880 
13 [Cp*Ir(biot-p-L)Cl]ꞏS112K@ferritin 0.40d 1a -47 0.09 46 
14 [Cp*Ir(biot-p-L)Cl]ꞏS112K@ferritin 0.40d 1c 24 5.57 2731 
15 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@ferritin 0.28
d 1a -44 0.17 117 
16 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A@ferritin 0.28
d 1c 20 5.55 3874 
17 S112A-K121A@ferritin 0 1a 0 0 0 
18 S112A-K121A@ferritin 0 1c 0 0 0 
19 Apoferritin 0 1a 0 0 0 
20 Apoferritin 0 1c 0 0 0 
21 Apoferritin + [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 50 1a 55 85 340 
22 Apoferritin + [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 50 1c 64 69 276 
23 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 1 1a 56 0.36 72 
24 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 1 1c 35 6 1108 
a Enantiomeric excess and conversion were determined by HPLC analysis. b Positive ee values 
correspond to (R)-product and negative ee values correspond to (S)-product. c Values were calculated 
based on the ICP-MS measurement of each batch (see Appendix D for details). 
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In the reduction of the less bulky 1c, no inversion of enantioselectivity was observed 
in any of the tested encapsulated ATHases. However, the TONs have tripled with 
[Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav@ferritin (entry 16) compared to the use of the free 
ATHase in buffer under similar conditions (entry 24). Similar TONs were also obtained for 
[Cp*Ir(biot-p-L)Cl]ꞏS112A@ferritin, which afforded (R)-2c in 24 % ee and 2880 TON. The 
[Cp*Ir(biot-p-L)Cl]ꞏS112K@ferritin afforded (R)-2c in 24 % ee and 2731 TON. 
The effect on enantioselectivity and catalytic efficiency of the encapsulated ATHases 
depends on both the substrate and the used Sav mutant. Further studies in regards to the 
effect of point-mutations on the kinetic behavior of the hybrid catalysts are currently 
undergoing in our research group. 
3.5.4. CONCLUSION 
Overall, these findings highlight the influence of the third coordination sphere on the 
catalytic performance of the ferritin-encapsulated ATHases. 
Taking advantage of the reversible dissociation and reassembly of apoferritin, we 
have compartmentalized an artificial metalloenzyme within a protein cage. The resulting 
ATHases maintained their catalytic activity, displaying up to > 3800 TON for the reduction 
of cyclic imines. The marked variation in enantioselectivity, observed upon ATHase 
encapsulation, highlights the combined effect of both the second- and third coordination 
sphere provided by Sav and ferritin respectively. 
These results highlight the possibility to encapsulate an ArM within ferritin following 
a reassembly route. The significant improvement in TON compared to the free ArM suggests 
that this strategy may offer an attractive means to protect a precious metal in a cellular 
environment and possibly to deliver it in vivo, without eliciting an immune response.380, 381
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SUMMARY AND OUTLOOK 
Artificial metalloenzymes have emerged as a promising and valuable approach to 
combine the attractive features of homogeneous catalysis, enzymatic catalysis and the vast 
reaction repertoire of metal-catalyzed chemical transformations. This doctoral thesis 
represents our optimization efforts of the activity of an artificial imine reductase based on 
the streptavidin-biotin technology by either genetic or nanotechnological means.  
First, the limitation of cellular matrix and the throughput of our screening efforts was 
addressed. Chapter II describes a design of a library of potentially active streptavidin mutants 
for the creation of artificial metalloenzymes and their following application in high 
throughput screening. Upon mutating 28 positions within the streptavidin active site lying in 
close proximity of the metal center of the catalyst, a library consisting of 335 mutants was 
prepared. Their implementation in two different reaction types was proven effective even 
without the need of protein purification and resulted in only 10 % deviations in conversion 
(results from 90 replicates of the same mutant). Following the optimized protocol, we 
continued with our efforts in directed evolution of an artificial imine reductase. After only 
four rounds of mutagenesis, expression and screening, two improved streptavidin variants 
with higher selectivity and activity toward the reduction of three cyclic imine substrates were 
identified. Moreover, these two variants were found to be active even in the presence of 
organic solvents, thus demonstrating the potential for future industrial utilization. 
The second chapter describes optimization of an artificial imine reductase for nano 
applications by immobilization on silica nanoparticles or by encapsulation within a ferritin 
nanocage. Our efforts in immobilization of three artificial imine reductases on silica 
nanoparticles followed by their protection in a soft organosilane layer yielded immobilized 
catalysts with remarkably higher activity compared to free hybrid catalysts. The soft 
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organosilane layer, resulting from polycondensation of two types of organosilanes, allows 
for substrate diffusion, and simultaneously shields the metal cofactor from various 
chaotropic agents such as methanol, glutathione and complex cellular media such as blood, 
urine, cell lysates and milk. The protected catalysts yielded over 46 000 turnovers in pure 
samples and 4000 turnovers in crude cellular extracts. Encapsulation of the artificial imine 
reductase within a ferritin nanocage brought an additional advantage; the complex 
microenvironment created by the protein cage serves as a tertiary coordination sphere for the 
metal catalyst within streptavidin. Upon encapsulation, the hybrid catalyst yielded over 3800 
turnovers in the reduction of cyclic imines and demonstrated different enantioselectivity 
when compared to the performance of the free artificial imine reductase. 
In the future, the nano-optimized versions of artificial metalloenzymes could be 
further optimized by introducing mutations within the apoferritin scaffold. The immobilized 
hybrid catalysts protected in organosilane layer represent an intriguing possibility of 
preparing a flow-reactor for the production of enantioenriched or enantiopure cyclic imines. 
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A.1 MATERIALS 
All commercially available chemicals were purchased from commercial suppliers (Sigma-
Aldrich, ABCR,Acros Organics, Alfa Aesar, AppliChem, Baker, BD, NEB, AnaSpec, Fisher 
Scientific, Fluka, Merck, or WWR) and used without further purification. E. coli bacterial 
strains (BL21 and TOP10) were purchased from NEB or Invitrogen, respectively. Empty 
vector plasmid pET-24a empty vector was purchased from Novagen.  
PCR reactions were performed with an Eppendorf Mastercycler Gradient. 1H and 13C spectra were 
recorded on a Bruker 400 MHz. The chemical shifts (δ) are reported in parts per million (ppm) 
relative to tetramethylsilane or a residual solvent peak. Analyses of the catalytic runs were performed 
on an Agilent 1100 normal phase HPLC with an analytical Chiralpak IC column (250 ꞏ 4.6 mm, 5 
μm), GC using Agilent CAM column (30 m x 0.25 µm) and CP-Chirasil-DEX CB (25m x 0.25 µm) 
using He as carrier gas, or by Aquity UPLC H-Class Bio from Waters using BEH C18 column 1.7 
µm, 2.1 x 50 mm for UPLC 
. The absorbance spectra were measured on a microplate reader Tecan, model Infinite M200. 
E. coli strains used: 
 TOP10 (Invitrogen, cat. no. C4040): F− mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δlac×74 recA1 araD139 Δ(araleu)7697 galU galK rpsL (StrR) endA1 nupG 
 BL21 (DE3; NEB, cat. no. C2527): E. coli B F−dcm ompT hsdS(rB−mB−) gal λ(DE3) 
A.2. REAGENT SETUP 
20xZYP-salts: Dissolve 1 M KH2PO4 (54.4 g), 1 M Na2HPO4 (56.8 g) and 0.5 M (NH4)2SO4 (26.4 
g) in MQ water (final volume of 400 ml)33. Autoclave (121°C for 20 min). The sterile solution can 
be stored at room temperature (RT corresponds to 25°C) for years. 
20xZYP-sugar: Dissolve 10 % (v/v) anhydrous glycerol (40 ml), 55.5 mM glucose-monohydrate 
(4.4 g) and 4 % (w/v) Lactose XM (16 g) in MQ water (final volume of 400 ml)33. Sterile filter with 
a cutoff of 0.22 µm. The sterile solution can be stored at 4°C for up to one year. 
100xMgSO4: Dissolve 200 mM MgSO4 (2.46 g) in MQ water (50 ml). Autoclave (121°C for 20 
min). The sterile solution can be stored at 4°C for years. 
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Normal ZYP-5052 Medium: Dissolve tryptone (8 g) and yeast extract (4 g) in 712 ml MQ water 
and autoclave (121°C for 20 min)33. Add 20xZYP-salts (40 ml), 20xZYP-sugar (40 ml) and MgSO4 
(8 ml) to the media. The sterile solution (without antibiotic) can be stored at 4°C for up to one year. 
Modified ZYP-5052 Medium: Dissolve tryptone (8 g) and yeast extract (4 g) in 664 ml MQ water 
and autoclave (121°C for 20 min). Add 20xZYP-salts (40 ml), 20xZYP sugar (80 ml) and MgSO4 
(16 ml) to the media. The sterile solution (without antibiotic) can be stored at 4°C for up to one year. 
Lysogeny Broth (LB): Dissolve 1 % tryptone (10 g), 0.5 % yeast extract and 1 % NaCl in MQ water 
(final volume of 1 l). Adjust pH to 7 using NaOH41. For LB-agar plates, use the same recipe but add 
1.5 % agar (15 g, bacteriology grade). Autoclave (121°C for 20 min). For agar plates, cool to 55°C, 
add antibiotic and pour plates. The sterile solution (without antibiotic) can be stored at 4°C for up to 
one year. The plates can be stored at 4°C for up to 3 months (for kanamycin). 
LBSoc: Dissolve 2 % tryptone (2 g), 0.5 % yeast extract (0.5 g), 10 mM NaCl (0.05 g) and 2.5 mM 
KCl (0.019 g) in MQ water (final volume of 100 ml). Adjust pH to 7 using NaOH.42 Autoclave 
(121°C for 20 min) and add filter sterilized solutions (0.22 µm cutoff) of 1 M MgCl2 (1 ml), 1 M 
MgSO4 (1 ml) and 1 M glucose (2 ml).  The sterile solution (without antibiotic) can be stored at 4°C 
for up to one year. 
LBSOB: Same composition as LBSoc but without glucose42. The sterile solution (without antibiotic) 
can be stored at 4°C for up to one year. 
RF 1-buffer: Weigh RbCl (100 mM, 2.42 g), MnCl2 x 4 H2O (50 mM, 1.98 g); KOAc (30 mM, 0.59 
g) and CaCl2 x 2 H2O (10 mM, 0.29 g) and fill up with 15 % (v/v) Glycerol (200 ml final volume). 
Set the pH to 5.8 using 0.2 M CH3COOH and filter sterilize solution43. Solution can be prepared in 
advance and stored at 2-8°C for up to 6 months. 
RF 2-buffer: Weigh in RbCl (10 mM); CaCl2 x 2 H2O (75 mM) and MOPS (10 mM) and fill up with 
15 % (v/v) glycerol in MQ water (50 ml final volume). Set the pH to 7 using NaOH and filter-sterilize 
the solution43. Solution can be prepared in advance and stored at 2-8°C for up to 6 months. 
Reaction buffer for ATHase: Dissolve MOPS (12.556 g) and sodium formate (20.403 g) in MQ 
water (final volume 50 ml) to obtain final concentrations of 1.2 M MOPS and 6 M formate. Adjust 
the pH to 6 using NaOH Solution can be prepared in advance and stored up to 6 months at 2-8°C. 
ATHase substrate stock solution: Dissolve 1-phenyl-3,4-dihydroisoquinoline 1c (165.8 mg, final 
concentration 400 mM) in DMSO (2 ml). Solution can be prepared in advance and stored up to 6 
months at 2-8°C. 
ATHase stock solution of the iridium catalyst: Dissolve [Cp*Ir(biot-p-L)Cl] ( (1.6 mg, final 
concentration of 2 mM) in DMSO (1 ml). This solution can be stored at 4° for 30 days. 
Diamide stock solution: Dissolve 1,1`-Azobis(N,N-dimethylformamide) [72.5 mg, final 
concentration 200 mM] in DMSO (2 ml). This solution needs to be prepared freshly before each 
catalysis campaign.  
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Lysis buffer for ATHase or methathesis: Dissolve MOPS (ATHase, 522.9 mg, final concentration 
50 mM) in MQ water (50 ml) or use PBS (metathesase, 12 mM phosphate, pH 7.5). Adjust the pH 
to 7.4 with NaOH. Dissolve lysozyme (20 mg) and DNAseI (20 µg) in this buffer (20 ml final 
volume). This solution needs to be prepared freshly before each catalysis campaign. 
FBS Assay buffer: Dissolve MOPS (ATHase, 2092 mg, final concentration 100 mM) in MQ water 
(100 ml). Adjust the pH to 7.5 with NaOH. The solution can be stored at RT for up to one year. 
Sav-stock solution for FBS determination: Prepare a pure 1 mM Sav FBS stock solution (Use the 
molecular weight of the monomer 16368 Da) in MQ water in a final volume of 1 ml. Dilute this in 
AB to a final concentration of 100 µM Sav FBS. The solution can be stored at -20°C for 3 months if 
multiple freeze and thaw cycles are avoided. 
B4F solution for FBS determination: First, prepare a B4F stock solution (10 mM) in DMSO. Then, 
dilute this stock solution to 0.4 mM using FBS assay buffer. The solutions can be stored at -20°C for 
1 year if multiple freeze and thaw cycles are avoided. As B4F is light-sensitive, protect the solutions 
with aluminum foil.  
Iminobiotin binding buffer: Adjust the pH of a NaHCO3 buffer solution containing (1 l, 50 mM) 
and NaCl (0.5 M) to pH 9.8 by dropwise addition of NaOH (5 M stock solution). The buffer can be 
stored at RT for up to one year but the pH should be controlled before use. 
Metathesase reaction buffer: For this buffer, add MgCl2(H2O)6 (101.5 g) to an acetic acid stock 
solution (847 ml of a 100 mM solution) and a sodium acetate stock solution (153 ml of a 100 mM 
solution). Adjust the pH to 4 by dropwise addition of NaOH (5 M stock solution). The buffer can be 
stored at RT for up to one year but the pH should be controlled before use.  
 
Scheme A1. Overview of the synthesis of the diolefinic substrate 4. 
tert-butyl (4-sulfamoylphenethyl)carbamate (abbreviated as compound 8 in Scheme A1): To a 
flask containing 4-(2-aminoethyl)benzenesulfonamide (abbreviated as compound 7 in Scheme 
A1) (5.01 g, 24.5 mmol, 1.00 eq.) add DCM (20 ml) and THF (40 ml). Then, add Boc-
anhydride (5.61 g, 25.7 mmol, 1.05 eq.) to the mixture and stir for 2 h. Dilute with 200 ml 
of EtOAc and wash with 1 M aq. HCl (2 x 100 ml) and brine (100 ml). Dry the organic phase 
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over MgSO4 and remove the solvent under vacuum. Wash the white solid with hexane twice 
and dry under high vacuum to obtain the desired product 8 as a white solid (6.20 g, 86 %). 
MP: 181.5 °C – 182.5 °C. 1H NMR (400 MHz, DMSO) δ = 7.74 (d, 3JHH = 8.3 Hz, 2H), 7.38 (d, 3JHH 
= 8.3 Hz, 2H), 7.29 (s, 2H), 6.93 (s, 1H), 3.20 – 3.11 (m, 2H), 2.81 – 2.73 (m, 2H), 1.38 (s, 9H).  
 
Figure A1. 1H NMR spectra of compound 8. 
 
tert-butyl (4-(N,N-diallylsulfamoyl)phenethyl)carbamate (abbreviated as compound 9 
in Scheme A1): To a solution of tert-butyl (4-sulfamoylphenethyl)carbamate (8) (6.19 g, 
20.6 mmol, 1.00 eq.) in ACN (100 ml), add allyl bromide (6.29 g, 4.53 ml, 51.5 mmol, 2.50 
eq.) and K2CO3 (7.12 g, 51.5 mmol, 2.50 eq.). Stir the mixture at 85°C overnight and allow 
it to cool to RT. Then, filter and remove the solvent from the filtrate under reduced pressure. 
Purify the residue by flash column chromatography (silica gel, Cyclohexane/EtOAc 2:1) to 
obtain 9 as a pale yellow oil (6.70 g, 86 %). 1H NMR (400 MHz, CDCl3) δ = 7.75 (d, 3JHH = 
8.4 Hz, 2H), 7.33 (d, 3JHH = 8.3 Hz, 2H), 5.67 – 5.56 (m, 2H), 5.19 – 5.10 (m, 4H), 4.62 (bs, 
1H), 3.81 (d, 3JHH = 6.3 Hz, 4H), 3.44 – 3.35 (m, 2H), 2.88 (t, 3JHH = 7.0 Hz, 2H), 1.43 (s, 
9H). 13C NMR (100 MHz, DMSO) δ = 155.8, 144.3, 138.5, 132.6, 129.5, 127.4, 119.1, 79.5, 
49.4, 41.3, 36.1, 28.4. HRMS [ESI(+)TOF]: calculated for C19H28N2NaO4S [M]+ 403.1662; 
found 403.1665.  
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Figure A2. 1H NMR spectra of compound 9. 
 
 
Figure A3. 3C NMR spectra of compound 9. 
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Substrate for metathesase (abbreviated as compound 4 in in Scheme 6 and Scheme A1): 
Dissolve tert-butyl (4-(N,N-diallylsulfamoyl)phenethyl)carbamate (9) (3.91 g, 10.3 mmol, 
1.00 eq.) in dioxane (15 ml) and add a solution of HCl in dioxane (15 ml, 4 M solution) and 
stir at RT for 4 h till TLC indicates complete conversion. Precipitate the hydrochloride salt 
by pouring the mixture into cold DEE (300 ml), collect it by filtration and dry it under high 
vacuum to obtain a colorless solid (2.91 g, 89 %). Then, redissolve it in DCM (150 ml), add 
saturated aqueous NaHCO3 (200 ml) and vigorously stir for 2 h. Collect the organic phase, 
extract the aqueous layer with DCM and dry the combined organic phases over MgSO4. 
Remove the solvent under vacuum to yield the amine as a pale yellow oil. Take up a fraction 
of the amine (1.00 g, 3.16 mmol, 1.00 eq.) in DME (20 ml). Add iodomethane (4.49 g, 1.97 
ml, 31.6 mmol, 10.0 eq.) and K2CO3 (2.62 g, 19.0 mmol, 6.00 eq.) and stir the mixture for 3 
h at RT. Add DCM (80 ml) to redissolve the precipitated ammonium salt and remove the 
carbonate by filtration. Concentrate the filtrate under vacuum, decant with DEE and dry 
under high vacuum to obtain the pure substrate (4) as a colorless solid (1.13 g, 79 %). Use 
the standard Schlenk technique to prepare the catalyst46. Degas solvents by flushing these 
with a nitrogen stream for 30 min. Use oven-dried glassware (110 °C, overnight). Remove 
traces of air using three vacuum- followed by nitrogen refills. Keep a small nitrogen 
overpressure throughout the entire reaction to prevent air from contaminating the flask. If 
you stir a reaction under reflux, place the tap connected to the Schlenk line at the top of the 
condenser, to prevent excessive evaporation. Use a rubber septum to add liquid via a syringe. 
Apply a gentle nitrogen overpressure before removing the septum to add a solid. When 
performing the ligand exchange or the biotinylation, remove the solvent using the Schlenk 
line equipped with a secondary cooling trap (not on a rotary evaporator). The catalyst should 
be stable in its solid form. However, it should always be kept in a freezer at -20 °C and under 
argon. Prepared aliquots of the catalyst should be used within 3 months. MP: 184 °C – 186 
°C. 1H NMR (400 MHz, DMSO) δ = 7.84 (d, 3JHH = 8.4 Hz, 2H), 7.58 (d, 3JHH = 8.4 Hz, 
2H), 5.60 (ddt, 3JHH = 16.3 Hz, 3JHH = 10.1 Hz, 3JHH = 6.2 Hz, 2H), 5.16 (d, 3JHH = 17.1 Hz, 
2H), 5.14 (d, 3JHH = 11.0 Hz, 2H), 3.75 (d, 3JHH = 6.2 Hz, 4H), 3.65 – 3.55 (m, 2H), 3.22 – 
3.12 (m, 11H). 13C NMR (100 MHz, DMSO) δ = 141.7, 138.3, 132.8, 130.0, 127.3, 118.8, 
65.0, 52.4, 49.3, 28.2. HRMS [ESI(+)TOF]: calculated for C17H27N2O2S [M]+ 323.1788; 
found 323.1791. 
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Figure A4. 1H NMR spectra of compound 4. 
 
 
Figure A5. 13C NMR spectra of compound 4. 
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Substrate stock solution: Dissolve the metathesase substrate 4 (90.1 mg) in the metathesase 
reaction buffer in a volumetric flask (10 ml). Metathesis catalyst (abbreviated as compound 
6 in Scheme 6) aliquots are prepared as follows: charge a flask with 6 (4 mg) and add 
dichloromethane (1 ml). Portion this stock solution into aliquots (50 µl) inside small flasks, 
dispense into five test tubes and seal these with a rubber septum. Remove the solvent from 
the aliquots by applying a gentle vacuum through a needle. Once evaporated, flush with 
nitrogen to obtain aliquots of 6 (0.2 mg). Aliquots should be stored at -20°C and be used 
within three months. Once DMSO is added to the aliquots, they have to be used immediately. 
Iminobiotin beads: The beads are sold as a suspension in 20 % ethanol. Adjust the total 
volume with 20 % ethanol to twice the volume of the completely settled beads. Upon 
homogenization by thorough shaking, the binding capacity is about 5 mg Sav ml-1 
suspension. The beads are stored at 4°C and maintain their Sav binding capacity for several 
years (> 5). 
Internal standard solution: Dissolve benzyltriethylammonium bromide (272.2 mg) in MQ 
water in a volumetric flask (100 ml) and fill up to the mark. The solution can be stored at 
4°C for several months. 
A.3 BOX 1 
Design of noncomplementary, site-directed mutagenesis primers, TIMING 1-2 d 
1. Basic primer construct:  
 Add in the 3´-prime direction from the mutation codon, approximately 18 
nucleotides from the sequence (corresponding to 6 amino acids) 
 Add in the 5´-prime direction from the mutation codon, approximately 6 
nucleotides from the sequence (corresponding to 2 amino acids) 
 This affords a basic primer construct containing approximately 27 nucleotides (e.g. 
XXXXXXYYYZZZZZZZZZZZZZZZZZZ; X=5´-direction nucleotides, Y= 
codon to be mutated Z= 3´-direction nucleotides) 
2. Substitute the codon YYY to one codon specific for the desired mutation. Mutate the 
wildtype codon as little as possible. If several codons are possible, select the one with 
the highest codon usage of E.coli K12.46 
3. Check the primer quality with e.g. OligoCalc: Oligonucleotide Properties Calculator. 
If possible, minimize the G/C-content (typically 40 - 60 %). Avoid as much as possible 
hairpins and 3´-primer complementary. To match the criteria listed above, the primer 
sequence may be optimized by addition or deletion of nucleotides from the template 
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sequence. Furthermore, other possible codons for the mutation position can be chosen. 
The resulting optimized “forward primer” should contain 25 - 35 nucleotides. Using 
the nearest neighbor method, estimate the primer melting temperature (hereafter Tm). 
It should be 55°C < Tm < 70°C (higher G/C content = higher Tm). To ensure binding of 
the primer at the 3´-end of the sequence, be sure to include at least one or two G/C. It 
is recommended to include one or two G/C nucleotides at the 5’-end as well. This 
ensures binding and amplification by the polymerase (the polymerase transcribes from 
the 5´-to 3´-end). Keep at least four nucleotides of the original sequence from the first 
mutated nucleotide towards the 5´end of the primer sequence. Avoid adding more than 
eight nucleotides, as this increases overlapping of the forward and the reverse primers.  
4. To amplify the double stranded plasmid, a second primer (reverse-primer) for the 
reverse DNA strand is needed. This reverse-primer is designed in the same manner as 
described for the forward primer: as template sequence however, the complementary 
strand is used. Importantly, the mutated codon must be complementary to that in the 
forward-primer. The final complementary overlapping part of both primers should be 
at least 10-16 nucleotides (maximum) including the mutated codon, to prevent 
3´overlapping. To ensure binding of both primers during the annealing step, the 
maximum difference in Tm for the forward and reverse primer should not exceed 5°C. 
5. To use the same annealing temperature during one PCR (96 well plate) for 96  mutants, 
place the primers for specific mutations with similar Tm (± 5°C) on one master plate. 
We strongly recommend to order and to use the pre-mixed forward and reverse-primers 
at the required concentration (10 µM) that companies provide for a minor fee in a 96-
well plate format.  
A.3 BOX 2 
Preparation of chemically competent cells in a 96-deep-well plates, TIMING 1.5 d 
The steps below are as described in the work of Hanahan and colleagues,42,43 All steps, 
including cell treatment, are performed under a laminar flow box to avoid contamination. 
1. Prepare an overnight culture of E.coli TOP10 or BL21 (DE3) in LB media (5 ml). 
Incubate overnight (37°C at 200 rpm).  
2. Inoculate LBSOB (150 ml) with the overnight culture (1.5 ml). Grow the culture (37°C 
and 200 rpm) to an OD600 nm = 0.35. 
3. Divide the culture into aliquots in sterile falcon tubes (50 ml) and centrifuge (5 min, 4 
°C, 4000 g).  
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4. Pool and resuspend the cell pellet in RF1 buffer (30 ml). Incubate on ice (15 min). 
Keep cells on ice and pre-cool RF1 and RF2.  
5. Centrifuge (5 min at 4 °C and 4000 g).  
6. Discard the supernatant and resuspend the cell pellet in RF2 (6 ml)  
7. Incubate on ice (15 min).  
8. Aliquot the cell suspension (50 µl) into a 96 deep well plate for E.coli TOP10 or a 24 
deep well plate for BL21 (DE3) on ice. Seal the plate with foil. It is recommended to 
use BL21 (DE3) in 24 deep well plates as this improves the transformation efficiency.  
9. Freeze the plate in liquid nitrogen and store cells at -80 °C. The transformation 
efficiency can decrease and therefore competent cells should not be stored for more 
than 6 months. Competent cells which have been thawed should not be frozen again. 
10. Test the transformation efficiency with e.g. pUC19 vector with a single aliquot. 
A.4 PROCEDURE 
Site-directed mutagenesis in 96-well format 9-10 days. 
1. Design oligos for site-directed mutagenesis (See Box 1 for more information). Spin the 
96-well plate (4000 g for 5 min) and either proceed immediately, or store at -20°C. For 
a list of oligos used in our analysis, see supplementary table 1. Primer solution can be 
stored at -20°C indefinitely. 
2. Produce the mutagenesis template plasmid by cloning the SavK121A sequence into 
pET-24a (Supplementary data). We recommend synthesizing the gene sequence 
commercially via a gene supplier where it can be precloned in the desired expression 
vector. In parallel, also prepare the pET-24a Sav WT plasmid and the pET-24a empty 
vector control. For the Sav sequence see supplementary data. 
3. Transform each plasmid into E. coli BL21(DE3). To do this, add 1 - 3 µl plasmid (~100 
ng) to 50 µl BL21(DE3) on ice, and incubate for 30 min. 
4. Heat-shock the cells in a water bath (42°C, 30 s) and then transfer the tubes back to ice 
for 2 min. Add LBSoc (250 µl) and incubate the tubes with shaker (300 rpm for 1 h at 
37°C). 
5. Mix the suspension by pipetting up and down. Plate out the suspension (250 µl) on 
LB-Agar plates containing the resistance marker kanamycin (50 µg ml-1). Incubate 
plates overnight at 37°C. 
6. Inoculate LB media (5 ml) containing kanamycin (50 µg ml-1) with a fresh single 
colony bearing the template plasmid and incubate overnight (37°C at 200 rpm). 
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7. Prepare a glycerol stock for each by mixing 0.7 ml overnight culture with sterile 
glycerol (0.3 ml) to obtain an end concentration of 30 % (v/v) glycerol and incubate 
on ice (30 min). Freeze in liquid nitrogen and store at -80°C. Then use a commercial 
MiniPrep plasmid isolation kit (e.g. MN NucleoBond®) and follow the instructions of 
the supplier for high copy plasmids. Use the remaining overnight culture for isolation. 
For the elution step, use sterilized MQ water (50 µl) to elute the template plasmid. For 
the DNA quantification, analyze the above solution (50 µl) with a NanoDrop ND-1000. 
The sample is pure if the absorbance ratio at 260 nm / 280 nm is ~1.8. Heat the plasmid 
solution (70°C, 10 min) to deactivate any DNase present. Plasmid solutions can be 
stored indefinitely at -20°C. 
8. Prepare the QuikChange mutagenesis PCR master mix using the pET-24a SavK121A 
plasmid. The following is described for one 96 well plate. For QuikChange 
mutagenesis, a methylated circular DNA template (plasmid) is amplified using 
mutagenic primers (forward and reverse) and a high fidelity polymerase. After PCR, a 
DpnI digestion is performed which cleaves only the methylated template plasmid 
DNA. As the newly synthesized DNA is non-methylated, it is not digested by DpnI. 
This eliminates all of the background template DNA. No ligation of the resulting nicks 
in the newly synthesized DNA occurs during the PCR. A transformation into an 
efficient cloning strain, like E. coli TOP10, is thus necessary to repair the nicks present 
in the newly synthesized DNA. 
Table A1. PCR reagents 
Compound  Volume [µl]  Final in 2500 µl 
MQ water 1687.5  
Q5 polymerase 5x buffer 500 1x 
Template plasmid pET-24a SavK121A (25 ng µl-1) 50 0.5 ng µl-1 
Dimethylsulfoxide (DMSO) 100 4 % 
dNTP mix 10 mM each 50 200 µM each 
Q5 polymerase (2 U µl-1) 12.5 25 U 
Final volume for 100 reactions 2500  
It is possible to apply an alternative high fidelity, thermostable DNA polymerase. Mix 
the solution gently and spin down. Add polymerase slowly to avoid air bubbles. 
9. With a multichannel pipette, aliquot the mutagenesis PCR master mix (24 µl) into each 
well of a 96 well plate. To avoid unnecessary loss of the master mix, use PCR tubes 
(0.2 ml) as reservoirs. Pipette gently to avoid air bubbles.  
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10. For each mutant, add the primer mix solution (1 µl of the 10 µM solution from step 1) 
to the master mix solution (24 µl). Be sure to contact the meniscus with the tip and do 
not mix afterwards. Close plate tightly with an appropriate PCR lid. 
11. Place the plate into a 96-well plate compatible thermocycler. Program the following 
temperatures, cycles and durations: 
Table A2. PCR conditions 
Cycle number Denature Anneal Extend 
1 95°C, 2 min   
2- 18 95°C, 15 s 60°C, 15 s 72°C, 5 min (~ 40 s kb-1) 
19   72°C, 10 min 
20 4 - 8°C  
Steps 3 to 6 should be performed without any interruption. 
12. After PCR, add DpnI (0.3 µl, 20 U µl-1) with a multichannel pipette to each well, seal 
the plate with a breathable membrane and incubate for two hours at 37°C. Deactivate 
DpnI by heating (10 min at 70°C). This step digests the methylated template DNA. 
Digested PCR samples can be stored at -20°C indefinitely if multiple freeze/ thaw 
cycles are avoided. 
13. Prepare an agarose gel to check for presence of the mutated PCR product. To do this, 
weigh agarose (1.5 g, molecular biology grade) in 0.5x TBE buffer (150 ml, 1 % (w/v) 
final concentration). Heat in a microwave until agarose dissolves. Add EtBr (10 µl), 
mix gently and pour it into the chamber. Add combs for 100 samples into the warm 
solution. Wait until the gel is solid (~30 min). Ethidium bromide (EtBr) is hazardous, 
toxic and maybe mutagenic for humans. Wear chemically resistant gloves for all steps 
and work under a ventilated hood.  
14. Place the gel into the running chamber containing 0.5x TBE and remove combs. Use 
DpnI digested PCR product (5 µl) and mix it with 6x loading buffer (1 µl). This mixture 
(5 µl) is then loaded into each lane. Use 1 kb DNA ladder (3 µl) as a standard. Run the 
gel at 100 V/ 400 mA for 40 min. Analyze the gel under an illuminator at 302 nm and 
search for an amplified band at 5.7 kb. Figure 6 displays a typical gel resulting from 
one 96 well PCR mutagenesis plate with a strong amplified band of the vector in each 
lane. A band at the size of the plasmid is a good hint that the PCR was successful.  
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Figure A6. DNA analysis of the plasmid amplification by agarose gel electrophoresis. Analytical 
agarose gel (1%) with a 1-kb marker (M) using the PCR product (5 µl) after DpnI digestion. DNA is 
visualized by ethidium bromide. Each lane corresponds to one mutation. 
15. Perform a transformation of each successfully mutagenized plasmid into competent E. 
coli TOP10 cells. Transfer gently (do not pipette up and down) the digested PCR 
product (3 - 5 µl) using a multichannel pipette into a 96 well plate containing 
chemically competent E. coli TOP10 cells (50 µl per well). Incubate on ice for 30 min. 
For the preparation of chemically competent E. coli cells in 96 well plates, see Box 2. 
Use a positive control (e.g. pUC19 vector). Depending on the E. coli strain used 
(TOP10 typically yields more colony forming units (cfu) than BL21 (DE3)), one can 
typically expect 30 – 800 cfu´s. Competent cells must be stored on ice the whole time 
until heat shock. Amplified plasmids are nicked: transformation into an efficient 
cloning strain is thus necessary. 
16. Heat-shock and plate cells on 96 separate LB plates containing kanamycin (50 µg ml-
1) as described in steps 4-6. Incubate overnight (37°C at 200 rpm). 
17. Pick one to three colonies per mutant and grow them overnight (37°C at 200 rpm) in 
96 well plates containing LB containing kanamycin (50 µg ml-1). Follow the 
manufacturer’s protocol from the 96 well plasmid isolation kit for the preparation of 
overnight cultures and for the plasmid isolation procedure. Elute twice with the elution 
buffer (2x30 µl). Alternatively, in a 24 deep well plate, LB can be used (6 ml per well) 
for overnight cultures to increase the final DNA content. Typical isolated plasmid 
yields are around 50 to 100 ngꞏµl-1. 
18. Sequence plasmids with the standard T7 promoter primer. Forward sequencing is 
sufficient to cover the whole Sav gene (< 500 bp). To minimize costs, it is recommend 
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to use 96 well plate format sequencing to confirm the introduction of the desired 
mutations. 
19. Perform transformation into competent E. coli BL21(DE3) cells. Add the mutated Sav 
plasmids (1 - 3 µl, ~100 ng) to chemically competent E. coli BL21 (DE3) (50 µl) in 24 
deep well plates on ice. Incubate for 30 min. Repeat steps 4-5. The remaining plasmid 
solution can be kept at -20°C for several years. 
20. Prepare overnight cultures in LB-media (5 ml) containing kanamycin (50 µgꞏml-1) 
from a single colony of each E. coli BL21 (DE3) Sav mutant (same as step 6). 
21. Create glycerol stocks as described in Step 7. Glycerol stocks can usually be stored for 
several years at -80°C. 
22. To validate the glycerol stocks, repeat steps 6 and 7 (glycerol stock preparation not 
necessary). Use the 96 well plasmid isolation kit (Step 17). Prepare overnight cultures 
directly from the stock.  Avoid thawing of the glycerol stocks by keeping them on dry 
ice. The remaining plasmid solution can be kept at -20°C for several years.  
Sav library expression using ZYP-5052 medium TIMING 3-4 days 
23. Prepare a sterile 24 deep well plate and fill the wells with LB (2 ml) containing 
kanamycin (50 µg ml-1). Use one 24 deep well plate for each amino acid position. 
Inoculate 12 wells with the twelve different mutants to be introduced at this position, 
three with pET-24a-empty vector controls, three with pET-24a SavK121A and three 
with pET-24a Sav WT. The remaining three are sterile controls. Seal the plate with a 
permeable membrane. Incubate overnight (210 rpm, 37°C). 
24. Transfer the overnight culture (10 µl) into a new sterile 24 deep well plate containing 
the modified ZYP-5052 medium (6 ml) (for the 24 h expression) and kanamycin (50 
µg ml-1). Seal with a permeable membrane and shake (210 rpm, 30°C). To increase the 
harvested Sav amount, it is recommended to set up two identical plates simultaneously. 
Both plates can be pooled for screening purposes. For the 24 hour expression protocol, 
add a sterile pipette tip (0.1-10 µl) into each well and use the modified ZYP-5052 
media. For the 48 hour expression protocol, addition of a pipette tip has no effect and 
the normal ZYP-5052 medium should be used. 
25. Determine the OD600nm of each well culture after 24 h, this should typically have an 
OD of 6 – 7. Centrifuge (4500 g, 10 min, 4°C) and discard the supernatant. Set the 
plate on ice for 2 min. Invert the plate on a tissue to remove remaining liquid and wait 
5 min. Freeze the pellet at -20°C. The cell pellet containing Sav can be stored at -20°C 
for several weeks. 
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26. Thaw the cell pellets and resuspend in 0.2 ml (ATHase, see step 28(A)) or 0.4 ml 
(metathesase, see step 28(B)) lysis buffer. Do not use EDTA as this inhibits artificial 
metalloenzymes. Incubate for 30 min at 37°C and 200 rom. Freeze for 1 to 2 h at -
20°C. Thaw the cell lysate at RT. The lysate should be a homogeneous suspension. If 
not, add more DNaseI (1 µg ml-1 to the initial concentration) and shake (30 min, RT). 
27. To prepare the CFE, clear the cell suspension by centrifugation of the plates (4500 g, 
4°C, 1 – 2 h). As an alternative, transfer the cell lysate into tubes (1.5 ml) and use a 
table centrifuge (21100 g, 20 min, 4°C). CFE containing Sav can be stored at 4°C for 
several weeks or at -20°C for up to 6 months. 
ATHase or metathesase screening 
28. At this point in the procedure, you can proceed with ATHase (option A) or metathesase 
(option B) screening.  
(A) ATHase screening TIMING 3 days + 10 hours of measurement time 
(i) Determine Sav FBS using the B4F absorption-fluorescence assay: One 96-well 
plate allows for determination of the Sav FBS concentration of one 24-well plate 
containing the twelve mutants at one amino acid position of Sav. Perform all 
measurements, including the calibration curve, in triplicate. Use rows A-H columns 
1-3 of a 96 well plate for the calibration curve with commercial full length 
streptavidin. Use the remaining wells to determine the Sav FBS of the twelve 
mutants for one amino acid position as well as all controls (WT Sav, K121A Sav 
and empty vector, each in triplicate). First, prepare the B4F working solution by 
combining 5.6 ml of FBS assay buffer and 0.8 ml of 0.4 mM B4F solution. As B4F 
is light-sensitive, protect the solutions with aluminum foil. Typically a subsequent 
assay dilution of the samples by five to ten is sufficient to remain in the range of 
the calibration curve under these conditions. By changing the amount of FBS assay 
buffer, other dilutions can be achieved. 
(ii) Use transparent 96 well plates (e.g., Brand, 350 µl per well, flat bottom). Measure 
each sample (final volume 100 µl) in triplicate. Follow the pipetting scheme for the 
calibration curve (rows A-H) displayed in the table below. Pipette the following 
into columns 1-3. 
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Table A3. Pipetting scheme for FBS determination 
 Amount (µl) 
Component  Row 
A 
Row 
B  
Row 
C  
Row 
D 
Row 
E  
Row 
F  
Row 
G  
Row 
H 
Final FBS Sav 
concentration (µM) 
[0] [5] [10] [15] [20] [25] [30] [40] 
B4F working solution 10 10 10 10 10 10 10 10 
Sav stock [100 µM] 0 5 10 15 20 25 30 40 
FBS assay buffer 90 85 80 75 70 65 60 50 
Total 100 100 100 100 100 100 100 100 
Follow the table in order during pipetting to avoid air bubbles. Hold the pipette vertically, 
contact the meniscus and the vessel wall with the tip when releasing the liquid. 
(iii) For measurements with the samples, pipette the B4F working solution (80 µl in 
each well) into the remaining 72 wells. Gently add 20 µl of the CFE into each well. 
Perform for each sample a triplicate determination. Shake the plate in the reader at 
306 rpm for 2 min. Incubate for 15 min. Determine the absorbance (493 nm) and 
the fluorescence (Excitation: 485 nm/ Emission 520 nm) at 25°C. Check plate for 
air bubbles. They strongly influence the resulting absorbance. The presence of air 
bubbles does not significantly influence the fluorescence determination.  
(iv) Typical standard curves are displayed in Figure 7. Data points yielding Sav FBS < 
10 µM or Sav FBS > 35 µM should be repeated at higher or lower concentrations 
respectively. Subtract the empty vector value and multiply by the assay dilution 
factor (5 when using of 20 µl CFE, see Step 26). 
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Figure A7. Typical calibration curve for Sav K121A using the B4F- assay. Absorption and relative 
fluorescence is displayed at increasing streptavidin concentrations. Measured data points are 
displayed as triangles. (a,b) The solid line corresponds to the linear regression: absorbance (max = 
493 nm, each symbol (circle, square, and triangle) corresponds to one independent determination) 
(a), and relative fluorescence (excit =485 nm and emis = 520 nm, each symbol (circle, square, and 
triangle) corresponds to one independent determination) (b). RFU, relative fluorescence units. 
(v) Diamide treatment: Based on the Sav FBS determination, add the appropriate 
amount of cell lysate or CFE to an HPLC vial with a magnetic stir bar. Each vial 
should contain a final Sav FBS = 100 µM. Add the diamide stock solution (5 µl) 
and pre-incubate the solution by stirring (> 2 h). After dilution to 200 µl, the final 
diamide concentration should be 5 mM. 
(vi) Catalysis set-up: Add 2x concentrated reaction buffer (100 µl) into the 
preincubated cell lysates or the CFEs. 
(vii) Dilute the samples with MQ water, so the final volume after addition of the iridium 
and the substrate stock solutions reaches 200 µl.  
(viii) Add the iridium stock solution (5 µl) and incubate the solutions by stirring (5 min.). 
Following dilutions, the final iridium concentration [Cp*Ir(Biot-p-L)Cl] 
(compound 3) should be 50 µM. 
(ix) Initiate the reaction by adding the substrate stock solution (5 µl) and seal the HPLC 
vials. The final substrate concentration should be 10 mM. 
(x) Stir the reaction at RT for 48 h. (e.g. in a standard plastic box for cryotubes) 
(xi) Workup of catalysis reactions and analysis: Dilute the reactions by addition of MQ 
water (500 µl). All chemicals must be handled with care and proper personal 
protective equipment, e.g. laboratory coat, gloves and eye protection. 
(xii) Transfer the reaction mixtures to a 2-ml polypropylene (PP) tube. 
(xiii) Add NaOH (50 µl of 20 % (w/w) solution). 
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(xiv) Extract the reaction mixture twice with dichloromethane (2 x 1 ml). If a gel-like 
layer forms during extraction, especially when using cell lysates, spin (2000 g, 1 
min) the 1.5-ml PP tubes before separating the organic layer. 
(xv) Combine the organic phases, transfer them into a new 2-ml PP tube and dry them 
by adding a spatula tip of anhydrous Na2SO4.  
(xvi) Spin down the tubes (2000 g, 5 min). 
(xvii) Transfer the supernatant into a HPLC vial using a Pasteur pipette. 
(xviii) Prepare the isocratic HPLC elution mixture containing 99.44 % hexane, 0.5 % 
isopropanol and 0.06 % diethylamine. 
(xix) Analyze the samples by HPLC using a Chiralpak IC column. Use a flow rate of 1 
ml min-1 at 25 °C, and determine the absorbance at 265 nm.  
(xx) For comparison purposes, the retention times are: (S)-1-phenyl-1,2,3,4-
tetrahydroisoquinoline (S)-2c (7.6 min), (R)-1-phenyl-1,2,3,4-
tetrahydroisoquinoline (R)-2c (10.5 min), and 1-phenyl-3,4-dihydroisoquinoline 1 
(16 min).  
(xxi) Determine the enantiomeric excess for each sample. The yield can be estimated 
using a response factor (substrate 1c)/(product 2c) = 13.613. Determine the 
response factor experimentally by measuring at least three different substrate to 
product ratios. 
(B) Metathesase screening TIMING 1 day + 10 hours measurement time for an entire 96-
well plate 
(i) Small scale imino-biotin immobilization: Transfer the CFEs (400 µl in PBS 
buffer) from the 24 deep-well plates into a 96 deep-well plate. Add iminobiotin 
binding buffer (1 ml) to each well to adjust to pH ~ 9. Add the iminobiotin-
sepharose beads (100 µl, shake the suspension thoroughly prior to pipetting 
(thanks to the dilution, pipetting and mixing is straightforward). Incubate the 96 
deep-well plate with rapid shaking (800 rpm, RT, 1 h). 
(ii) Centrifuge the plate (5300 g, 15 min.) and discard the supernatant. Resuspend the 
beads in iminobiotin binding buffer (1 ml), centrifuge (5300 g, 15 min.) and 
discard the supernatant. Repeat this washing step three times to avoid 
deactivation of the catalyst. Use the thoroughly washed beads for catalysis. 
(iii) Catalysis set-up: To each well containing iminobiotin beads, add the metathesase 
reaction buffer (97 µl).  
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(iv) Add a solution of the catalyst (6) in DMSO (3 µl of the 3.33 mmol stock solution) 
to each well (to obtain the 3.33 mmol solution, take a 0.2 mg aliquot and add 69 
µl of DMSO) to obtain a final concentration of 50 µM. 
(v) Add the solution of substrate (100 µl of the 20 mM stock solution) to each well 
to get a final substrate concentration of 10 mM and place the 96 deep-well plate 
into a shaking incubator (37°C, 200 rpm, 12 h). 
(vi) Workup of catalysis reactions and analysis: Remove the plate from the incubator 
and add the internal standard solution (100 µl) to each well and methanol (700 
µl). Then, centrifuge the plate (5346 g, 25 min). From each supernatant, transfer 
an aliquot (250 µl) into a new 96 deep-well plate and dilute with MQ water (750 
µl).  
(vii) Schedule 10 h for an entire 96 well plate. Analyze the wells on an Aquity UPLC 
H-Class Bio from Waters (or a similar instrument, retention times may vary) 
using a BEH C18 column (1.7 µm, 2.1 x 50 mm). Use MQ water + 0.1 % TFA as 
A solvent and acetonitrile + 0.1 % TFA as B solvent. Apply a gradient method as 
follows: 0 min 80 % A 20 % B; 1 min 80 % A 20 % B; 3 min 10 % A 90 % B; 
3.5min 80 % A 20 % B and 4.5min 80 % A 20 % B. Plan 5 minutes for each 
sample. 
(viii) For quantification purposes, integrate the peaks of the absorbance at 210 nm. The 
retention times are as follows: starting material 4, 2.15 min; internal standard, 
0.47 min; product 5, 0.67 min. 
(ix) Determine the concentration of the product with a calibration curve. For this, 
record samples of different concentrations of the purified product: 500 µM, 300 
µM, 200 µM, 100 µM, 80 µM, 50 µM, 30 µM and 10 µM as well as constant 
concentrations of internal standard (250 µM). A linear regression is obtained by 
plotting area(product)/area(standard) against the calculated product 
concentration.  
(x) The total turnover number is obtained by dividing the calculated concentration in 
the sample by the catalyst concentration (50 µM) and multiplying it with the 
dilution factor from the workup (20). 
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A.5 TIMING 
Steps 1-22: site-directed mutagenesis in 96-well format: 9-10 days 
Step 1 – 16: 3–4 days 
Step 17 – 18 (depending on shipping duration): 4 days 
Step 19 – 22: 2 days 
Steps 23-27: Sav library expression using ZYP-5052 medium: 3-4 days 
Step 23: 1 day 
Step 24 – 25: 1 – 2 days 
Step 26 – 27: 6 hours 
Step 28A, ATHase screening: Total time 2.5 days + 10 hours measurement time 
Step 28A (i–iv): 1 – 3 hours 
Step 28A (v): 3 hours 
Step 28A (vi–x): 2 days 
Step 28A (xi – xxi): 12 hours for 18 samples 
Step 28B, metathesase screening: 1 day + 10 hours measurement time for an entire 96-well plate 
Step 28B (i, ii): 3.5 hours 
Step 28B (iii–v): 19 hours 
Step 28B (vi–x): 12 hours for an entire 96-well plate analysis 
Box 1, primer design for noncomplementary, overlapping site-directed mutagenesis primer pair in 
96-well plate format: 1-2 days 
Box 2, preparation of chemically competent cells in 96-deep-well plates: 1.5 days 
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A. 6 SUPPLEMENTARY METHOD 
A.6.1. SYNTHESIS OF BIOTINYLATED METATHESIS AND ATHASE CATALYST 
A.6.1.1. Synthesis of metathesis catalyst 6 
The synthesis is performed according to Scheme A2. 
 
Scheme A2: Synthesis of metathesis catalyst 6.  
 
4-((2-(mesitylamino)ethyl)amino)-3,5-dimethylbenzonitrile 11: 
Stir a mixture of N1-(4-bromo-2,6-dimethylphenyl)-N2-mesitylethane-1,2-diamine (10, 
1.50 g, 4.14 mmol, 1.00 eq.) and copper (I) cyanide (749 mg, 8.28 mmol, 1.00 eq.) in NMP 
(7 mL) at 160°C overnight. Then, let the reaction mixture cool to room temperature and add 
water (10 mL) and ammonium hydroxide (10 mL). Extract the product with ethyl acetate 
(2×50 mL) and dry with Na2SO4. Purify the product by flash chromatography (CH2Cl2) to 
obtain 11 as a white solid (700 mg, 86%). 1H NMR (400 MHz, CDCl3): δ = 7.25 (s, 2H), 
6.85 (s, 2H), 3.40 (t, 3JHH = 8 Hz, 2H), 3.13 (t, 3JHH = 8 Hz, 2H), 2.30 (s, 6H), 2.26 (s, 6H), 
2.24 (s, 3H). 13C NMR (100 MHz, CDCl3): δ = 150.7, 142.7, 133.0, 132.5, 130.5, 129.7, 
127.4, 120.1, 102.7, 48.8, 48.3, 20.7, 19.2, 18.3. ESI-MS for C20H25N3 : 308.2 [M+H]+. 
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tert-butyl (4-((2-(mesitylamino)ethyl)amino)-3,5-dimethylbenzyl) carbamate 12: 
Add a solution of 11 (2.27 g, 7.41mmol, 1.00 eq.) in THF (10 mL) dropwise to a suspension 
of LiAlH4 (0.702 g, 18.5 mmol, 2.50 eq.) in THF (30 mL). Stir the reaction mixture for 3 
hours at 70 °C and let it cool to room temperature. Quench the reaction mixture with 1.0N 
NaOH aqueous solution. Filter off the precipitate and evaporate the solvent in vacuo to 
provide the crude amine product, which can be used without purification. 1H NMR (400 
MHz, CDCl3): δ = 6.95 (s, 2H), 6.84 (s, 2H), 3.74 (s, 2H), 3.16-3.20 (m, 4H), 2.32 (s, 6H), 
2.28 (s, 6H), 2.24 (s, 3H). 13C NMR (400 MHz, CDCl3): δ = 144.8, 143.3, 137.0, 131.6, 
129.9, 129.8, 129.6, 127.8, 49.2, 49.1, 46.1, 20.6, 18.7, 18.4. ESI-MS for C20H29N3: 295.3 
[M-NH2]+. Purge a round-bottom flask, equipped with a magnetic stir-bar, with nitrogen and 
charge it with the above crude product and add Boc2O (1.4 g, 6.4 mmol, 1.0 eq.), and 
degassed CH2Cl2 (3 mL). cool the flask to 0 °C with an ice/water bath prior to the addition 
of DMAP (79 mg, 0.64 mmol, 0.10 eq.). Stir at 0 °C for an additional 30 minutes prior to 
warming to room temperature and stir for 2 additional hours. Extract the reaction mixture 
with water and brine. Dry over Na2SO4, and evaporate the CH2Cl2. Chromatography on 
silica-gel 60 (15% EtOAc in hexanes) yields 2.0 g (85%) carbamate 12 as a white powder. 
1H NMR (400 MHz, CDCl3): δ = 6.91 (s, 2H), 6.83 (s, 2H), 4.73 (brs, 1H), 4.18 (d, 3JHH = 4 
Hz, 2H), 3.31 (brs, 1H), 3.12-3.20 (m, 4H), 2.29 (s, 6H), 2.27 (s, 6H), 2.23 (s, 3H), 1.46 (s, 
9H). 13C NMR (100 MHz, CDCl3): δ = 155.9, 145.4, 143.3, 131.7, 130.0, 129.7, 129.6, 
128.3, 110.1, 49.2, 49.1, 28.5, 27.0, 20.6, 20.0, 18.7, 18.5. ESI-MS for C25H37N3O2 : 412.3 
[M+H]+. 
3-(4-(((tert-butoxycarbonyl)amino)methyl)-2,6-dimethylphenyl)-1-mesityl-4,5-dihydro-
1H-imidazol-3-ium chloride 13: 
Charge an oven-dried round-bottom flask, equipped with a magnetic stir-bar, with carbamate 
12 (2.00 g, 5.05 mmol), NH4Cl (270 mg, 5.05 mmol, 1.00 eq.), HC(OEt)3 (16.6 mL, 101 
mmol, 20.0 eq.). and equip it with a condenser and purge with N2 prior to stirring under an 
N2 atmosphere at 120 °C for 16 hours. After cooling to RT, precipitate the product by 
addition of ether. Isolate the solid  by vacuum-filtration and rinse with ether to yield 2.20 g 
(95 %) of product 13 as a grey powder. 1H NMR (400 MHz, CDCl3): δ = 9.54 (s, 1H), 7.00 
(s, 2H), 6.91 (s, 2H), 5.35 (brs, 1H), 4.51 (s, 4H), 4.15 (d, 3JHH = 4 Hz, 2H), 2.36 (s, 6H), 
2.34 (s, 6H), 2.25 (s, 3H), 1.41 (s, 9H). 13C NMR (400 MHz, CDCl3): δ = 163.9, 160.1, 
155.9, 141.4, 140.0, 135.3, 134.7, 131.5, 130.1, 129.7, 127.8, 79.2, 57.3, 51.5, 43.5, 28.1, 
20.8, 17.7. ESI-MS for C26H36ClN3O2 : 422.3 [M-Cl]+. 
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Chloroform adduct 14: 
Add dry, degassed toluene (15 mL) to an oven-dried, 50 mL Schlenk flask equipped with 
stir bar and a reflux condenser. Add a large excess of powdered potassium hydroxide (5.37 
g, 95.6 mmol, 127 eq.) to the flask, and stir the resulting suspension. Add chloroform (0.405 
mL, 5.00mmol, 6.67 eq.) to the suspension. After 10 min at RT, add 13 (0.344 g, 0.750mmol, 
1.00 eq.) and heat the reaction mixture at 60 °C for 75 min. Allow the mixture to cool to 
room temperature and filter it. Concentrate the filtrate under vacuum to obtain a light brown 
solid. Purify this crude product by column chromatography (20% ethyl acetate/hexane, Rf = 
0.2) to yield 0.185 g (45 %) of the desired chloroform adduct 14 as a light yellow solid. 1H 
NMR (400 MHz, CDCl3): δ = 6.95 (s, 1H), 6.92 (s, 1H), 6.87 (s, 1H), 6.83 (s, 1H), 5.58 (s, 
1H), 4.76 (brs, 1H), 4.22 (d, 3JHH = 4 Hz, 2H), 3.89-3.92 (m, 2H), 3.25-3.35 (m, 2H), 2.49 
(s, 3 H), 2.47 (s, 6H), 2.45 (s, 3H), 2.25 (s, 3H), 1.47 (s, 9H). 
Precatalyst 15: 
Charge an oven-dried, 10 mL Schlenk tube with Hov I (36 mg, 60µmol, 1.0 eq.), the 
chloroform adduct 14 (65 mg, 0.12 mmol, 2.0 eq.), and dry, degassed toluene (2 mL). Stir 
the reaction mixture at 70 °C for 90 min under a nitrogen atmosphere. After cooling to room 
temperature, remove the solvent under vacuum. Filter the dark-brown solid through a short 
silica gel column using ethyl acetate/cyclohexane (1:1) as eluent. Collect the green band and 
concentrate it to yield a green solid (15, 27 mg, 60%). 1H NMR (400 MHz, CDCl3): δ = 
16.52 (s, 1H), 7.48 (t, 3JHH = 8 Hz, 1H), 7.16 (s, 2H), 7.07 (s, 2H), 6.92-6.96 (m, 1H), 6.83-
6.87 (m, 1H), 6.79 (d, 3JHH = 8 Hz, 1H), 4.84-4.94 (m, 1H), 4.36 (d, 3JHH = 4 Hz, 2H), 4.18 
(s, 4H), 2.51 (s, 6H), 2.46 (s, 6H), 2.41 (s, 3H), 1.50 (s, 9H), 1.26 (d, 3JHH = 4 Hz, 6H). ESI-
MS for C36H48Cl2N3O3Ru : 706.3 [M-Cl]+. 
Metathesis catalyst 6 
Dissolve the boc-protected complex 15 (30 mg, 0.041mmol, 1.0 eq.) (30 mg, 0.041mmol, 
1.0 eq.) in CH2Cl2 (2 mL) and purge HCl gas through the solution for 1 h at room 
temperature. Generate the gaseous HCl by dropwise addition of concentrated H2SO4 to solid 
NH4Cl. Stir the solution for an additional 2 h at room temperature. Upon completion of the 
reaction as revealed by TLC (hexane/AcOEt 2:1), evaporate under reduced pressure. 
Dissolve the green solid in DMF (2 mL) and add biotin pentafluorophenol (13 mg, 0.032 
mmol, 0.80eq) and Et3N (0.12 mL, 0.82mmol) to the solution and stir at RT for 16 h. Remove 
the solvent under reduced pressure and purify the crude product by flash chromatography on 
silica gel using 10% MeOH/CH2Cl2 to yield metathesis catalyst 6 as a green solid (25 mg, 
67%). 1H NMR (400 MHz, CD2Cl2): δ = 16.17 (s, 1H), 7.97 (s, 1H),7.55-7.60 (m, 1H), 7.09 
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(s, 2H), 6.95-7.00 (m, 3H), 5.14-5.20 (m, 2H), 4.84-4.96 (m, 2H), 4.53-4.57 (m, 1H), 4.35-
4.38 (m, 1H), 4.07-4.11 (brs, 1H), 3.87-3.96 (m, 4H), 3.22 (m, 2H), 2.95 (s, 6H), 2.86 (s, 
4H), 2.69-2.77 (m, 2H), 2.52 (m, 2H), 2.46 (s, 3H), 2.18 (s, 6H), 1.90 (m, 1H), 1.74 (d, 3JHH 
= 4 Hz, 6H). HRMS [ESI(+)]calculated for C37H51ClN5O3RuS: 782.2445 [M-Cl]+; found 
782.2414. 
A.6.1.2 Synthesis of transfer hydrogenation catalyst 3 
The synthesis is performed as summarized in Scheme A3. 
 
Scheme A3: Synthesis of hydrogenation catalyst 3. 
N-Boc-N’-(4-nitrophenylsulfonyl)-ethylenediamine 18: 
To a solution of N-Boc-ethylenediamine 17 (1.74 g, 10.8 mmol, 1.0 eq.) and Et3N (3 mL, 
21.5 mmol, 2.0 eq.) in DCM (300 mL) add dropwise a solution of 4-nitrophenylsulfonyl 
chloride 16 (2.51 g, 11.3 mmol, 1.05 eq.) in DCM (100 mL) at 5°C and stir overnight. Then, 
concentrate the solution to 100 mL, wash with water (3 x 20 mL), dry it with MgSO4 and 
evaporate the solvent under reduced pressure. Purify the crude product by flash 
chromatography (silicagel, EtOAc : hexane (2 : 3)) to obtain the pure product 18 as a white 
powder (2.87 g, 8.32 mmol, 77% yield). 1H NMR (200 MHz, CDCl3-CD3OD, 22 °C): δ 1.40 
(s, 9H; tBu), 3.03 (m, 2H; CH2-CH2- NH-S), 3.12 (m, 2H; CH2-CH2-NH-S), 4.47 (br, 2H; 
NH), 8.04 (d, J = 8.7 Hz, 2H; ArH), 8.37 (d, J = 8.7 Hz, 2H; ArH).  
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N-Boc-N’-(4-aminophenylsulfonyl)-ethylenediamine 19:  
Charge an autoclave containing a suspension of Pd/C (5%, 330 mg) in methanol (20 mL) 
with N-Boc-N’-(4-nitrophenylsulfonyl)-ethylenediamine 18 (2.10 g, 6.08 mmol). Purge the 
autoclave three times with nitrogen and fill with hydrogen (3 bars). Stir the reaction 
vigorously for 3 hours at RT. Then, carefully release the hydrogen pressure and remove the 
resulting suspension by filtration through a celite plug. Evaporate the solvent under reduced 
pressure to obtain 19 as a white powder (1.78 g, 5.65 mmol, 93%). 1H NMR (400 MHz, 
CDCl3-CD3OD, 22 °C): δ 1.40 (s, 9H; tBu), 2.88 (m, 2H; CH2-CH2- NH-S), 3.12 (m, 2H; 
CH2-CH2-NH-S), 3.57 (br, 3H; NH; NH2), 4.50 (br, 1H; NH), 6.62 (m, 2H; ArH), 7.47 (m, 
2H; ArH). 
N-Boc-N’-(4-biotinamidophenylsulfonyl)-ethylenediamine 21:  
Mix a suspension of (+)-biotin 20 (1.4 g, 5.74 mmol, 1.02 eq.), N-Boc-N ’-(4-
aminophenylsulfonyl)-ethylenediamine 19 (1.77 g, 5.63 mmol, 1.0 eq.) and 2- chloro-4,6-
dimethoxy-1,3,5-triazine (CDMT) as a coupling agent (1.08 g, 5.96 mmol, 1.06 eq.) in 
acetonitrile (110 mL). Add N-methylmorpholine (NMM) (0.93 mL, 8 mmol, 1.5 eq.) and stir 
at RT for 24 hours. Heat the reaction mixture to reflux and for 6 hours. After cooling the 
reaction mixture cool to room temperature, add water (30 mL). Evaporate the solvent under 
reduced pressure until the product starts to precipitate. Collect the crude product by filtration, 
wash with DCM and purify by flash chromatography (silicagel using EtOAc : MeOH (4 : 
1)) to obtain the product a white powder (1.4 g, 2.30 mmol, 46% yield).  
1H NMR (200 MHz, DMSO-d6, 22 °C): δ 1.20-1.78 (m, 15H; CH2; tBu), 2.30 (m, 2H; CH2), 
2.60-2.88 (m, 4H; CH2-S; CH2-CH2-NH-S), 2.95-3.15 (m, 3H; CH-S; CH2-CH2- NH-S), 
4.18 (br, 1H; CH-N), 4.38 (br, 1H; CH-N), 6.28 (br, 3H; NH), 7.65 (d, J = 8.3 Hz, 2H; ArH), 
7.72 (d, J = 8.3 Hz, 2H; ArH).  
Add trifluoroacetic acid (2.3 mL, 30 mmol, 10 eq.) dropwise to a suspension of N-Boc-N’-
(biotin-4-amidophenylsulfonyl)-ethylenediamine (1.60 g, 2.95 mmol) in dry DCM (150 mL) 
at 0 °C and stir for 6 hours. Evaporate the solvent under reduced pressure, dissolve the crude 
product in MeOH and add diethyl ether until a white precipitate forms. Collect the 
precipitated product by filtration and dry under reduced pressure to obtain 21 as white 
powder (1.29 g, 2.33 mmol, 79%).  
1H NMR (400 MHz, DMSO-d6, 22 °C): δ 1.23-1.63 (m, 6H; CH2), 2.35 (m, 2H; CH2), 2.58 
(d, J = 12.4 Hz, 1H; CH2-S), 2.69 (br s, 2H; CH2-CH2-NH-S), 2.82 (dd, J = 12.4, 4.9 Hz, 1H; 
CH2-S), 2.89 (m, 2H; CH2-CH2-NH-S), 3.12 (m, 1H; CH-S), 3.48 (br, 2H; NH2), 4.15 (br, 
1H; CH-N), 4.31 (br, 1H; CH-N), 5.33 (br, 1H; NH), 6.44 (br, 1H; NH), 6.58 (br, 1H; NH), 
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7.68 (d, J = 8.5 Hz, 2H; ArH), 7.79 (d, J = 8.5 Hz, 2H; ArH), 10.6 (br, 1H; NH); 13C NMR 
(100.6 MHz, DMSO-d6, 22 °C): δ 25.8 (CH2), 28.9 (CH2), 29.0 (CH2), 37.0 (CH2), 
40.7(CH2-S), 41.3 (CH2-CH2-NH-S), 46.5 (CH2-CH2-NH-S), 56.2 (CH-S), 60.1 (CH-N), 
61.9 (CH-N), 119.5 (2C; Ar-H), 128.4 (2C; Ar-H), 134.8 (Ar-S), 143.6 (ArN), 163.7 (N-
CO-N), 172.8 (CO-N); ESI-MS for C18H27N5O4S2: 464.2 (15) [M+Na]+ , 442.3 (100) 
[M+H]+. 
Synthesis of [Cp*Ir(Biot-p-L)Cl] 3: 
 
Dissolve the [Cp*IrCl2]2 dimer (136.4 mg, 0.171 mmol, 0.475 eq.), the biotinylated ligand 
21 (200 mg, 0.36 mmol, 1 eq.) and Et3N (12.5 µL, 90 µmol, 2.25 eq.) in dry DCM (30 mL) 
under inert atmosphere. After stirring for 24 hours at room temperature, collect the 
precipitate, wash with DCM (3x5 mL) and cold water (3x4 mL) and dry under reduced 
pressure to obtain the pure catalyst 3 as a bright yellow powder (212.3 mg, 0.26 mmol, 73%). 
1H NMR (400 MHz, DMSO-d6) δ 10.06 (s, 1H, NH), 7.80 – 7.51 (m, 4H, Ar-H), 6.44 (s, 
1H, NH), 6.36 (s, 1H, NH), 5.26 (s, 2H, NH), 4.31 (dd, J = 7.8, 5.0 Hz, 1H, CH), 4.18 – 4.10 
(ddd, J = 7.7, 4.5, 1.8 Hz, 1H, CH), 3.18 – 3.07 (m, 1H, CH), 2.83 (dd, J = 12.4, 5.1 Hz, 1H, 
CH), 2.58 (d, J = 12.4 Hz, 1H, CH), 2.47 – 2.26 (m, 6H, CH2- CH2-CH2), 1.68 (s, 15H, Cp*-
CH3), 1.66 – 1.20 (m, 6H, CH2-CH2, CH2).  ESI-MS for IrC28H41N5O4S2Cl: [Cp*Ir(Biot–p–
L)Cl] : 442.1 (10) [LH+H]+ , 768 (100) [M-Cl+H]+. 
A7. SEQUENCES 
A.7.1 SAVK121A CODON OPTIMIZED SEQUENCE USED IN THIS PROTOCOL (CONSTRUCT 
CLONED INTO PET-24A) 
 
5´ATGGCAAGCATGACCGGTGGCCAGCAGATGGGTCGTGATCAGGCAGGTATT
ACCGGCACCTGGTATAATCAGCTGGGTAGCACCTTTATTGTTACCGCAGGCGC
AGATGGTGCACTGACCGGTACGTATGAAAGCGCAGTTGGTAATGCAGAAAGCC
GTTATGTTCTGACAGGTCGTTATGATAGCGCACCGGCAACCGATGGTAGCGGC
ACCGCACTGGGTTGGACCGTTGCATGGAAAAATAACTATCGTAATGCACATAG
CGCAACCACCTGGTCAGGTCAGTATGTTGGTGGTGCAGAAGCACGCATTAATA
CCCAGTGGCTGCTGACCAGCGGCACCACCGAAGCAAATGCCTGGGCAAGCAC
CCTGGTTGGTCATGATACCTTTACCAAAGTTAAACCGAGCGCAGCAAGCATTG
ATGCAGCAAAAAAAGCCGGTGTGAATAATGGTAATCCGCTGGATGCAGTTCAG
CAG 3´ 
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A.7.2. PRIMER SEQUENCES USED FOR MUTAGENESIS IN THIS PROTOCOL 
Table A4. Primer sequences used for the mutagenesis protocol. For clarity after three nucleotides a 
“space” is introduced. This does not corresponds to the specific triplet code for the amino acids. 
Primer 
Name 
Sequence (5´‐3´)  Primer 
Name 
Sequence (5´‐3´) 
48A_FW  GCA GTT GCT AAT GCA GAA AGC CGT TAT G  48A_RV  CTG CAT TAG CAA CTG CGC TTT CAT ACG 
48V_FW  GCA GTT GTT AAT GCA GAA AGC CGT TAT G  48V_RV  CTG CAT TAA CAA CTG CGC TTT CAT ACG 
48L_FW  GCA GTT CTT AAT GCA GAA AGC CGT TAT G 48L_RV CTG CAT TAA GAA CTG CGC TTT CAT ACG
48D_FW  GCA GTT GAT AAT GCA GAA AGC CGT TAT G  48D_RV  CTG CAT TAT CAA CTG CGC TTT CAT ACG 
48E_FW  GCA GTT GAA AAT GCA GAA AGC CGT TAT G  48E_RV  CTG CAT TTT CAA CTG CGC TTT CAT ACG 
48Q_FW  GCA GTT CAA AAT GCA GAA AGC CGT TAT G  48Q_RV  CTG CAT TTT GAA CTG CGC TTT CAT ACG 
48K_FW  GCA GTT AAG AAT GCA GAA AGC CGT TAT G 48K_RV CTG CAT TGT TAA CTG CGC TTT CAT ACG
48H_FW  GCA GTT CAT AAT GCA GAA AGC CGT TAT G  48H_RV  CTG CAT TAT GAA CTG CGC TTT CAT ACG 
48M_FW  GCA GTT ATG AAT GCA GAA AGC CGT TAT G  48M_RV  CTG CAT TCA TAA CTG CGC TTT CAT ACG 
48Y_FW  GCA GTT TAT AAT GCA GAA AGC CGT TAT G  48Y_RV  CTG CAT TAT AAA CTG CGC TTT CAT ACG 
48S_FW  GCA GTT AGT AAT GCA GAA AGC CGT TAT G 48S_RV CTG CAT TAC TAA CTG CGC TTT CAT ACG
48P_FW  GCA GTT CCT AAT GCA GAA AGC CGT TAT G  48P_RV  CTG CAT TAG GAA CTG CGC TTT CAT ACG 
69A_FW  GAT GGT GCC GGC ACC GCA CTG GGT TG  69A_RV  GTG CCG GCA CCA TCG GTT GCC GGT G 
69L_FW  GAT GGT CTC GGC ACC GCA CTG GGT TG  69L_RV  GTG CCG AGA CCA TCG GTT GCC GGT G 
69D_FW  GAT GGT GAC GGC ACC GCA CTG GGT TG 69D_RV GTG CCG TCA CCA TCG GTT GCC GGT G
69E_FW  GAT GGT GAA GGC ACC GCA CTG GGT TG  69E_RV  GTG CCT TCA CCA TCG GTT GCC GGT G 
69Q_FW  GAT GGT CAA GGC ACC GCA CTG GGT TG  69Q_RV  GTG CCT TGA CCA TCG GTT GCC GGT G 
69K_FW  GAT GGT AAG GGC ACC GCA CTG GGT TG  69K_RV  GTG CCC TTA CCA TCG GTT GCC GGT G 
69H_FW  GAT GGT CAT GGC ACC GCA CTG GGT TG 69H_RV GTG CCA TGA CCA TCG GTT GCC GGT G
69M_FW  GAT GGT ATG GGC ACC GCA CTG GGT TG  69M_RV  GTG CCC ATA CCA TCG GTT GCC GGT G 
69Y_FW  GAT GGT TAC GGC ACC GCA CTG GGT TG  69Y_RV  GTG CCG TAA CCA TCG GTT GCC GGT G 
69V_FW  GAT GGT GTC GGC ACC GCA CTG GGT TG  69V_RV  GTG CCG ACA CCA TCG GTT GCC GGT G 
69P_FW  GAT GGT CCA GGC ACC GCA CTG GGT TG  69P_RV  GTG CCT GGA CCA TCG GTT GCC GGT G 
69N_FW  GAT GGT AAC GGC ACC GCA CTG GGT TG 69N_RV GTG CCG TTA CCA TCG GTT GCC GGT G 
84A_FW  CTA TGC TAA TGC ACA TAG CGC AAC CAC C  84A_RV  CAT TAG CAT AGT TAT TTT TCC ATG CAA CGG 
84V_FW  CTA TGT TAA TGC ACA TAG CGC AAC CAC C  84V_RV  CAT TAA CAT AGT TAT TTT TCC ATG CAA CGG 
84L_FW  CTA TCT TAA TGC ACA TAG CGC AAC CAC C  84L_RV  CAT TAA GAT AGT TAT TTT TCC ATG CAA CGG 
84D_FW  CTA TGA TAA TGC ACA TAG CGC AAC CAC C 84D_RV CAT TAT CAT AGT TAT TTT TCC ATG CAA CGG
84E_FW  CTA TGA GAA TGC ACA TAG CGC AAC CAC C  84E_RV  CAT TCT CAT AGT TAT TTT TCC ATG CAA CGG 
84Q_FW  CTA TCA GAA TGC ACA TAG CGC AAC CAC C  84Q_RV  CAT TCT GAT AGT TAT TTT TCC ATG CAA CGG 
84K_FW  CTA TAA GAA TGC ACA TAG CGC AAC CAC C  84K_RV  CAT TCT TAT AGT TAT TTT TCC ATG CAA CGG 
84H_FW  CTA TCA TAA TGC ACA TAG CGC AAC CAC C 84H_RV CAT TAT GAT AGT TAT TTT TCC ATG CAA CGG
84M_FW  CTA TAT GAA TGC ACA TAG CGC AAC CAC C  84M_RV  CAT TCA TAT AGT TAT TTT TCC ATG CAA CGG 
84Y_FW  CTA TTA TAA TGC ACA TAG CGC AAC CAC C  84Y_RV  CAT TAT AAT AGT TAT TTT TCC ATG CAA CGG 
84S_FW  CTA TAG TAA TGC ACA TAG CGC AAC CAC C  84S_RV  CAT TAC TAT AGT TAT TTT TCC ATG CAA CGG 
84P_FW  CTA TCC TAA TGC ACA TAG CGC AAC CAC C 84P_RV CAT TAG GAT AGT TAT TTT TCC ATG CAA CGG
85A_FW  CTA TCG TGC TGC ACA TAG CGC AAC C  85A_RV  CTA TGT GCA GCA CGA TAG TTA TTT TTC CAT GC 
85V_FW  CTA TCG TGT TGC ACA TAG CGC AAC C  85V_RV  CTA TGT GCA ACA CGA TAG TTA TTT TTC CAT GC 
85L_FW  CTA TCG TCT TGC ACA TAG CGC AAC C  85L_RV  CTA TGT GCA AGA CGA TAG TTA TTT TTC CAT GC 
85D_FW  CTA TCG TGA TGC ACA TAG CGC AAC C  85D_RV  CTA TGT GCA TCA CGA TAG TTA TTT TTC CAT GC 
85E_FW  CTA TCG TGA AGC ACA TAG CGC AAC C  85E_RV  CTA TGT GCT TCA CGA TAG TTA TTT TTC CAT GC 
85Q_FW  CTA TCG TCA AGC ACA TAG CGC AAC C  85Q_RV  CTA TGT GCT TGA CGA TAG TTA TTT TTC CAT GC 
85K_FW  CTA TCG TAA AGC ACA TAG CGC AAC C  85K_RV  CTA TGT GCT TTA CGA TAG TTA TTT TTC CAT GC 
85H_FW  CTA TCG TCA TGC ACA TAG CGC AAC C  85H_RV  CTA TGT GCA TGA CGA TAG TTA TTT TTC CAT GC 
85M_FW  CTA TCG TAT GGC ACA TAG CGC AAC C  85M_RV  CTA TGT GCC ATA CGA TAG TTA TTT TTC CAT GC 
85Y_FW  CTA TCG TTA TGC ACA TAG CGC AAC C  85Y_RV  CTA TGT GCA TAA CGA TAG TTA TTT TTC CAT GC 
85S_FW  CTA TCG TAG TGC ACA TAG CGC AAC C  85S_RV  CTA TGT GCA CTA CGA TAG TTA TTT TTC CAT GC 
85P_FW  CTA TCG TCC TGC ACA TAG CGC AAC C  85P_RV  CTA TGT GCA GGA CGA TAG TTA TTT TTC CAT GC 
87A_FW  GTA ATG CAG CTA GCG CAA CCA CCT GGT C 87A_RV GCG CTA GCT GCA TTA CGA TAG TTA TTT TTC C
87V_FW  GTA ATG CAG TTA GCG CAA CCA CCT GGT C  87V_RV  GCG CTA ACT GCA TTA CGA TAG TTA TTT TTC C 
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87L_FW  GTA ATG CAC TTA GCG CAA CCA CCT GGT C 87L_RV GCG CTA AGT GCA TTA CGA TAG TTA TTT TTC C
87D_FW  GTA ATG CAG ATA GCG CAA CCA CCT GGT C  87D_RV  GCG CTA TCT GCA TTA CGA TAG TTA TTT TTC C 
87E_FW  GTA ATG CAG AAA GCG CAA CCA CCT GGT C  87E_RV  GCG CTT TCT GCA TTA CGA TAG TTA TTT TTC C 
87Q_FW  GTA ATG CAC AGA GCG CAA CCA CCT GGT C  87Q_RV  GCG CTC TGT GCA TTA CGA TAG TTA TTT TTC C 
87K_FW  GTA ATG CAA AGA GCG CAA CCA CCT GGT C 87K_RV GCG CTC TTT GCA TTA CGA TAG TTA TTT TTC C
87M_FW  GTA ATG CAA TGA GCG CAA CCA CCT GGT C  87M_RV  GCG CTC ATT GCA TTA CGA TAG TTA TTT TTC C 
87Y_FW  GTA ATG CAT ATA GCG CAA CCA CCT GGT C  87Y_RV  GCG CTA TAT GCA TTA CGA TAG TTA TTT TTC C 
87S_FW  GTA ATG CAT CAA GCG CAA CCA CCT GGT C  87S_RV  GCG CTT GAT GCA TTA CGA TAG TTA TTT TTC C 
87P_FW  GTA ATG CAC CTA GCG CAA CCA CCT GGT C  87P_RV  GCG CTA GGT GCA TTA CGA TAG TTA TTT TTC C 
87N_FW  GTA ATG CAA ATA GCG CAA CCA CCT GGT C 87N_RV GCG CTA TTT GCA TTA CGA TAG TTA TTT TTC C
98A_FW  GTA TGT TGC TGG TGC AGA AGC ACG CAT TAA TAC C  98A_RV  CTG CAC CAG CAA CAT ACT GAC CTG ACC AG 
98V_FW  GTA TGT TGT TGG TGC AGA AGC ACG CAT TAA TAC C  98V_RV  CTG CAC CAA CAA CAT ACT GAC CTG ACC AG 
98L_FW  GTA TGT TCT TGG TGC AGA AGC ACG CAT TAA TAC C  98L_RV  CTG CAC CAA GAA CAT ACT GAC CTG ACC AG 
98D_FW  GTA TGT TGA TGG TGC AGA AGC ACG CAT TAA TAC C  98D_RV  CTG CAC CAT CAA CAT ACT GAC CTG ACC AG 
98E_FW  GTA TGT TGA AGG TGC AGA AGC ACG CAT TAA TAC C  98E_RV  CTG CAC CTT CAA CAT ACT GAC CTG ACC AG 
98Q_FW  GTA TGT TCA AGG TGC AGA AGC ACG CAT TAA TAC C  98Q_RV  CTG CAC CTT GAA CAT ACT GAC CTG ACC AG 
98K_FW  GTA TGT TAA GGG TGC AGA AGC ACG CAT TAA TAC C  98K_RV  CTG CAC CGT TAA CAT ACT GAC CTG ACC AG 
98H_FW  GTA TGT TCA TGG TGC AGA AGC ACG CAT TAA TAC C  98H_RV  CTG CAC CAT GAA CAT ACT GAC CTG ACC AG 
98M_FW  GTA TGT TAT GGG TGC AGA AGC ACG CAT TAA TAC C  98M_RV  CTG CAC CCA TAA CAT ACT GAC CTG ACC AG 
98Y_FW  GTA TGT TTA TGG TGC AGA AGC ACG CAT TAA TAC C  98Y_RV  CTG CAC CAT AAA CAT ACT GAC CTG ACC AG 
98S_FW  GTA TGT TAG TGG TGC AGA AGC ACG CAT TAA TAC C  98S_RV  CTG CAC CAC TAA CAT ACT GAC CTG ACC AG 
98P_FW  GTA TGT TCCTGG TGC AGA AGC ACG CAT TAA TAC C  98P_RV  CTG CAC CAG GAA CAT ACT GAC CTG ACC AG 
119V_FW  GCA AAT GTC TGG GCA AGC ACC CTG G 119V_RV GCC CAG ACA TTT GCT TCG GTG GTG C 
119L_FW  GCA AAT CTC TGG GCA AGC ACC CTG G  119L_RV  GCC CAG AGA TTT GCT TCG GTG GTG C 
119D_FW  GCA AAT GAC TGG GCA AGC ACC CTG G  119D_RV  GCC CAG TCA TTT GCT TCG GTG GTG C 
119E_FW  GCA AAT GAA TGG GCA AGC ACC CTG G  119E_RV  GCC CAT TCA TTT GCT TCG GTG GTG C 
119Q_FW  GCA AAT CAG TGG GCA AGC ACC CTG G 119Q_RV GCC CAC TGA TTT GCT TCG GTG GTG C 
119K_FW  GCA AAT AAA TGG GCA AGC ACC CTG G  119K_RV  GCC CAT TTA TTT GCT TCG GTG GTG C 
119H_FW  GCA AAT CAC TGG GCA AGC ACC CTG G  119H_RV  GCC CAG TGA TTT GCT TCG GTG GTG C 
119M_FW  GCA AAT ATG TGG GCA AGC ACC CTG G  119M_RV  GCC CAC ATA TTT GCT TCG GTG GTG C 
119Y_FW  GCA AAT TAC TGG GCA AGC ACC CTG G 119Y_RV GCC CAG TAA TTT GCT TCG GTG GTG C 
119S_FW  GCA AAT TCC TGG GCA AGC ACC CTG G  119S_RV  GCC CAG GAA TTT GCT TCG GTG GTG C 
119P_FW  GCA AAT CCC TGG GCA AGC ACC CTG G  119P_RV  GCC CAG GGA TTT GCT TCG GTG GTG C 
119N_FW  GCA AAT AAC TGG GCA AGC ACC CTG G  119N_RV  GCC CAG TTA TTT GCT TCG GTG GTG C 
150A_FW  GTG AAT GCT GGT AAT CCG CTG GAT GC 150A_RV GAT TAC CAG CAT TCA CAC CGG CTT TTT TTG C
150V_FW  GTG AAT GTT GGT AAT CCG CTG GAT GC  150V_RV  GAT TAC CAA CAT TCA CAC CGG CTT TTT TTG C 
150L_FW  GTG AAT CTT GGT AAT CCG CTG GAT GC  150L_RV  GAT TAC CAA GAT TCA CAC CGG CTT TTT TTG C 
150D_FW  GTG AAT GAT GGT AAT CCG CTG GAT GC  150D_RV  GAT TAC CAT CAT TCA CAC CGG CTT TTT TTG C 
150E_FW  GTG AAT GAA GGT AAT CCG CTG GAT GC 150E_RV GAT TAC CTT CAT TCA CAC CGG CTT TTT TTG C
150Q_FW  GTG AAT CAA GGT AAT CCG CTG GAT GC  150Q_RV  GAT TAC CTT GAT TCA CAC CGG CTT TTT TTG C 
150K_FW  GTG AAT AAA GGT AAT CCG CTG GAT GC  150K_RV  GAT TAC CTT TAT TCA CAC CGG CTT TTT TTG C 
150H_FW  GTG AAT CAT GGT AAT CCG CTG GAT GC  150H_RV  GAT TAC CAT GAT TCA CAC CGG CTT TTT TTG C 
150M_FW  GTG AAT ATG GGT AAT CCG CTG GAT GC 150M_RV GAT TAC CCA TAT TCA CAC CGG CTT TTT TTG C
150Y_FW  GTG AAT TAT GGT AAT CCG CTG GAT GC  150Y_RV  GAT TAC CAT AAT TCA CAC CGG CTT TTT TTG C 
150S_FW  GTG AAT AGT GGT AAT CCG CTG GAT GC  150S_RV  GAT TAC CAC TAT TCA CAC CGG CTT TTT TTG C 
150P_FW  GTG AAT CCT GGT AAT CCG CTG GAT GC  150P_RV  GAT TAC CAG GAT TCA CAC CGG CTT TTT TTG C 
64A_FW  GAT AGC GCA GCG GCA ACC GAT GGT AGC  64A_RV  GGT TGC CGC TGC GCT ATC ATA ACG ACC TGT C 
64V_FW  GAT AGC GCA GTG GCA ACC GAT GGT AGC  64V_RV  GGT TGC CAC TGC GCT ATC ATA ACG ACC TGT C 
64L_FW  GAT AGC GCA CTG GCA ACC GAT GGT AGC  64L_RV  GGT TGC CAG TGC GCT ATC ATA ACG ACC TGT C 
64D_FW  GAT AGC GCA GAT GCA ACC GAT GGT AGC  64D_RV  GGT TGC ATC TGC GCT ATC ATA ACG ACC TGT C 
64E_FW  GAT AGC GCA GAG GCA ACC GAT GGT AGC  64E_RV  GGT TGC CTC TGC GCT ATC ATA ACG ACC TGT C 
64Q_FW  GAT AGC GCA CAG GCA ACC GAT GGT AGC  64Q_RV  GGT TGC CTG TGC GCT ATC ATA ACG ACC TGT C 
64K_FW  GAT AGC GCA AAG GCA ACC GAT GGT AGC  64K_RV  GGT TGC CTT TGC GCT ATC ATA ACG ACC TGT C 
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64H_FW  GAT AGC GCA CAT GCA ACC GAT GGT AGC  64H_RV  GGT TGC ATG TGC GCT ATC ATA ACG ACC TGT C 
64M_FW  GAT AGC GCA ATG GCA ACC GAT GGT AGC  64M_RV  GGT TGC CAT TGC GCT ATC ATA ACG ACC TGT C 
64Y_FW  GAT AGC GCA TAT GCA ACC GAT GGT AGC  64Y_RV  GGT TGC ATA TGC GCT ATC ATA ACG ACC TGT C 
64S_FW  GAT AGC GCA TCG GCA ACC GAT GGT AGC  64S_RV  GGT TGC CGA TGC GCT ATC ATA ACG ACC TGT C 
64N_FW  GAT AGC GCA AAT GCA ACC GAT GGT AGC  64N_RV  GGT TGC ATT TGC GCT ATC ATA ACG ACC TGT C 
65V_FW  CAC CGG TAA CCG ATG GTA GCG GCA CC  65V_RV  CAT CGG TTA CCG GTG CGC TAT CAT AAC G 
65L_FW  CAC CGC TAA CCG ATG GTA GCG GCA CC  65L_RV  CAT CGG TTA GCG GTG CGC TAT CAT AAC G 
65D_FW  CAC CGG ACA CCG ATG GTA GCG GCA CC  65D_RV  CAT CGG TGT CCG GTG CGC TAT CAT AAC G 
65E_FW  CAC CGG AAA CCG ATG GTA GCG GCA CC 65E_RV CAT CGG TTT CCG GTG CGC TAT CAT AAC G
65Q_FW  CAC CGC AAA CCG ATG GTA GCG GCA CC  65Q_RV  CAT CGG TTT GCG GTG CGC TAT CAT AAC G 
65K_FW  CAC CGA AAA CCG ATG GTA GCG GCA CC  65K_RV  CAT CGG TTT TCG GTG CGC TAT CAT AAC G 
65H_FW  CAC CGC ATA CCG ATG GTA GCG GCA CC  65H_RV  CAT CGG TAT GCG GTG CGC TAT CAT AAC G 
65M_FW  CAC CGA TGA CCG ATG GTA GCG GCA CC 65M_RV CAT CGG TCA TCG GTG CGC TAT CAT AAC G
65Y_FW  CAC CGT ACA CCG ATG GTA GCG GCA CC  65Y_RV  CAT CGG TGT ACG GTG CGC TAT CAT AAC G 
65S_FW  CAC CGT CAA CCG ATG GTA GCG GCA CC  65S_RV  CAT CGG TTG ACG GTG CGC TAT CAT AAC G 
65P_FW  CAC CGC CAA CCG ATG GTA GCG GCA CC  65P_RV  CAT CGG TTG GCG GTG CGC TAT CAT AAC G 
65N_FW  CAC CGA ACA CCG ATG GTA GCG GCA CC 65N_RV CAT CGG TGT TCG GTG CGC TAT CAT AAC G
113A_FW  CCA GCG CCA CCA CCG AAG CAA ATG CC  113A_RV  GGT GGT GGC GCT GGT CAG CAG CCA C 
113V_FW  CCA GCG TCA CCA CCG AAG CAA ATG CC  113V_RV  GGT GGT GAC GCT GGT CAG CAG CCA C 
113L_FW  CCA GCC TCA CCA CCG AAG CAA ATG CC  113L_RV  GGT GGT GAG GCT GGT CAG CAG CCA C 
113D_FW  CCA GCG ACA CCA CCG AAG CAA ATG CC 113D_RV GGT GGT GTC GCT GGT CAG CAG CCA C
113E_FW  CCA GCG AAA CCA CCG AAG CAA ATG CC  113E_RV  GGT GGT TTC GCT GGT CAG CAG CCA C 
113Q_FW  CCA GCC AGA CCA CCG AAG CAA ATG CC  113Q_RV  GGT GGT CTG GCT GGT CAG CAG CCA C 
113K_FW  CCA GCA AAA CCA CCG AAG CAA ATG CC  113K_RV  GGT GGT TTT GCT GGT CAG CAG CCA C 
113H_FW  CCA GCC ACA CCA CCG AAG CAA ATG CC 113H_RV GGT GGT GTG GCT GGT CAG CAG CCA C
113M_FW  CCA GCA TGA CCA CCG AAG CAA ATG CC  113M_RV  GGT GGT CAT GCT GGT CAG CAG CCA C 
113Y_FW  CCA GCT ACA CCA CCG AAG CAA ATG CC  113Y_RV  GGT GGT GTA GCT GGT CAG CAG CCA C 
113S_FW  CCA GCA GCA CCA CCG AAG CAA ATG CC  113S_RV  GGT GGT GCT GCT GGT CAG CAG CCA C 
113P_FW  CCA GCC CCA CCA CCG AAG CAA ATG CC  113P_RV  GGT GGT GGG GCT GGT CAG CAG CCA C 
117V_FW  CCG AAG TAA ATG CCT GGG CAA GCA CC 117V_RV GCA TTT ACT TCG GTG GTG CCG CTG G 
117L_FW  CCG AAC TAA ATG CCT GGG CAA GCA CC  117L_RV  GCA TTT AGT TCG GTG GTG CCG CTG G 
117D_FW  CCG AAG ACA ATG CCT GGG CAA GCA CC  117D_RV  GCA TTG TCT TCG GTG GTG CCG CTG G 
117E_FW  CCG AAG AAA ATG CCT GGG CAA GCA CC  117E_RV  GCA TTT TCT TCG GTG GTG CCG CTG G 
117Q_FW  CCG AAC AAA ATG CCT GGG CAA GCA CC 117Q_RV GCA TTT TGT TCG GTG GTG CCG CTG G 
117K_FW  CCG AAA AAA ATG CCT GGG CAA GCA CC  117K_RV  GCA TTT TTT TCG GTG GTG CCG CTG G 
117H_FW  CCG AAC ATA ATG CCT GGG CAA GCA CC  117H_RV  GCA TTA TGT TCG GTG GTG CCG CTG G 
117M_FW  CCG AAA TGA ATG CCT GGG CAA GCA CC  117M_RV  GCA TTC ATT TCG GTG GTG CCG CTG G 
117Y_FW  CCG AAT ACA ATG CCT GGG CAA GCA CC 117Y_RV GCA TTG TAT TCG GTG GTG CCG CTG G
117S_FW  CCG AAT CAA ATG CCT GGG CAA GCA CC  117S_RV  GCA TTT GAT TCG GTG GTG CCG CTG G 
117P_FW  CCG AAC CAA ATG CCT GGG CAA GCA CC  117P_RV  GCA TTT GGT TCG GTG GTG CCG CTG G 
117N_FW  CCG AAA ACA ATG CCT GGG CAA GCA CC  117N_RV  GCA TTG TTT TCG GTG GTG CCG CTG G 
122A_FW  CTG GGC AGC CAC CCT GGT TGG TCA TGA TAC C  122A_RV  CAG GGT GGC TGC CCA GGC ATT TGC TTC G 
122V_FW  CTG GGC AGT CAC CCT GGT TGG TCA TGA TAC C  122V_RV  CAG GGT GAC TGC CCA GGC ATT TGC TTC G 
122L_FW  CTG GGC ACT CAC CCT GGT TGG TCA TGA TAC C  122L_RV  CAG GGT GAG TGC CCA GGC ATT TGC TTC G 
122D_FW  CTG GGC AGA CAC CCT GGT TGG TCA TGA TAC C  122D_RV  CAG GGT GTC TGC CCA GGC ATT TGC TTC G 
122E_FW  CTG GGC AGA AAC CCT GGT TGG TCA TGA TAC C  122E_RV  CAG GGT TTC TGC CCA GGC ATT TGC TTC G 
122Q_FW  CTG GGC ACA GAC CCT GGT TGG TCA TGA TAC C  122Q_RV  CAG GGT CTG TGC CCA GGC ATT TGC TTC G 
122K_FW  CTG GGC AAA AAC CCT GGT TGG TCA TGA TAC C  122K_RV  CAG GGT TTT TGC CCA GGC ATT TGC TTC G 
122H_FW  CTG GGC ACA CAC CCT GGT TGG TCA TGA TAC C  122H_RV  CAG GGT GTG TGC CCA GGC ATT TGC TTC G 
122M_FW  CTG GGC AAT GAC CCT GGT TGG TCA TGA TAC C  122M_RV  CAG GGT CAT TGC CCA GGC ATT TGC TTC G 
122Y_FW  CTG GGC ATA CAC CCT GGT TGG TCA TGA TAC C  122Y_RV  CAG GGT GTA TGC CCA GGC ATT TGC TTC G 
122P_FW  G GGC ACC CAC CCT GGT TGG TCA TGA TAC C  122P_RV  G GGT GGG TGC CCA GGC ATT TGC TTC G 
122N_FW  CTG GGC AAACAC CCT GGT TGG TCA TGA TAC C  122N_RV  CAG GGT GTT TGC CCA GGC ATT TGC TTC G 
123A_FW  GGC AAG CGC CCT GGT TGG TCA TGA TAC C  123A_RV  CAA CCA GGG CGC TTG CCC AGG CAT TTG C 
123V_FW  GGC AAG CGT CCT GGT TGG TCA TGA TAC C  123V_RV  CAA CCA GGA CGC TTG CCC AGG CAT TTG C 
123L_FW  GGC AAG CCT CCT GGT TGG TCA TGA TAC C 123L_RV CAA CCA GGA GGC TTG CCC AGG CAT TTG C
A30 
 
123D_FW  GGC AAG CGA CCT GGT TGG TCA TGA TAC C 123D_RV CAA CCA GGT CGC TTG CCC AGG CAT TTG C
123E_FW  GGC AAG CGA ACT GGT TGG TCA TGA TAC C  123E_RV  CAA CCA GTT CGC TTG CCC AGG CAT TTG C 
123Q_FW  GGC AAG CCA ACT GGT TGG TCA TGA TAC C  123Q_RV  CCA GTT GGC TTG CCC AGG CAT TTG C 
123K_FW  GGC AAG CAA ACT GGT TGG TCA TGA TAC C  123K_RV  CAA CCA GTT TGC TTG CCC AGG CAT TTG C 
123H_FW  GGC AAG CCA CCT GGT TGG TCA TGA TAC C 123H_RV CAA CCA GGT GGC TTG CCC AGG CAT TTG C
123M_FW  GGC AAG CAT GCT GGT TGG TCA TGA TAC C  123M_RV  CAA CCA GCA TGC TTG CCC AGG CAT TTG C 
123Y_FW  GGC AAG CTA CCT GGT TGG TCA TGA TAC C  123Y_RV  CAA CCA GGT AGC TTG CCC AGG CAT TTG C 
123S_FW  GGC AAG CTC CCT GGT TGG TCA TGA TAC C  123S_RV  CAA CCA GGG AGC TTG CCC AGG CAT TTG C 
123P_FW  GGC AAG CCC CCT GGT TGG TCA TGA TAC C  123P_RV  CAA CCA GGG GGC TTG CCC AGG CAT TTG C 
124A_FW  CAA GCA CCG CGG TTG GTC ATG ATA CCT TTA CC  124A_RV  CCA ACC GCG GTG CTT GCC CAG GCA TTTGC 
124V_FW  CAA GCA CCG TGG TTG GTC ATG ATA CCT TTA CC  124V_RV  CCA ACC ACG GTG CTT GCC CAG GCA TTTGC 
124D_FW  CAA GCA CCG ATG TTG GTC ATG ATA CCT TTA CC  124D_RV  CCA ACA TCG GTG CTT GCC CAG GCA TTTGC 
124E_FW  CAA GCA CCG AGG TTG GTC ATG ATA CCT TTA CC  124E_RV  CCA ACC TCG GTG CTT GCC CAG GCA TTTGC 
124Q_FW  CAA GCA CCC AGG TTG GTC ATG ATA CCT TTA CC  124Q_RV  CCA ACC TGG GTG CTT GCC CAG GCA TTTGC 
124K_FW  CAA GCA CCA AGG TTG GTC ATG ATA CCT TTA CC  124K_RV  CA ACC TTG GTG CTT GCC CAG GCA TTTGC 
124H_FW  CAA GCA CCC ACG TTG GTC ATG ATA CCT TTA CC  124H_RV  CCA ACG TGG GTG CTT GCC CAG GCA TTTGC 
124M_FW  CAA GCA CCA TGG TTG GTC ATG ATA CCT TTA CC  124M_RV  CCA ACC ATG GTG CTT GCC CAG GCA TTTGC 
124Y_FW  CAA GCA CCT ACG TTG GTC ATG ATA CCT TTA CC  124Y_RV  CCA ACG TAG GTG CTT GCC CAG GCA TTTGC 
124S_FW  CAA GCA CCT CGG TTG GTC ATG ATA CCT TTA CC  124S_RV  CCA ACC GAG GTG CTT GCC CAG GCA TTTGC 
124P_FW  CAA GCA CCC CGG TTG GTC ATG ATA CCT TTA CC  124P_RV  CCA ACC GGG GTG CTT GCC CAG GCA TTTGC 
124N_FW  CAA GCA CCA ACG TTG GTC ATG ATA CCT TTA CC  124N_RV  CCA ACG TTG GTG CTT GCC CAG GCA TTTGC 
144A_FW  GCA GCA GCA AAA GCC GGT GTG AAT AAT GG  144A_RV  GGC TTTTGCTGCTGCATCAATGCTTGC 
144V_FW  GCA GCA GTA AAA GCC GGT GTG AAT AAT GG 144V_RV GGC TTTTACTGCTGCATCAATGCTTGC 
144L_FW  GCA GCA CTA AAA GCC GGT GTG AAT AAT GG  144L_RV  GGC TTTTAGTGCTGCATCAATGCTTGC 
144D_FW  GCA GCA GAT AAA GCC GGT GTG AAT AAT GG  144D_RV  GGC TTT ATC TGC TGC ATC AAT GCT TGC 
144E_FW  GCA GCA GAA AAA GCC GGT GTG AAT AAT GG  144E_RV  GGC TTT TTC TGC TGC ATC AAT GCT TGC 
144Q_FW  GCA GCA CAA AAA GCC GGT GTG AAT AAT GG 144Q_RV GGC TTT TTG TGC TGC ATC AAT GCT TGC 
144H_FW  GCA GCA CAT AAA GCC GGT GTG AAT AAT GG  144H_RV  GGC TTT ATG TGC TGC ATC AAT GCT TGC 
144M_FW  GCA GCA ATG AAA GCC GGT GTG AAT AAT GG  144M_RV  GGC TTT CAT TGC TGC ATC AAT GCT TGC 
144Y_FW  GCA GCA TAC AAA GCC GGT GTG AAT AAT GG  144Y_RV  GGC TTT GTA TGC TGC ATC AAT GCT TGC 
144S_FW  GCA GCA AGC AAA GCC GGT GTG AAT AAT GG 144S_RV GGC TTT GCT TGC TGC ATC AAT GCT TGC 
144P_FW  GCA GCA CCA AAA GCC GGT GTG AAT AAT GG  144P_RV  GGC TTT TGG TGC TGC ATC AAT GCT TGC 
144N_FW  GCA GCA AAC AAA GCC GGT GTG AAT AAT GG  144N_RV  GGC TTT GTT TGC TGC ATC AAT GCT TGC 
67A_FW  CAA CCG CTG GTA GCG GCA CCG CAC TG  67A_RV  GCT ACC AGC GGT TGC CGG TGC GCT ATC 
67V_FW  CAA CCG TTG GTA GCG GCA CCG CAC TG 67V_RV GCT ACC AAC GGT TGC CGG TGC GCT ATC 
67L_FW  CAA CCC TTG GTA GCG GCA CCG CAC TG  67L_RV  GCT ACC AAG GGT TGC CGG TGC GCT ATC 
67E_FW  CAA CCG AAG GTA GCG GCA CCG CAC TG  67E_RV  GCT ACC TTC GGT TGC CGG TGC GCT ATC 
67Q_FW  CAA CCC AAG GTA GCG GCA CCG CAC TG  67Q_RV  GCT ACC TTG GGT TGC CGG TGC GCT ATC 
67K_FW  CAA CCA AAG GTA GCG GCA CCG CAC TG 67K_RV GCT ACC TTT GGT TGC CGG TGC GCT ATC 
67H_FW  CAA CCC ATG GTA GCG GCA CCG CAC TG  67H_RV  GCT ACC ATG GGT TGC CGG TGC GCT ATC 
67M_FW  CAA CCA TGG GTA GCG GCA CCG CAC TG  67M_RV  GCT ACC CAT GGT TGC CGG TGC GCT ATC 
67Y_FW  CAA CCT ATG GTA GCG GCA CCG CAC TG  67Y_RV  GCT ACC ATA GGT TGC CGG TGC GCT ATC 
67S_FW  CAA CCT CTG GTA GCG GCA CCG CAC TG 67S_RV GCT ACC AGA GGT TGC CGG TGC GCT ATC 
67P_FW  CAA CCC CTG GTA GCG GCA CCG CAC TG  67P_RV  GCT ACC AGG GGT TGC CGG TGC GCT ATC 
67N_FW  CAA CCA ATG GTA GCG GCA CCG CAC TG  67N_RV  GCT ACC TTA GGT TGC CGG TGC GCT ATC 
86A_FW  CCG ATGCTA GCG GCA CCG CAC TGG GTT GG  86A_RV  GTG CCG CTA GCA TCG GTT GCC GGT GCG 
86V_FW  CCG ATGTTA GCG GCA CCG CAC TGG GTT GG  86V_RV  GTG CCG CTA ACA TCG GTT GCC GGT GCG 
86L_FW  CCG ATCTTA GCG GCA CCG CAC TGG GTT GG 86L_RV GTG CCG CTA AGA TCG GTT GCC GGT GCG 
86D_FW  CCG ATGATA GCG GCA CCG CAC TGG GTT GG  86D_RV  GTG CCG CTA TCA TCG GTT GCC GGT GCG 
86E_FW  CCG ATGAAA GCG GCA CCG CAC TGG GTT GG  86E_RV  GTG CCG CTT TCA TCG GTT GCC GGT GCG 
86Q_FW  CCG ATCAAA GCG GCA CCG CAC TGG GTT GG  86Q_RV  GTG CCG CTT TGA TCG GTT GCC GGT GCG 
86K_FW  CCG ATAAAA GCG GCA CCG CAC TGG GTT GG 86K_RV GTG CCG CTT TTA TCG GTT GCC GGT GCG 
86H_FW  CCG ATCATA GCG GCA CCG CAC TGG GTT GG  86H_RV  GTG CCG CTA TGA TCG GTT GCC GGT GCG 
86M_FW  CCG ATATGA GCG GCA CCG CAC TGG GTT GG  86M_RV  GTG CCG CTC ATA TCG GTT GCC GGT GCG 
86Y_FW  CCG ATTATA GCG GCA CCG CAC TGG GTT GG  86Y_RV  GTG CCG CTA TAA TCG GTT GCC GGT GCG 
86S_FW  CCG ATAGTA GCG GCA CCG CAC TGG GTT GG 86S_RV GTG CCG CTA CTA TCG GTT GCC GGT GCG 
86P_FW  CCG ATCCTA GCG GCA CCG CAC TGG GTT GG  86P_RV  GTG CCG CTA GGA TCG GTT GCC GGT GCG 
110A_FW  GCT GGC GAC CAG CGG CAC CAC CGA AG  110A_RV  GCT GGT CGC CAG CCA CTG GGT ATT AAT GCG 
110V_FW  GCT GGT GAC CAG CGG CAC CAC CGA AG  110V_RV  GCT GGT CAC CAG CCA CTG GGT ATT AAT GCG 
110D_FW  GCT GGA TAC CAG CGG CAC CAC CGA AG 110D_RV GCT GGT ATC CAG CCA CTG GGT ATT AAT GCG
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110E_FW  GCT GGA GAC CAG CGG CAC CAC CGA AG 110E_RV GCT GGT CTC CAG CCA CTG GGT ATT AAT GCG
110Q_FW  GCT GCA GAC CAG CGG CAC CAC CGA AG  110Q_RV  GCT GGT CTG CAG CCA CTG GGT ATT AAT GCG 
110K_FW  GCT GAA GAC CAG CGG CAC CAC CGA AG  110K_RV  GCT GGT CTT CAG CCA CTG GGT ATT AAT GCG 
110H_FW  GCT GCA CAC CAG CGG CAC CAC CGA AG  110H_RV  GCT GGT GTG CAG CCA CTG GGT ATT AAT GCG 
110M_FW  GCT GAT GAC CAG CGG CAC CAC CGA AG 110M_RV GCT GGT CAT CAG CCA CTG GGT ATT AAT GCG
110Y_FW  GCT GTA CAC CAG CGG CAC CAC CGA AG  110Y_RV  GCT GGT GTA CAG CCA CTG GGT ATT AAT GCG 
110S_FW  GCT GTC GAC CAG CGG CAC CAC CGA AG  110S_RV  GCT GGT CGA CAG CCA CTG GGT ATT AAT GCG 
110P_FW  GCT GCC GAC CAG CGG CAC CAC CGA AG  110P_RV  GCT GGT CGG CAG CCA CTG GGT ATT AAT GCG 
110N_FW  GCT GAA CAC CAG CGG CAC CAC CGA AG  110N_RV  GCT GGT GTT CAG CCA CTG GGT ATT AAT GCG 
111A_FW  CTG CTG GCC AGC GGC ACC ACC GAA GC  111A_RV  CCG CTG GCC AGC AGC CAC TGG GTA TTA ATG C 
111V_FW  CTG CTG GTC AGC GGC ACC ACC GAA GC  111V_RV  CCG CTG ACC AGC AGC CAC TGG GTA TTA ATG C 
111L_FW  CTG CTG CTC AGC GGC ACC ACC GAA GC  111L_RV  CCG CTG AGC AGC AGC CAC TGG GTA TTA ATG C 
111D_FW  CTG CTG GAC AGC GGC ACC ACC GAA GC  111D_RV  CCG CTG TCC AGC AGC CAC TGG GTA TTA ATG C 
111E_FW  CTG CTG GAA AGC GGC ACC ACC GAA GC  111E_RV  CCG CTT TCC AGC AGC CAC TGG GTA TTA ATG C 
111Q_FW  CTG CTG CAA AGC GGC ACC ACC GAA GC  111Q_RV  CCG CTT TGC AGC AGC CAC TGG GTA TTA ATG C 
111K_FW  CTG CTG AAA AGC GGC ACC ACC GAA GC  111K_RV  CCG CTT TTC AGC AGC CAC TGG GTA TTA ATG C 
111H_FW  CTG CTG CAC AGC GGC ACC ACC GAA GC  111H_RV  CCG CTG TGC AGC AGC CAC TGG GTA TTA ATG C 
111M_FW  CTG CTG ATG AGC GGC ACC ACC GAA GC  111M_RV  CCG CTC ATC AGC AGC CAC TGG GTA TTA ATG C 
111Y_FW  CTG CTG TAC AGC GGC ACC ACC GAA GC  111Y_RV  CCG CTG TAC AGC AGC CAC TGG GTA TTA ATG C 
111S_FW  CTG CTG TCC AGC GGC ACC ACC GAA GC  111S_RV  CCG CTG GAC AGC AGC CAC TGG GTA TTA ATG C 
111P_FW  CTG CTG CCC AGC GGC ACC ACC GAA GC  111P_RV  CCG CTG GGC AGC AGC CAC TGG GTA TTA ATG C 
114A_FW  GCG GCG CCA CCG AAG CAA ATG CCT GG  114A_RV  CTT CGG TGG CGC CGC TGG TCA GCA GCC 
114V_FW  GCG GCG TCA CCG AAG CAA ATG CCT GG 114V_RV CTT CGG TGA CGC CGC TGG TCA GCA GCC
114L_FW  GCG GCC TCA CCG AAG CAA ATG CCT GG  114L_RV  CTT CGG TGA GGC CGC TGG TCA GCA GCC 
114D_FW  GCG GCG ACA CCG AAG CAA ATG CCT GG  114D_RV  CTT CGG TGT CGC CGC TGG TCA GCA GCC 
114E_FW  GCG GCG AAA CCG AAG CAA ATG CCT GG  114E_RV  CTT CGG TTT CGC CGC TGG TCA GCA GCC 
114Q_FW  GCG GCC AAA CCG AAG CAA ATG CCT GG 114Q_RV CTT CGG TTT GGC CGC TGG TCA GCA GCC
114K_FW  GCG GCA AAA CCG AAG CAA ATG CCT GG  114K_RV  CTT CGG TTT TGC CGC TGG TCA GCA GCC 
114H_FW  GCG GCC ACA CCG AAG CAA ATG CCT GG  114H_RV  CTT CGG TGT GGC CGC TGG TCA GCA GCC 
114M_FW  GCG GCA TGA CCG AAG CAA ATG CCT GG  114M_RV  CTT CGG TCA TGC CGC TGG TCA GCA GCC 
114Y_FW  GCG GCT ACA CCG AAG CAA ATG CCT GG 114Y_RV CTT CGG TGT AGC CGC TGG TCA GCA GCC
114S_FW  GCG GCT CCA CCG AAG CAA ATG CCT GG  114S_RV  CTT CGG TGG AGC CGC TGG TCA GCA GCC 
114P_FW  GCG GCC CCA CCG AAG CAA ATG CCT GG  114P_RV  CTT CGG TGG GGC CGC TGG TCA GCA GCC 
115A_FW  GCA CCG CCG AAG CAA ATG CCT GGG CAA GC  115A_RV  GCT TCG GCG GTG CCG CTG GTC AGC AG 
115V_FW  GCA CCG TCG AAG CAA ATG CCT GGG CAA GC 115V_RV GCT TCG ACG GTG CCG CTG GTC AGC AG
115L_FW  GCA CCC TCG AAG CAA ATG CCT GGG CAA GC  115L_RV  GCT TCG AGG GTG CCG CTG GTC AGC AG 
115D_FW  GCA CCG ACG AAG CAA ATG CCT GGG CAA GC  115D_RV  GCT TCG TCG GTG CCG CTG GTC AGC AG 
115E_FW  GCA CCG AAG AAG CAA ATG CCT GGG CAA GC  115E_RV  GCT TCT TCG GTG CCG CTG GTC AGC AG 
115Q_FW  GCA CCC AAG AAG CAA ATG CCT GGG CAA GC 115Q_RV GCT TCT TGG GTG CCG CTG GTC AGC AG
115K_FW  GCA CCA AAG AAG CAA ATG CCT GGG CAA GC  115K_RV  GCT TCT TTG GTG CCG CTG GTC AGC AG 
115H_FW  GCA CCC ACG AAG CAA ATG CCT GGG CAA GC  115H_RV  GCT TCG TGG GTG CCG CTG GTC AGC AG 
115M_FW  GCA CCA TGG AAG CAA ATG CCT GGG CAA GC  115M_RV  GCT TCC ATG GTG CCG CTG GTC AGC AG 
115Y_FW  GCA CCT ACG AAG CAA ATG CCT GGG CAA GC 115Y_RV GCT TCG TAG GTG CCG CTG GTC AGC AG
115S_FW  GCA CCT CCG AAG CAA ATG CCT GGG CAA GC  115S_RV  GCT TCG GAG GTG CCG CTG GTC AGC AG 
115P_FW  GCA CCC CCG AAG CA A ATG CCT GGG CAA GC  115P_RV  GCT TCG GGG GTG CCG CTG GTC AGC AG 
116A_FW  CAC CAC CGC AGC AAA TGC CTG GGC AAG C  116A_RV  CAT TTG CTG CGG TGG TGC CGC TGG TCA G 
116V_FW  CAC CAC CGT AGC AAA TGC CTG GGC AAG C  116V_RV  CAT TTG CTA CGG TGG TGC CGC TGG TCA G 
116L_FW  CAC CAC CTT AGC AAA TGC CTG GGC AAG C 116L_RV CAT TTG CTA AGG TGG TGC CGC TGG TCA G
116D_FW  CAC CAC CGA TGC AAA TGC CTG GGC AAG C  116D_RV  CAT TTG CAT CGG TGG TGC CGC TGG TCA G 
116Q_FW  CAC CAC CCA AGC AAA TGC CTG GGC AAG C  116Q_RV  CAT TTG CTT GGG TGG TGC CGC TGG TCA G 
116K_FW  CAC CAC CAA AGC AAA TGC CTG GGC AAG C  116K_RV  CAT TTG CTT TGG TGG TGC CGC TGG TCA G 
116H_FW  CAC CAC CCA CGC AAA TGC CTG GGC AAG C 116H_RV CAT TTG CGT GGG TGG TGC CGC TGG TCA G
116M_FW  CAC CAC CAT GGC AAA TGC CTG GGC AAG C  116M_RV  CAT TTG CCA TGG TGG TGC CGC TGG TCA G 
116Y_FW  CAC CAC CTA TGC AAA TGC CTG GGC AAG C  116Y_RV  CAT TTG CAT AGG TGG TGC CGC TGG TCA G 
116S_FW  CAC CAC CTC AGC AAA TGC CTG GGC AAG C  116S_RV  CAT TTG CTG AGG TGG TGC CGC TGG TCA G 
116P_FW  CAC CAC CCC AGC AAA TGC CTG GGC AAG C 116P_RV CAT TTG CTG GGG TGG TGC CGC TGG TCA G
116N_FW  CAC CAC CAA TGC AAA TGC CTG GGC AAG C  116N_RV  CAT TTG CAT TGG TGG TGC CGC TGG TCA G 
118A_FW  GAA GCA GCT GCC TGG GCA AGC ACC CTG  118A_RV  CAG GCA GCT GCT TCG GTG GTG CCG C 
118V_FW  GAA GCA GTT GCC TGG GCA AGC ACC CTG  118V_RV  CAG GCA ACT GCT TCG GTG GTG CCG C 
118L_FW  GAA GCA CTT GCC TGG GCA AGC ACC CTG 118L_RV CAG GCA AGT GCT TCG GTG GTG CCG C
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118D_FW  GAA GCA GAT GCC TGG GCA AGC ACC CTG 118D_RV CAG GCA TCT GCT TCG GTG GTG CCG C 
118E_FW  GAA GCA GAA GCC TGG GCA AGC ACC CTG  118E_RV  CAG GCT TCT GCT TCG GTG GTG CCG C 
118Q_FW  GAA GCA CAA GCC TGG GCA AGC ACC CTG  118Q_RV  CAG GCT TGT GCT TCG GTG GTG CCG C 
118K_FW  GAA GCA AAA GCC TGG GCA AGC ACC CTG  118K_RV  CAG GCT TTT GCT TCG GTG GTG CCG C 
118H_FW  GAA GCA CAT GCC TGG GCA AGC ACC CTG 118H_RV CAG GCA TGT GCT TCG GTG GTG CCG C 
118M_FW  GAA GCA ATG GCC TGG GCA AGC ACC CTG  118M_RV  CAG GCC ATT GCT TCG GTG GTG CCG C 
118Y_FW  GAA GCA TAT GCC TGG GCA AGC ACC CTG  118Y_RV  CAG GCA TAT GCT TCG GTG GTG CCG C 
118S_FW  GAA GCA AGT GCC TGG GCA AGC ACC CTG  118S_RV  CAG GCA CTT GCT TCG GTG GTG CCG C 
118P_FW  GAA GCA CCT GCC TGG GCA AGC ACC CTG  118P_RV  CAG GCA GGT GCT TCG GTG GTG CCG C 
50V_FW  GGT AAT GTA GAA AGC CGT TAT GTT CTG 50V_RV CTT TCT ACA TTA CCA ACT GCG CTT TC 
50L_FW  GGT AAT CTA GAA AGC CGT TAT GTT CTG  50L_RV  CTT TCT AGA TTA CCA ACT GCG CTT TC 
50D_FW  GGT AAT GAC GAA AGC CGT TAT GTT CTG  50D_RV  CTT TCG TCA TTA CCA ACT GCG CTT TC 
50E_FW  GGT AAT GAA GAA AGC CGT TAT GTT CTG  50E_RV  CTT TCT TCA TTA CCA ACT GCG CTT TC 
50Q_FW  GGT AAT CAA GAA AGC CGT TAT GTT CTG 50Q_RV CTT TCT TGA TTA CCA ACT GCG CTT TC 
50K_FW  GGT AAT AAA GAA AGC CGT TAT GTT CTG  50K_RV  CTT TCT TTA TTA CCA ACT GCG CTT TC 
50H_FW  GGT AAT CAT GAA AGC CGT TAT GTT CTG  50H_RV  CTT TCA TGA TTA CCA ACT GCG CTT TC 
50M_FW  GGT AAT ATG GAA AGC CGT TAT GTT CTG  50M_RV  CTT TCC ATA TTA CCA ACT GCG CTT TC 
50Y_FW  GGT AAT TAC GAA AGC CGT TAT GTT CTG 50Y_RV CTT TCG TAA TTA CCA ACT GCG CTT TC 
50S_FW  GGT AAT TCA GAA AGC CGT TAT GTT CTG  50S_RV  CTT TCT GAA TTA CCA ACT GCG CTT TC 
50P_FW  GGT AAT CCA GAA AGC CGT TAT GTT CTG  50P_RV  CTT TCT GGA TTA CCA ACT GCG CTT TC 
50N_FW  GGT AAT AAC GAA AGC CGT TAT GTT CTG  50N_RV  CTT TCG TTA TTA CCA ACT GCG CTT TC 
53A_FW  GAA AGC GCC TAT GTT CTG ACA GGT CG 53A_RV GAA CAT AGG CGC TTT CTG CAT TAC CAA C 
53V_FW  GAA AGC GTT TAT GTT CTG ACA GGT CG  53V_RV  GAA CAT AAA CGC TTT CTG CAT TAC CAA C 
53L_FW  GAA AGC CTT TAT GTT CTG ACA GGT CG  53L_RV  GAA CAT AAA GGC TTT CTG CAT TAC CAA C 
53D_FW  GAA AGC GAT TAT GTT CTG ACA GGT CG  53D_RV  GAA CAT AAT CGC TTT CTG CAT TAC CAA C 
53E_FW  GAA AGC GAG TAT GTT CTG ACA GGT CG 53E_RV GAA CAT ACT CGC TTT CTG CAT TAC CAA C 
53Q_FW  GAA AGC CAG TAT GTT CTG ACA GGT CG  53Q_RV  GAA CAT ACT GGC TTT CTG CAT TAC CAA C 
53K_FW  GAA AGC AAG TAT GTT CTG ACA GGT CG  53K_RV  GAA CAT ACT TGC TTT CTG CAT TAC CAA C 
53H_FW  GAA AGC CAT TAT GTT CTG ACA GGT CG  53H_RV  GAA CAT AAT GGC TTT CTG CAT TAC CAA C 
53M_FW  GAA AGC ATG TAT GTT CTG ACA GGT CG 53M_RV GAA CAT ACA TGC TTT CTG CAT TAC CAA C 
53Y_FW  GAA AGC TAT TAT GTT CTG ACA GGT CG  53Y_RV  GAA CAT AAT AGC TTT CTG CAT TAC CAA C 
53S_FW  GAA AGC AGT TAT GTT CTG ACA GGT CG  53S_RV  GAA CAT AAC TGC TTT CTG CAT TAC CAA C 
53P_FW  GAA AGC CCT TAT GTT CTG ACA GGT CG  53P_RV  GAA CAT AAG GGC TTT CTG CAT TAC CAA C 
86V_FW  GTA ATG TAC ATA GCG CAA CCA CCT GG  86V_RV  GCG CTA TGT ACA TTA CGA TAG TTA TTT TTC C 
86L_FW  GTA ATC TAC ATA GCG CAA CCA CCT GG 86L_RV GCG CTA TGT AGA TTA CGA TAG TTA TTT TTC C
86D_FW  GTA ATG ACC ATA GCG CAA CCA CCT GG  86D_RV  GCG CTA TGG TCA TTA CGA TAG TTA TTT TTC C 
86E_FW  GTA ATG AAC ATA GCG CAA CCA CCT GG  86E_RV  GCG CTA TGT TCA TTA CGA TAG TTA TTT TTC C 
86Q_FW  GTA ATC AAC ATA GCG CAA CCA CCT GG  86Q_RV  GCG CTA TGT TGA TTA CGA TAG TTA TTT TTC C 
86K_FW  GTA ATA AAC ATA GCG CAA CCA CCT GG 86K_RV GCG CTA TGT TTA TTA CGA TAG TTA TTT TTC C
86H_FW  GTA ATC ATC ATA GCG CAA CCA CCT GG  86H_RV  GCG CTA TGA TGA TTA CGA TAG TTA TTT TTC C 
86M_FW  GTA ATA TGC ATA GCG CAA CCA CCT GG  86M_RV  GCG CTA TGC ATA TTA CGA TAG TTA TTT TTC C 
86Y_FW  GTA ATT ACC ATA GCG CAA CCA CCT GG  86Y_RV  GCG CTA TGG TAA TTA CGA TAG TTA TTT TTC C 
86S_FW  GTA ATT CAC ATA GCG CAA CCA CCT GG 86S_RV GCG CTA TGT GAA TTA CGA TAG TTA TTT TTC C
86P_FW  GTA ATC CAC ATA GCG CAA CCA CCT GG  86P_RV  GCG CTA TGT GGA TTA CGA TAG TTA TTT TTC C 
86N_FW  GTA ATA ACC ATA GCG CAA CCA CCT GG  86N_RV  GCG CTA TGG TTA TTA CGA TAG TTA TTT TTC C 
K121A_FWa  CTG GGC GTC CAC GCT GGT CGG  K121A_RVa  GGA CGC CCA GGC GTT GGC CTC 
POSITIVE__  
CONTROL_ 
FW 
CAT ATG GCA AGC ATG ACC GGT G 
POSITIVE__ 
CONTROL_ 
RV 
GGA TCC CTA TTA CTG CTG AAC TGC 
a This primer pair was used for the design of the S112XK121A mutants. Here available Sav112X 
mutants derived from the natural Sav sequence where mutated to K121A to obtain S112XK121A. 
This constructs are derived from pET-11b vector and therefore ampicillin (100 µg ml-1 culture 
media) has to be used as antibiotic. 
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APPENDIX B 
Supporting information for Angew. Chem. Int. Ed.. 2018, 130, 1881–1886 
B.1 GENERAL INFORMATION 
All commercially available chemicals were purchased from commercial suppliers (Sigma-
Aldrich, Acros Organics, Alfa Aesar, AppliChem, NEB, AnaSpec, Fluka or Merck) and used 
without further purification. Solvents for HPLC measurements were purchased from Baker 
and Biosolve. E. coli bacterial strains (BL21 and TOP10) were purchased from NEB or 
Invitrogen, respectively. Empty vector plasmid pET-24a empty vector was purchased from 
Novagen.  
Milli-Q water (resistivity ≥ 18 MΩ cm-1) was produced with a Millipore Synergy purification 
system. Sav mutants were produced, purified and characterized as previously described.[B1] 
Protein mass spectral analysis was performed on a Bruker Daltonics, ESI/micrOTOF MS. 
Protein purification was performed my means of affinity column chromatography on an 
Äktaprime Plus chromatography system, using a 2-iminobiotin sepharose column. PCR 
reactions were performed with an Eppendorf Mastercycler Gradient. 1H and 13C spectra were 
recorded on a Bruker 400 MHz. The chemical shifts (δ) are reported in parts per million 
(ppm) relative to TMS or a residual solvent peak. Analyses of the catalytic runs were 
performed on an Agilent 1100 normal phase HPLC with an analytical Chiralpak IC column 
(250 ꞏ 4.6 mm, 5 μm), or by GC using Agilent CAM column (30 m x 0.25 µm) and CP-
Chirasil-DEX CB (25m x 0.25 µm) using He as carrier gas. The absorbance spectra were 
measured on a microplate reader Tecan, model Infinite M200. 
E. coli strains used: 
 TOP10 (Invitrogen, cat. no. C4040): F− mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δlac×74 recA1 araD139 Δ(araleu)7697 galU galK rpsL (StrR) endA1 nupG 
 BL21 (DE3; NEB, cat. no. C2527): E. coli B F−dcm ompT hsdS(rB−mB−) gal λ(DE3) 
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B.2 STOCK SOLUTIONS AND BUFFERS 
Lysogeny broth (LB) medium: Bactotryptone (10 g / l), yeast extract (5 g / l) and sodium 
chloride (10 g / l) were dissolved in Milli-Q water and the resulting solution was autoclaved 
(121°C for 20 min).  Before use, kanamycin (KAN) was added to a final concentration of 50 
µgꞏml-1. 
LB-agar plates: Bactotryptone (10 g / l), yeast extract (5 g / l), sodium chloride (10 g / l) and 
agar (15 g / l) were dissolved in Milli-Q water. The resulting mixture was boiled for 1 minute 
to dissolve the agar. After cooling to approx. 50°C, KAN was added to a final concentration 
of 50 µgꞏml-1. 
20 x ZYP-salts: KH2PO4 (54.4 g, final conc. 1 M), (NH4)2SO4 (26.4 g, final conc. 0.5 M) and 
Na2HPO4 (56.8 g, final conc. 1 M) were dissolved in Milli-Q water (final volume 400 ml). 
The resulting solution was autoclaved (121°C for 20 min). For details, see reference [B1]. 
20 x ZYP-sugars: Anhydrous glycerol (40 ml, final conc. 10 % v/v), ) Lactose (16 g, final 
conc. 4% w/v) and glucose monohydrate (4.4 g, final conc. 55.5 mM) were dissolved in 
(final volume 400 ml). The resulting solution was sterile filtered (filter pore size 0.22 µm). 
200 x MgSO4: MgSO4 (4.92 g, final conc. 400 mM) was dissolved in Milli-Q water (final 
volume 50 ml) and sterile filtered (filter pore size 0.22 µm). 
Modified ZYP-5052 medium: Bactotryptone (8 g, final conc. 10 g / l), yeast extract (4 g, final 
conc. 5 / l) were dissolved in Milli-Q water (664 ml) and autoclaved (121°C for 20 min). 
20xZYP-salts (40 ml), 20xZYP sugars (80 ml), MgSO4 (16 ml) stock solutions were added 
to the media. KAN (final conc. 50 µgꞏml-1) was added before use.  
100 mM MOPS buffer: MOPS (2.092 g) was dissolved in Milli-Q water and the pH of the 
resulting solution was adjusted to 7.5 using NaOH pellets. 
Lysis buffer: Lysozyme (1 mg / ml) and DNaseI (4 µg / ml) were dissolved in a MOPS buffer 
(100 µM, pH 7.5). 
MOPS/formate buffer: 3-(N-morpholino)propanesulfonic acid and sodium formate were 
dissolved in Milli-Q water to the concentrations of 6M (formate) and 1.2 M (MOPS). The 
pH was adjusted to 6 or 7 by addition of NaOH or HCl respectively. 
Diamide stock solution (DiAm): 1,1`-Azobis(N,N-dimethylformamide) (72.5 mg, final conc. 
200 mM) was dissolved in degassed DMSO (2 ml). 
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Cp*Ir-complex 3: 1.6 mg of [Cp*Ir(biot-p-L)Cl] was dissolved in degassed DMF to a final 
concentration of 2 mM. For a detailed synthesis procedure, see reference.[B2] 
Substrates: 1-phenyl-3,4-dihydroisoquinoline 1c (synthesis procedure see reference[B3]) or 
5-phenyl-3,4-dihydro-2H-pyrrole 1d[B4] were dissolved in degassed DMSO (2 ml) to a final 
concentration of 400 mM. 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 1a was 
dissolved in Milli-Q water (2 ml) to a final concentration of 400 mM. 
B.3. EXPERIMENTAL PROCEDURES 
B.3.1 PRIMER DESIGN 
Precise and unique primers were designed for each mutation. Mature Sav [5] with K121A 
mutation on a codon-optimized plasmid pET-24a SavK121A with reduced G/C content 
(52%) was used. The positions for mutagenesis were selected by identifying residues that lie 
within a 10 Å radius around the averaged position of the biotinylated metal moiety bound to 
Sav. After the identification of a successful “hit”, the position was fixed and new primers 
were designed to create another generation of Sav isoforms.  
B.3.2 SITE-DIRECTED MUTAGENESIS 
In PCR tubes, the following components were mixed (total volume 50 µl): 
Table B1- PCR conditions 
Component Volume used (µl) Final concentration: 
Template 1 0.1-0.5 ng / µl 
Primer (+) 2.5 0.3 µM 
Primer (-) 2.5 0.3 µM 
dNTPs 1 4 x 0.1 mM 
DMSO 4 5 % 
H2O 29 - 
Q5 polymerase 0.5 0.06 U / µl 
5x Q5 polymerase reaction buffer 10 5 x 
 
The samples were prepared in triplicates and placed in an Eppendorf Mastercycler Gradient 
and the following temperature program was applied: 
1. 95 °C for 2 min. 
2. PCR-cycle (25x): 95 °C for 1 min.; 60 - 68 °C gradient for 1 min.; 72 °C for 4 min. 
3. 72 °C for 10 min. 
4. Hold at 8 °C 
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Afterwards, an agarose gel (0.7 % agarose, TBE-buffer, Red nucleic acid stain 10'000x as 
marker) was carried out to determine the success of the PCR (Figure B1). Samples with 
amplified templates were incubated with 1 µl of DpnI (20 U) at 42°C for 3 h. 
 
Figure B1- Analytical agarose gel (1%) with a 1-kb marker (L) using the PCR products (5 μl) before 
DpnI digestion. DNA is visualized by Red nucleic acid stain 10'000x. Each lane triad (A-T) 
corresponds to one mutation; the numbers (1-3) correspond to different temperature (50-65°C) during 
the PCR. 
B.3.3 TRANSFORMATION OF PLASMIDS INTO CLONING OR EXPRESSION STRAIN 
Chemically competent E.coli cells (100 µl, TOP10 strain) were transformed with 5 µl of the 
PRC product by applying a heat shock (30 sec, 42°C). The cells were grown in LB medium 
w/o antibiotic (0.5 ml, 37°C, 200 rpm) and plated on LB-agar plates containing KAN. The 
plates were incubated (overnight, 37°C).  
LB medium (5 ml, KAN) were inoculated with a single colony from the LB-agar plate and 
incubated (overnight, 37°C, 200 rpm). Mini-prep was performed for each sample, following 
the Macherey-Nagel NucleoSpin® Plasmid kit (low-copy number protocol).[B1] The purified 
plasmids were sent to Microsynth AG (Balgach, Switzerland) for sequencing. 
The mutagenized plasmids were transformed into competent E. coli cells (100 µl, 
(BL21(DE3) strain) using 1 µl of the corresponding purified plasmid and the same protocol 
as described above.  
B.3.4 LARGE SCALE EXPRESSION IN 3L CONICAL FLASKS 
Precultures were grown in sterile Erlenmeyer flasks (250 ml) in LB medium (100 ml, 50 
µgꞏml-1 KAN). After incubation (overnight, 37°C, 200 rpm), the preculture (10 ml) was 
transferred into a 3l conical shaking flask containing the modified ZYP-5052 medium (1 l, 
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50 µgꞏml-1 KAN) and incubated (24 h, 30°C, 200 rpm). For expression in 24-deep well plates 
see reference.[B1] 
B.3.5 CELL HARVEST AND LYSIS 
After Sav overexpression, the OD600nm of each well culture was measured. Typical values 
after 24 h were between OD of 5-7. The cells were harvested by centrifugation (4400 rpm, 
10 min, 4°C) and the supernatant was discarded. The cell pellet was frozen at -20°C. 
Afterwards, the pellet was thawed and resuspended in freshly prepared lysis buffer. The cell 
lysates were incubated (37°C, 200 rpm, 1h), frozen and thawed again at RT. 
Cell free extracts were prepared by further centrifugation of the cell lysates in tubes (1.5 ml, 
4400 rpm, 10 min, 4°C).  
B.3.6 PROTEIN PURIFICATION 
Cell lysates were transferred to dialysis bags (Spectra/Por, 6-8.000 MWCO) and dialyzed in 
guanidinium hydrochloride (6 M, pH 1.5, RT, overnight). The dialysis bags were then placed 
into a Tris/HCl buffer (20 mM, pH 7.4, 10 °C, 8 - 12h), followed by an iminobiotin binding 
buffer (500 mM NaCl, 50 mM NaHCO3, pH 9.8, overnight). The cell lysates were clarified 
by centrifugation (45 min. at 9’000 g, 4 °C) and the supernatant was filtered (filter pore size 
0.22 µm). 
The resulting solution was purified by affinity chromatography (ÄKTA prime Plus 
chromatography system, 2-iminobiotin sepharose column). The column was first pre-
washed with the iminobiotin binding buffer, followed by sample loading. After elution of 
the material not binding to the column, the immobilized Sav was washed using 1 % acetic 
acid and collected in falcon tubes and neutralized using Tris/HCl buffer (1 M, pH 8). The 
joined Sav-containing fractions were transferred into dialysis bags (Spectra/Por, 6-8’000 
MWCO) and dialyzed in Milli-Q-water (3 x, 24 h). Finally, the samples were flash-frozen 
and lyophilized. 
The identity of each purified Sav isoform was confirmed by mass spectrometry (Figure B2, 
Table B2). 
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Table B2 – Theoretical mass values for the Sav monomeric units and measured data.  
Entry Sav isoform 
Theoretical mass of 
the 
monomer (Da) 
Measured mass 
(Da) 
1 S112T-K121A 16381.80 16381.17 
2 S112R-K121A 16436.90 16436.15 
3 N118P-K121A 16350.80 16350.63 
4 S112A-N118P-K121A 16334.80 16334.70 
5 S112T-N118K-K121A 16395.92 16395.94 
6 S112T-N118K-K121A-S122K 16437.02 16437.18 
7 S112A-N118P-K121A-S122M 16378.95 16377.59 
8 S112R-N118P-K121A-S122M 16464.06 16463.00 
9 S112R-N118P-K121A-S122M-L124Y 16514.08 16513.96 
 
Figure B2- ESI-TOF mass spectrum after deconvolution of K121A-N118P isoform (displayed as an 
example). The measured value of 16350.63 gꞏmol-1 for the monomeric protein unit corresponds to 
the theoretical value of 16350.8 gꞏmol-1. 
B.3.7 DETERMINATION OF STREPTAVIDIN BIOTIN BINDING CAPACITY ON PURIFIED 
PROTEINS SAMPLES 
The determination of biotin binding capacity in the purified protein samples was performed 
using a B4F assay described elsewhere.[B6] The fluorescence assay was performed in a black 
96-well plate. Each Sav isoform was dissolved in BSA / phosphate buffer (0.1 mg / ml BSA, 
0.1 M phosphate, pH 7). Sav in BSA buffer (100 µl) were mixed with increasing amounts of 
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B4F volumes. The volume was adjusted to 130 µl using BSA in phosphate buffer, the plates 
was shaken (2 min) and the fluorescence was measured (λexcit = 485 nm and λemis = 520 nm). 
The measured fluorescence was plotted as a function of B4F equivalents added and the 
concentration of biotin binding sites was calculated from the concentration at the 
equivalence point.  
 
Figure B3  B4F analysis of the Sav mutant K121A-S112T-N118K-S122K. After occupation 
of all biotin binding sites by B4F, a strong increase in fluorescence occurs proportional to 
the free B4F. In this example, the biotin-binding capacity is 3.4  0.09 per tetramer. 
For determination of Sav Free Binding Sites in CFE, see reference.[B1] 
B.3.8 TYPICAL CATALYSIS PROCEDURE IN BUFFER 
Lyophilized Sav isoforms were dissolved  in MOPS / formate buffer (final conc. 200 µM of 
free biotin binding sites). This solution (100 µl) was transferred to a HPLC vial equipped 
with a magnetic stirrer followed by the addition of Milli-Q water and the Cp*Ir-complex 
stock solution (5 µl). After 5 min., the reaction was initiated by the addition of the substrate 
stock solution. The HPLC vials were sealed and the reaction mixtures were stirred for 48 h 
at RT. Final V = 200 µl; [Sav free binding sites] = 100 µM; [Cp*Ir complex] = 50 µM; 
[MOPS] = 0.6 M; [formate] =3 M; [S] = 10 mM. 
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Scheme B1 - ATHase of cyclic imines using purified Sav mutants. 
B.3.9 TYPICAL CATALYSIS PROCEDURE IN CELL FREE EXTRACTS 
To HPLC vials equipped with a stirring bar, the reaction buffer (100 µl) was added, followed 
by the Sav- containing cell free extracts volume corresponding to a conc. of 100 µM free 
binding sites) and Milli-Q water. The resulting mixture was preincubated with the DiAm 
stock solution (5 µl, final conc. 5 mM) for 2 h and the reaction was initiated by the addition 
of a substrate stock solution (5 µl).  The resulting reaction mixtures were stirred for 48 hours 
at RT. Final V = 200 µl; [Sav free binding sites] = 100 µM; [Cp*Ir complex] = 50 µM; 
[MOPS] = 0.6 M; [formate] =3 M; [DiAm] = 5 mM; [S] = 10 mM. The results are 
summarized in Figure B4. 
B.3.10 TYPICAL CATALYSIS PROCEDURE IN A BIPHASIC SYSTEM 
Lyophilized Sav isoforms were dissolved  in MOPS / formate buffer (final conc. 200 µM of 
free biotin binding sites). This solution (450 µl) was transferred to a HPLC vial followed by 
the addition the Cp*Ir-complex stock solution in DMSO (45 µl, final conc. 100 µM). After 
5 min., the reaction was initiated by the addition of the substrate stock solution in EtOAc 
(500 µl, 100 mM). The HPLC vials were sealed and the reaction mixtures were vigorously 
shaken for the corresponding reaction time (2'000 rpm, 25°C). The procedure was adapted 
from reference.[B7] Final V = 1000 µl; [Sav free binding sites] = 200 µM; [Cp*Ir complex] 
= 100 µM; [MOPS] = 0.6 M; [formate] =3 M; [S] = 100 mM. 
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Figure B4 –Artificial Imine Reductase activity displayed as bubble chart representation for 
the conversion (size of the bubble) and the enantioselectivity (color of the bubble) substrate 
1a, 1c or 1d. The mutant Sav variants were used in the form of cfe in the presence of DiAm 
as a GSH neutralizing agent  
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B.3.11 WORK UP AND ANALYSIS 
Each reaction was diluted with Milli-Q water (400 μl) and basified using NaOH solution (20 
%, 50 μl). The resulting mixture was extracted with dichloromethane (2 x, 1 ml), the 
combined organic fractions were collected in a PP tube containing anhydrous sodium sulfate, 
and centrifuged (18800 x g, 5 min). The supernatant was analyzed by HPLC or GC. 
Catalysis results for substrate 1a were analyzed using a Chiralpak IC column (5 μm, 4.6 mm 
ꞏ 25 mm) and dichloromethane containing diethylamine (0.06 %) and  isopropanol (0.5 %) 
as an eluent (1 ml / min flow; λ=280 nm, 25 °C). TR 8.5 min ((S)- 6,7-dimethoxy-1-methyl-
1,2,3,4-tetrahydroisoquinoline), 9.8 min (6,7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline), 14.6 min ((R)- 6,7-dimethoxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline). Yields were calculated using a response factor of 1.95, as 
determined elsewhere.[B7] 
 
Screening with substrate 1c was analyzed using a Chiralpak IC column (5 μm, 4.6 mm ꞏ 25 
mm) and dichloromethane containing diethylamine (0.06 %) and  isopropanol (3 %) as an 
eluent (1 ml / min flow; λ=265 nm, 25 °C). TR 7.6 min ((S)-1-phenyl-1,2,3,4-
tetrahydroisoquinoline, 10.5 min ((R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline), and  16 min 
(1-phenyl-3,4-dihydroisoquinoline). Yields were calculated using a response factor of 
13.613 as determined elsewhere.[B1] 
 
Screening with substrate 1d was analyzed by GC. Conversion was determined using an 
Agilent CAM column (30 m x 0.25 µm) and He as carrier gas (1.7 ml / min) at 240°C 
(injector temp. 250°C, split 30). TR 8.82 min (5-phenyl-3,4-dihydro-2H-pyrrole), 6.14 (2-
phenylpyrrolidine). For the determination of enantioselectivity, the samples were derivatized 
by the addition of trifluoroacetic anhydride (TFAA, 200 µl) followed by evaporation using 
a gentle stream of N2. The measurement was performed using a chiral stationary phase 
column CP-Chirasil-DEX CB (25m x 0.25 µm) and He as carrier gas (1.7 ml / min) at 140°C 
(injector temp. 250°C, split 50). 9.76 min ((S)-2-phenylpyrrolidine), 10.29 ((R)-
phenylpyrrolidine); assignment of the absolute configuration was based on ref.[B9] 
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Table B3- Selected results obtained from the reduction of cyclic imines 1a or 1d using purified 
proteins. The reactions were performed with 10 mM substrate concentration at RT for 48 h. 
Nr. Substrate Sav source ee[a,b](%) Conv. (%)[a]
1 
 
[Cp*Ir(biot-p-L)Cl 3 0 11 
2 K121A 30 72 
3 N118P-K121A -16 81 
4 S112R-K121A -34 38 
5 S112T-K121A -13 58 
6 S112A-N118P-K121A 22 68 
7 S112T-N118K-K121A -36 85 
8 S112T-N118K-K121A-S122K -50 75 
9 S112A-N118P-K121A-S122M 5 56 
10 S112R-N118P-K121A-S122M 29 77 
11 S112R-N118P-K121A-S122M-L124Y 4 91 
12 
 
[Cp*Ir(biot-p-L)Cl 3 0 1 
13 K121A 32 68 
14 N118P-K121A -17 79 
15 S112R-K121A -40 14 
16 S112T-K121A 28 30 
17 S112A-N118P-K121A 33 85 
18 S112T-N118K-K121A 30 92 
19 S112T-N118K-K121A-S122K 36 35 
20 S112A-N118P-K121A-S122M 20 25 
21 S112R-N118P-K121A-S122M -46 48 
22 S112R-N118P-K121A-S122M-L124Y -55 86 
Reactions were performed with purified proteins in 200 µl of reaction mixture with 10 mM substrate 
concentration for 48 hours on substrate 1a or 1d. [a] Enantiomeric excess and conversion were 
determined by means of HPLC or GC analysis. [b] Positive ee values correspond to (R)-product and 
negative ee values correspond to (S)-product.  
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 Figure B5 – Evolution tree of ATHase using substrate 1a. 
 
 Figure B6 – Evolution tree of ATHase using substrate 1d. 
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B.3.12 KINETIC MEASUREMENTS 
In order to determine the saturation kinetics profiles, catalytic reactions were carried 
out with constant concentrations streptavidin (100 µM), the iridium cofactor (50 µM), 
MOPS (0.6M) and sodium formate (3 M). Each Sav mutant was dissolved in Milli-Q water 
to a concentration of 400 mM. Next, 75 µl of this solution was added to 150 µl of the 2x 
concentrated MOPS and formate buffer (1.2 M MOPS, 6 M sodium formate, pH 7). 10 µl of 
the Cp*Ir stock solution (2 mM in DMSO) was added and the resulting solution was 
incubated at 25°C for 15 minutes. Corresponding amounts of Milli-Q water were added 
before the addition of the substrate stock solution (2.307 M, 1a or 1c). The final 
concentration of the substrate was varied (5 – 50 mM for 1c, 500 – 25 mM for 1a). After 10, 
15, 20, 30 and 45 minutes, aliquots (50 µl) were collected and added to a freshly prepared 
GSH solution (40 µl, 0.25 M) to quench the catalysis. Milli-Q water (300 µl) was added to 
aliquots, and 200 µl of the resulting solution was further diluted in Milli-Q water (500 200 
µl) to prepare the HPLC sample.  
Experiments using 1c were analyzed by normal phase HPLC using a Chiralpak IC 
column (5 μm, 4.6 mm ꞏ 25 mm) and hexane containing diethylamine (0.06 %) and 
isopropanol (3 %) as an eluent (1 ml / min flow; λ = 265 nm, 25 °C). TR 7.6 min ((S)-1-
phenyl-1,2,3,4-tetrahydroisoquinoline, 10.5 min ((R)-1-phenyl-1,2,3,4-
tetrahydroisoquinoline), and  16 min (1-phenyl-3,4-dihydroisoquinoline). Yields were 
calculated using a response factor of 13.613 at 265 nm, as determined elsewhere.[B1] The 
data are collected in Table B4. 
Experiments using 1a were analyzed by reverse phase HPLC using an Eclipse XDB-
C18 column (5 µm, 4.6 x 150 mm) and H2O/MeOH/TFA 85:14.9:0.1 as an eluent (25°C, 1 
mlꞏmin-1, 280 nm). The retention times were 11.9 min for 6,7-dimethoxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline 2a and 16.3 min for 1-methyl-6,7-dimethoxy-3,4-
dihydroisoquinoline 1a. Conversions were determined by integration of the corresponding 
HPLC signals, using the calibration curve to correct for the difference in extinction 
coefficient between substrate 1a and product 2a. The response factor used for the conversion 
determination is 1.26 at 280 nm. The data are collected in Table B4. 
The resulting conversion values were plotted against the corresponding reaction 
times. Initial rates for measured substrate concentration were obtained by linear regression 
of the data (the initial rate is equal to the slope of the regression line). These were divided 
by the Ir-catalyst concentration and plotted against the initial substrate concentrations. A 
non-linear regression was applied, using GraphPad Prism 7.03® (least square method) with 
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the Michaelis-Menten equation [B10] for the reduction of 1c, or with Haldane equation [B11] 
for substrate inhibition for the reduction of 1a using Sav WT and mutants K121A and 
K121A-N118P-S112R-S122M-L124Y. 
Table B4- Kinetic parameters of the reduction of imines 1a or 1c, using ATHases based on 
streptavidin isoforms 
Nr Mutation Sub. kcat  (min-1) ± 
KM  
(mM) ± 
Ki 
(mM) ± 
kcat/KM  ee  
(%) (min
–1 
mM–1) 
1 no protein 1c 3.2 2.2 182.5 152.9 - - 0.02 rac. 
2  1a 0.4 0.04 7.4 9 - - 0.05 rac. 3 K121A 1c 8.3 0.9 38.5 7 234.5 72.4 0.22 30 
4  1a 3.1 0.5 11 6.9 - - 0.28 54 
5 S112A-N118P-K121A-S122M 1c 4.4 0.1 15.8 0.9 - - 0.28 5 
6  1a 1.7 0.08 42.2 8.9 - - 0.04 92 7 S112A-N118P-
K121A-
S122M-L124Y 
1c 5.4 0.8 58.3 13 249.3 78.8 0.09 4 
8 1a 9.5 1.7 50.5 17 - - 0.19 -78 
 
Scheme B2 – Saturation kinetic experiments of the ATHase isoforms with substrate 1c. 
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 Scheme B3 - Saturation kinetic experiments of the ATHase isoforms with substrate 1b. 
B.3.13 PREPARATIVE SCALE CATALYSIS 
The lyophilized Sav isoform was dissolved in a 100 ml round bottom flask in MOPS / 
formate buffer (30 ml, final conc. 200 µM of free biotin binding sites) and thoroughly 
degassed. The resulting mixture was preincubated with the Cp*Ir-complex stock solution in 
freshly degassed DMSO (1.5 ml, final concentration 100 µM) for 15 minutes followed by 
the addition of degassed Milli-Q water (27 ml). The reaction was initiated by the addition of 
the substrate stock solution in freshly degassed DMSO (1.5 ml). The reaction mixtures were 
stirred for 48 h at 37°C. Final V = 60 ml; [Sav free binding sites] = 100 µM; [Cp*Ir complex] 
= 50 µM; [MOPS] = 0.6 M; [formate] =3 M; [S] = 10 mM (corresponds to 124 mg of 
substrate). The reaction mixture was basified using NaOH solution (20 %, 15 ml). The 
resulting mixture was extracted with dichloromethane (3 x, 100 ml), the combined organic 
fractions were dried over anhydrous sodium sulfate, filtered and analysed by HPLC for ee 
determination using the above mentioned conditions.  
 
Figure B7 - HPLC chromatograms of 2c produced in preparative scale experiments (>120 mg of 
substrate) using [a] [Cp*Ir(biot-p-L)Cl] ꞏ S112A-N118P-K121A-S122M or [b] [Cp*Ir(biot-p-L)Cl] 
ꞏ S112R-N118P-K121A-S122M-L124Y.  
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After concentrating the sample under reduced pressure, the crude reaction mixture was 
purified by flash column chromatography with hexane / EtOAc to give 86.9 mg of 2c  in 70 
% yield (S112A-N118P-K121A-S122M) and 68 mg in 55 % yield (S112R-N118P-K121A-
S122M-L124Y).  
1H NMR (500 MHz, CDCl3) δ 7.31 (dd, J = 8.4, 6.3 Hz, 2H), 7.28 – 7.21 (m, 3H), 7.13 (d, 
J = 4.2 Hz, 2H), 7.02 (dt, J = 8.2, 4.4 Hz, 1H), 6.74 (d, J = 7.8 Hz, 1H), 5.09 (s, 1H), 3.31 – 
3.20 (m, 1H), 3.12 – 2.98 (m, 2H), 2.82 (dt, J = 16.0, 3.9 Hz, 1H), 2.14 (br s, 1H). 
 
13C NMR (126 MHz, CDCl3) δ 144.88, 138.30, 135.54, 129.1, 129.2, 128.56, 128.24, 
127.54, 126.41, 125.78, 62.20, 42.37, 29.87.  
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 Figure B8 - a) 1H-NMR and b) 13C-NMR spectra of 2c obtained in the preparative scale reaction. 
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B.4. X-RAY ANALYSIS 
B.4.1 CRYSTALLIZATION OF APO-SAV MUTANTS S112A-N118P-K121A-S122M AND 
S112R-N118P-K121A-L124Y  
Apo-Sav protein crystals were obtained at 20°C within two days using the hanging-drop 
vapor diffusion technique mixing 1.5 µl crystallization buffer (2.0 M ammonium sulfate, 0.1 
M sodium acetate, pH 4.0) and 3.5 µL protein solution (26 mg/ml lyophilized protein in 
water). The droplet was equilibrated against a reservoir solution of 100 µl crystallization 
buffer. 
B.4.2 SOAKING APO-SAV CRYSTALS WITH COMPLEX [(CP*)IR(BIOT-P-L)CL]: 
Single crystals of Sav were soaked for 1 day at 20 °C in a soaking buffer, which was prepared 
by mixing 0.5 µl of a 10 mM stock solution of complex [(Cp*)Ir(biot-p-L)Cl] (50 % DMSO), 
4.5 µl crystallization buffer (2.6 M ammonium sulfate, 0.1 M sodium acetate, pH 4.0), and 
0.25 µl of the original protein solution. After soaking overnight, crystals were transferred 
for 10 seconds into a cryo-protectant solution (30 % (v/v) glycerol in crystallization buffer). 
Next, crystals were shock-frozen in liquid nitrogen. 
B.4.3 DATA PROCESSING: 
X-ray diffraction data were collected at the Swiss Light Sourec (SLS) at a wavelength of 1 
Å and processed with software XDS[B12] and scaled with AIMLESS (CCP4 Suite).[B13] The 
structure was solved by molecular replacement using program PHASER (CCP4 Suite)[B13] 
and the structure 2QCB from the PDB as input model with ligand and water molecules 
removed. For structure refinement REFMAC5 (CCP4 Suite) [B14] and PHENIX.REFINE[B15] 
were used. 3D coordinates of ligand 4IR were imported from structure PDB 3PK2 to model 
the iridium cofactor. For water picking, electron density, and structure visualization, the 
software COOT[B16] was used. Figures were generated with PyMOL (the PyMOL Molecular 
Graphics System, Version 1.5.0.5, Schrödinger, LLC). Crystallographic details, processing 
and refinement statistics are collected in Supplementary Table S5. 
B.4.4 STRUCTURE REFINEMENT: 
Overall Structures: 
Apo-crystals of Sav mutants soaked with [(Cp*)Ir(biot-p-L)Cl] constituted space group 
I4122 with unit cell parameters reported in Table S5. A single Sav monomer was obtained 
per asymmetric unit after molecular replacement. Protein residues 2-11 and 135-159 (141-
159 in case of Sav mutant S112R-N118P-K121A-S122M-L124Y) of the N- and C-terminus, 
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respectively, were not resolved in the electron density, presumably due to disorder. Starting 
from the Sav monomer, the biological homotetramer is generated by application of 
crystallographic C2-symmetry axes along the x-, y- and z-axes of the unit cell. The overall 
protein structures are virtually identical to structure biotinꞏWT Sav (PDB 1STP, Table S5). 
Structure Refinement of complex [(Cp*)Ir(biot-p-L)]+ ꞏ Sav S112A-N118P-K121A-S122M 
Residual electron density in the Fo-Fc map was observed in the biotin binding pocket and in 
the biotin vestibule. Anomalous dispersion density was observed in the biotin vestibule. 
Modeling of cofactor [(Cp*)Ir(biot-p-L)Cl] into the electron density projected the iridium in 
the position of the anomalous density peak (Figure 12a). For details of the final active site 
model of this crystal structure, please refer to the main text. Additional anomalous density 
was found in close proximity to H87 and H127 (Table B5). This suggests either partial 
dissociation of iridium from [(Cp*)Ir(Biot-p-L)Cl] or partial cofactor binding to these Lewis-
basic residues. 
Structure Refinement of complex [(biot-p-L)] ꞏ Sav S112R-N118P-K121A-S122M-L124Y 
Residual electron density in the Fo-Fc map was observed in the biotin binding pocket and in 
the biotin vestibule. No anomalous dispersion density was observed in the biotin vestibule. 
Cofactor [(Cp*)Ir(biot-p-L)Cl] was modeled lacking the {Cp*IrCl}+ moiety (Figure 12b). 
For details of the final active site model of this crystal structure, refer to the main text. 
Anomalous density however was found in close proximity to H87, H127 and M122 (Table 
B5). This suggests either partial dissociation of iridium from [(Cp*)Ir(biot-p-L)Cl] or partial 
cofactor binding to these Lewis basic residues. 
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Figure B9- Superposition of crystal structures of ATHase isoforms. A) Complexes [(Cp*)Ir(biot-p-
L)]+ ꞏ Sav S112A-N118P-K121A-S122M (green, PDB 6ESS) and [(Cp*)Ir(biot-p-L)Cl] ꞏ Sav 
S112A (salmon, PDB 3PK2); B) Complexes [(biot-p-L)] ꞏ Sav S112R-N118P-K121A-S122M-
L124Y (cyan, PDB 6ESU) and [Ir(biot-p-L)]2+ ꞏ Sav S112K (magenta, PDB 4OKA); C)  Complexes 
[(Cp*)Ir(biot-p-L)]+ꞏ Sav S112A-N118P-K121A-S122M (green, PDB 6ESS) and [(biot-p-L)] ꞏ 
S112R-N118P-K121A-S122M-L124Y (cyan, PDB 6ESU). H-bonds between protein and cofactor 
are highlighted with dashed lines. 
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 Figure B10- B-factor trace of crystal structures of ATHase isoforms: A) [(Cp*)Ir(biot-p-L)]+ꞏ Sav 
S112A-N118P-K121A-S122M (PDB 6ESS); B) [(Cp*)Ir(biot-p-L)Cl] ꞏ Sav S112A (PDB 3PK2); 
C) [(biot-p-L)] ꞏ Sav S112R-N118P-K121A-S122M-L124Y (PDB 6ESU); D) [Ir(biot-p-L)]2+ꞏ Sav 
S112K (PDB 4OKA); E) [(benzene)Ru(biot-p-L)Cl] ꞏ Sav S112K (PDB 2QCB). Mutations are 
highlighted as red sticks model: 1 = 112, 2 = 122, 3 = 118, 4 = 121, 5 = 124. Cofactors are displayed 
in grey as a stick model. 
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Figure B11. Deletion of H-bonds within loop 7,8 positions 118 (A) and 122 (B). Crystal structures 
3PK2 (salmon) and 6ESU (cyan) are superimposed. H-bonds are displayed as black dashed lines, 
water molecules as red spheres. Sav monomers are labelled as superscripts. 
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Table B5. Crystal structure refinement statistics. 
Sav Mutant S112A-N118P-K121A-S122M S112R-N118P-K121A-S122M-
L124Y 
PDB code 6ESS 6ESU 
Data Processing 
Unit Cell a, b, c = 58.1 Å, 58.1 Å, 185.1 Å;  
α, β, γ = 90° 
a, b, c = 57.8 Å, 57.8 Å, 178.3 Å; 
α, β, γ = 90° 
Space group I4122 I4122 
Resolution (Å) 46.3 – 1.91 55.0-1.78 
Highest resolution shell (Å) 1.96 - 1.91 1.81-1.78 
Rmerge (%) 19.1 (109.8) 8.2 (244.2) 
No. of unique reflections 12759 (816) 15084 (824) 
Multiplicity 11.2 (7.1) 25.4 (25.1) 
I/sig(I) 99.6 (97.6) 99.9 (98.0) 
CC1/2 10.2 (1.5) 18.7 (1.6) 
Structure Refinement 
Rwork 0.276 0.1944 
Rfree 0.3270 0.2113 
Rmsd bond length (Å) 0.019 0.022 
Rmsd bond angle (°) 2.628 2.073 
No ligands 
Cofactor 
Water 
Sulfate 
Acetate 
 
1 
19 
- 
- 
 
1 
29 
1 
1 
B-factor (Å2) 
Overall protein 
Ir complex 
{Cp*Ir}+ 
H2O 
 
33 
56 
104 
31 
 
52 
47 
- 
52 
Anomalous dispersion density 
peaks () 
Ir complex 
Ir1 (His87) 
Ir2 (H127) 
Ir3 (H127) 
Ir4 (M122) 
 
 
 
7 
7 
5 
4 
- 
 
 
 
- 
11 
18 
26 
14 
Distance Ir---Ir (Å) 6.4 - 
Rmsd to BiotinꞏSav (PDB 
1STP) (Å) 0.693 0.846 
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B.5 COMPUTATIONAL DETAILS: 
B.5.1 MODEL SYSTEMS. 
A conformation of the cofactor bound to the S112A Sav from a previous study (unpublished) 
was used to build models of streptavidin variant S112A-N118P-K121A-S122M. For each 
point mutation, side chain conformations based on the Drunbak library of rotamers [B17] 
implemented in Chimera program [18] were selected to minimize steric contacts between the 
cofactor and the protein. For variant S112R-N118P-K121A-S122M-L124Y, the X-ray 
structure was used to build the model. 
B.5.2. FORCE FIELD PARAMETERS FOR THE COFACTOR. 
The GAFF parameters were used where available for bonding interactions. Missing bonding 
and bending parameters for the organometallic moiety were derived from the method 
proposed by Seminario.[19] Accordingly, model compounds were optimized at the DFT 
(BP86) level using the def2-TZVPP basis set and the hessian matrix computed using the 
ORCA code.[B20] The Ir-Cp* interaction was treated as follows. All ring C atoms of the 
cyclopentadienyl were bonded to the Ir. The bending terms involving the Cp* and the other 
ligands were handled using the geometric center of the Cp* ring, distributing the forces on 
the ring atoms via the chain rule. These bending terms were computed from a tcl script at 
each Molecular Dynamics step. All torsional terms involving the metal ion were set to zero. 
Atomic charges of the biocatalyst peptide chain were computed according to the RESP 
methodology [B21] with the N-terminal group capped with an acetyl moiety. RESP charges 
were also derived for the biotin fragment, which, in this case, was capped with an N-Methyl 
residue. 
 
Figure B12. Comparison of the MM(red) and DFT(blue) optimized structures for the intermediate 
(left) and hydride (right) species. The heavy atoms RMSD is 0.20 Å for the intermediate and 0.12 Å 
for the hydride.  
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B.5.3 LIGAND-PROTEIN DOCKING. 
Representative structures from selected clusters were used to dock the substrate 1c in its 
protonated state. The substrate was first optimized with Gaussian09[22] at 
DFT/B3LYP[B23,B24] level with the 6-31g(d,p) basis set.[B25,B26] Dockings were performed 
with the GOLD5.2 program (available through the Cambridge Crystallographic Data Center 
(CCDC)) and evaluated based on the ChemScore scoring function.[B27] Aiming to discard 
the poses in which the asymmetric carbon of the imine would be too far from the metal centre 
or blocked by the Cp* fragment of the catalyst, the distance between the asymmetric carbon 
and the iridium were set to a range between 2 Å and 4.5 Å. Rotamers based on the GOLD 
rotamer library were used for all residues occupying the active pocket aiming to improve the 
fit of the substrate into the host active site. 
MOLECULAR DYNAMICS (MD) SIMULATIONS.  
Implicit solvent generalized Born molecular dynamics simulations were performed for the 
tetramer of streptavidin with the biotinylated Ir complex (the 16 e- complex [Cp*Ir(biot-p-
L)]+). Simulations were perfomed with the NAMD code,[B28] which implements the Born 
model developed by Onufriev et al.[B29] Simulations were performed at 300 K and 0 ionic 
strength, using a 16 Å cutoff for non-bonded interactions. The surface tension was set to 
0.006 kcal/(molꞏÅ2).   
Models initially underwent 1 ns MD simulation followed by 4 ns metadynamics simulations 
to enhance the exploration of the cofactor conformational space.[B30] The dihedral angles 
around the C4 – S1 and S1 – N2 bonds were biased with an history-dependent potential 
composed of repulsive gaussian functions of 0.1 kcal/mol height and 10 degrees width added 
every 100 MD steps. Unfortunately, during the metadynamics simulations rotation around 
the N1 – C1 bond also took place, so that it was not possible to assign unique conformational 
basins to the metadynamics potential. We have thus used a different strategy. For each 
variant, 10 conformations, showing maximal cofactor RMSD, were extracted from the 
metadynamics trajectories and used to initialize ten independent 2 ns long GB MDs. In most 
of the runs, the cofactor explores more than one conformation. Because of this, the resulting 
trajectories were merged and used for a clustering analysis based on the cofactor RMSD 
(heavy, non equivalent atoms) after a best fitting of streptavidin’s backbone (subunits 1 and 
2). Clusters showing a population > 1% were used to estimate the cofactor binding energy 
based on the MM/GBSA approach (the entropic term was not included).[31] 
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Figure B13. Cluster population (a, b) and [Ir] cofactor (excluding biotin fragment) interaction 
energies (c, d) for Sav variants S112A-N118P-K121A-S122M (left) and S112R-N118P-K121A-
S122M-L124Y (right). 
 
 
Figure B14. Comparison of the X-ray structure (turquoise and sticks) and the representative structure 
from the most populated cluster in the MD simulation of Sav variant a) S112A-N118P-K121A-
S122M and c) S112R-N118P-K121A-S122M-L124Y, and c) the second most populated cluster for 
Sav variant S112A-N118P-K121A-S122M 
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Figure B15. Comparison of the X-ray structure (orange) and the representative structures from the 
most populated cluster in the MD simulations (grey) of Sav variant S112A-N118P-K121A-S122M 
(a) and S112R-N118P-K121A-S122M-L124Y (c). In b, the representative structure from the second 
most populated cluster for Sav variant S112A-N118P-K121A-S122M is shown. 
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APPENDIX C 
Supporting information for Chem. Commun. 2016, 52, 9462–9465 
 
C.1 GENERAL INFORMATION 
Tetraethyl orthosilicate (TEOS, ≥ 99 %), (3-aminopropyl)-triethoxysilane (APTES, ≥ 98 %), 
ammonium hydroxide (ACS reagent, 28–30 %), ethanol (anhydrous), glutaraldehyde (Grade 
I, 25 % in water), 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline, 2-(N-
morpholino)ethanesfonic acid, 3-(N-morpholino)propanesulfonic acid, sodium formate, 
sodium hydroxide, DCM, isopropanol, diethylamine, DMF, DMSO, N-Boc-
ethylenediamine, 4-nitrophenylsulfonyl chloride, diethyl ether, N-methylmorpholine, 2- 
chloro-4,6-dimethoxy-1,3,5-triazine, Et3N, acetonitrile, [Cp*IrCl2]2 dimer and NAD+ were 
purchased from commercial suppliers and used without further purification. 
Mili-Q water (resistivity ≥ 18 MΩ cm-1) was produced with a Millipore Synergy purification 
system. Streptavidin Sav mutants were produced, purified and characterized as previously 
described. [C1] 
1H and 13C spectra were recorded on a Bruker 400 MHz. The chemical shifts (δ) are reported 
in parts per million (ppm) relative to tetramethylsilane or a residual solvent peak, and the J 
values are given in Hz. Signals are quoted as s (singlet), d (doublet), t (triplet) and m 
(multiplet). Analyses of the catalytic runs were performed on an Agilent 1100 normal phase 
HPLC with an analytical Chiralpack IC column (250 ꞏ 4.6 mm, 5 μm). ESI-MS 
measurements were performed on a Bruker AmaZonTM X. The absorbance spectra were 
measured on a microplate reader Tecan, model Infinite M200. 
Nanoparticles were imaged using a Zeiss SUPRA 40VP field emission scanning electron 
microscope, their size was measured using the acquired micrographs with the Olympus 
Analysis® software package. 
ICP-MS analysis was performed on a 7500cx ICP-MS system (Agilent, Basel, Switzerland). 
191Ir was used for quantification, 193Ir for verification of the results. 
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C.2 STOCK SOLUTIONS AND BUFFERS 
MOPS/formate buffer: 3-(N-morpholino)propanesulfonic acid and sodium formate were 
dissolved in Milli-Q water to the concentrations of 6M (formate) and 1.2 M (MOPS). The 
pH was adjusted to 7 by addition of NaOH. 
MES buffer: 2-(N-morpholino)ethanesulfonic acid was dissolved in Mili-Q  water to a final 
concentration of 10 mM. The pH was adjusted to 6.2 by the addition of NaOH. 
Activity assay buffer: Sodium formate and K2HPO4 were dissolved in Mili-Q water to a final 
concentration of 200 mM (formate) and 50 mM (phosphate). The pH was adjusted to 7.5 by 
addition of NaOH. 
Cp*Ir-complexes: [Cp*Ir(biot-p-L)Cl)] was dissolved in DMF to a final concentration of 
500 mM. For a detailed synthesis procedure, see reference.[C2] [Cp*Ir(4C-L)Cl] was 
dissolved in DMF to a final concentration of 400 mM. 
Substrate: 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 1a was dissolved in Mili-Q 
water (2 ml) to a final concentration of 1 M.  
C.3 SYNTHESIS OF THE NON-BIOTINYLATED CATALYST 22 
The synthesis was performed as summarized in following Scheme C1. 
 
Scheme C20- Synthesis of catalyst 22 
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C.3.1 N-BOC-N’-(4-NITROPHENYLSULFONYL)-ETHYLENEDIAMINE 18 
To a solution of N-Boc-ethylenediamine 17 (1.74 g, 10.8 mmol, 1.0 eq.) and Et3N (3 ml, 
21.5 mmol, 2.0 eq.) in DCM (300 ml), a solution of 4-nitrophenylsulfonyl chloride 16 (2.51 
g, 11.3 mmol, 1.05 eq.) in DCM (100 ml) was added dropwise at 5 °C and stirred overnight. 
The solution was concentrated to 100 ml, washed with water (3 x 20 ml), and dried over 
Na2SO4. The solvent was evaporated under reduced pressure and the crude product was 
purified by flash chromatography (silicagel, EtOAc : hexane (2 : 3)) The pure product 18 
was obtained as a white powder (2.87 g, 8.32 mmol, 77 % yield).  
 
1H NMR (200 MHz, CDCl3-CD3OD, 22 °C): δ 1.40 (s, 9H; t-Bu), 3.03 (m, 2H; CH2-CH2- 
NH-S), 3.12 (m, 2H; CH2-CH2-NH-S), 4.47 (br, 2H; NH), 8.04 (d, J = 8.7 Hz, 2H; ArH), 
8.37 (d, J = 8.7 Hz, 2H; ArH).  
 Figure C1- 1H NMR of 18 
C.3.2 N-BOC-N’-(4-AMINOPHENYLSULFONYL)-ETHYLENEDIAMINE 19 
An autoclave containing a suspension of Pd/C (5 %, 330 mg) in methanol (20 ml) was 
charged with N-Boc-N’-(4-nitrophenylsulfonyl)-ethylenediamine 18 (2.10 g, 6.08 mmol). 
The autoclave was purged three times with nitrogen and filled with hydrogen (3 bars). The 
reaction was stirred vigorously for 3 hours at RT. The hydrogen pressure was carefully 
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released and the resulting suspension was removed by filtration through a celite plug. The 
solvent was evaporated under reduced pressure, which yielded product 19 as a white powder 
(1.78 g, 5.65 mmol, 93 %).  
1H NMR (400 MHz, CDCl3-CD3OD, 22 °C): δ 1.40 (s, 9H; t-Bu), 2.88 (m, 2H; CH2-CH2- 
NH-S), 3.12 (m, 2H; CH2-CH2-NH-S), 3.57 (br, 3H; NH; NH2), 4.50 (br, 1H; NH), 6.62 (m, 
2H; ArH), 7.47 (m, 2H; ArH). 
 Figure C2- 1H NMR of 19 
C.3.3 N-BOC-N'-(4-(N'-BOC-4-AMINOBUTANAMIDO)PHENYLSULFONYL)-ETHYLENEDIAMINE 
24 
To a suspension of N-Boc-4-aminobutanoic acid 23 (13.2 mg, 0.065 mmol, 1.03 eq.), N-
Boc-N ’-(4-aminophenylsulfonyl)-ethylenediamine 19 (20 mg, 0.063 mmol, 1.0 eq.) and 2- 
chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) as a coupling agent (11.8 mg, 0.067 mmol, 
1.06 eq.) in acetonitrile (10 ml),  N-methylmorpholine (NMM) (9.6 µl, 0.095 mmol, 1.5 eq.) 
was added. The resulting reaction mixture was stirred at RT for 24 hours and heated to reflux 
for 6 hours. After cooling the reaction mixture to room temperature, water (3 ml) was added. 
The solvent was evaporated under reduced pressure. The crude product was purified by flash 
C5 
 
chromatography (silicagel using EtOAc : n-hexane (2:1)) to obtain the product 24 as a white 
powder (12.6 mg, 0.025 mmol, 40 % yield).  
1H NMR (400 MHz, Chloroform-d) δ 9.66 (s, 1H, NH), 7.78 (s, 4H, ArH), 5.40 (s, 1H, NH), 
4.92 (s, , 2H, NH), 3.24 (m, , 4H, CH2), 3.03 (q, J = 5.7 Hz, 2H, CH2), 2.42 (m, 2H, CH2), 
1.88 (m, 2H, CH2), 1.48 (s, 9H, t-Bu), 1.42 (s, 9H, t-Bu).  
13C NMR (101 MHz, Methanol-d4) δ 174.69 (CO, t-Bu), 158.93 (CO, t-Bu), 144.45 (Ar-
NH), 136.47 (Ar-S), 129.46 (2C, Ar-H) , 120.97 (2C, Ar-H), 80.66 (O-C-(CH3)3, t-Bu) , 
80.43 (O-C-(CH3)3, t-Bu), 44.21 (CH2-NH), 41.70 (CH2-NH),  41.21 (CH2-NH), 35.70 
(CH2-CO), 29.18 (3C, CH3, t-Bu), 29.13 (3C, CH3, t-Bu), 27.37 (CH2- CH2- CH2). 
 Figure C3- 1H NMR of 24. 
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 Figure C4- 13C NMR of 24 
C.3.4 N-(4-(4-AMINOBUTANAMIDO)PHENYLSULFONYL)-ETHYLENEDIAMINE 25 
TFA (300 µl, 3 mmol, 30 eq.) was added dropwise to a suspension of N-Boc-N'-(4-(N'-Boc-
4-aminobutanamido)phenylsulfonyl)-ethylenediamine 24 (50 mg, 0.1 mmol) in dry DCM (5 
ml) at 0 °C. The resulting solution was stirred at RT for 6 hours. The solvent was evaporated 
under reduced pressure. The crude product dissolved in MeOH and diethyl ether was added 
until a white precipitate formed. The precipitated product was collected by filtration and 
dried under reduced pressure. Pure product 25 was obtained as white powder (39 mg, 0.074 
mmol, 75 %).  
1H NMR (400 MHz, Methanol-d4) δ 7.82 (s, 4H, ArH), 3.11 – 3.00 (m, 6H, CH2-CH2- CH2), 
2.59 (t, J = 7.0 Hz, 2H, CH2), 2.02 (p, J = 7.1 Hz, 2H, CH2). 
13C NMR (101 MHz, Methanol-d4) δ 173.77 (CO), 144.91 (Ar-NH) , 135.82 (Ar-S), 129.90 
(2C, ArH), 121.29 (2C, ArH), 41.97 (CH2-NH2), 41.29 (CH2-NH2), 40.94 (CH2-NH2), 
35.00(CH2-NH2), 24.61 (CH2-CH2- CH2).  
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 Figure C5- 1H NMR of 25 
 
 Figure C6- 13C NMR of 25 
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C.3.5 SYNTHESIS OF CATALYST [CP*IR(4C-L)CL] 22 
The [Cp*IrCl2]2 dimer (30 mg, 0.038 mmol, 0.475 eq.), the sulfonamide ligand 25 (40 mg, 
0.076 mmol, 1 eq.) and Et3N (26 µl, 0.19 mmol, 5 eq.) were dissolved in dry DCM (5 ml) 
under inert atmosphere. After stirring for 24 hours at room temperature, the solution was 
heated to reflux for 3 hours. The precipitate was filtrated, dissolved in MeOH (1 ml) and 
precipitated with diethyl ether. The pure catalyst 22 was obtained as a dark orange powder 
(15 mg, 0.022 mmol, 60 %).  
1H NMR (400 MHz, Methanol-d4) δ 7.90 (d, J = 8.9, 2.7 Hz, 2H, ArH), 7.62 (d, J = 8.8, 2.0 
Hz, 2H, ArH), 3.02 (t, 2H, CH2), 2.63 – 2.51 (m, 4H, CH2- CH2), 2.48 – 2.42 (m, 2H, CH2), 
2.04 – 1.96 (m, 2H CH2), 1.73 (s, 15H, Cp*- CH3).  
13C NMR (101 MHz, Methanol-d4) δ 172.95 (CO) , 142.07(Ar-NH) , 139.41 (Ar-S), 130.09 
(2C, ArH) , 119.98(2C, ArH) , 86.76 (5C, Cp*-C) , 40.42 (2C, CH2-NH2) , 34.50 (2C, CH2) 
, 24.11 (CH2), 9.45 (5C, Cp*-CH3). ESI-MS for C22H34ClIrN4O3S: [Cp*Ir(4C–L)Cl] : 625,2 
[M-Cl]. 
 
Figure C7- 1H NMR of [Cp*Ir(4C–L)Cl] 22. 
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 Figure C8- 13C NMR of [Cp*Ir(4C–L)Cl] 22. 
 Figure C9- ESI-MS of [Cp*Ir(4C–L)Cl] 22. 
C.4 SNPS PREPARATION AND CHARACTERIZATION 
C.4.1 SNPS SYNTHESIS  
The SNPs were prepared by adapting the procedure described elsewhere [C3] as follows. All 
chemicals and solvents were equilibrated in a water bath (20 °C, 1 h) before use. Ammonium 
hydroxide (40 ml, 28–30 %) and ethanol (345 ml) were mixed in a round bottom flask (1 l), 
under stirring (600 rpm). TEOS (15 ml) was added and the solution kept under stirring for 
20 h. The resulting milky suspension was centrifuged (3'220 g, 10 min) and the white pellet 
resuspended in ethanol. This operation (hereafter called ‘washing cycle’) was repeated once 
with ethanol and three times with water to yield the SNPs (4 g). Into the stock solution of 
SNPs in water (18 ml of 3.2 mgꞏml−1), APTES was added (11 μl , 0.047 mmol) and incubated 
in a water bath (30 min, 20 °C, 400 rpm). After two washing cycles, the  resulting 
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nanoparticles were stored at 4 °C.  
All washing steps were performed by centrifugation (3'220 g, 5 min) and the pellets were 
resuspended by ultrasonic treatment using an ultrasonic bath (2 min).  
C.4.2SAV PREINCUBATION AND LYOPHILISATION 
In a typical experiment, purified Sav mutant (25 mg , approx. 3,8 x 10-7 mol) was dissolved 
in water. The average number of free binding sites per purified Sav tetramer was determined 
with a biotin-4-fluorescein assay, as described elsewhere.[C4] The corresponding amount of 
[Cp*Ir(biot-p-L)Cl] ligand stock solution was added to produce protein with binding sites 
fully filled with the iridium cofactor (ratio of Ir : free binding sites 1 : 1) , or half fulled 
respectively (ratio of Ir : free binding sites 1 : 2). Samples were incubated (37 °C, 2 h), frozen 
(-80°C) and lyophilised to dryness. A stock solution (3 mg / ml) was used for protein 
immobilization. 
C.4.3 SNPS SYNTHESIS AND PROTECTION 
The aminomodified nanoparticles (15 ml, 3 mg / ml)  were incubated (30 min) with aqueous 
glutaraldehyde solution (60 µl of 25% (v/v)). After two washing cycles with Mili-Q water, 
the particles were spinned down (3'220 g for 10 min), resuspended in MES buffer (14 ml, 10 
mM, pH 6.2) and incubated with the corresponding Sav mutant or iridium catalyst 22 while 
stirring (1 h, 400 rpm). Subsequently, TEOS was added to the reaction mixture (72 μl, 
0.324 mmol) and allowed to react for 1 h.  To produce the protected SNPs, the nanoparticles 
were incubated with APTES (18 μl, 4 , 20°C). Protected nanoparticles were centrifuged 
(4000 rpm, 5 min) and, after two washing cycles, resuspended in Mili-Q water. The 
concentration of each SNPs stock solution was determined by freeze-drying of each stock 
solution (100 μl) and weighted using a microbalance.   
C.4.4 ACTIVITY ASSAY 
In a typical experiment, SNPs (3.2 mg) were resuspended in MES buffer (250 μl, 10 mM, 
pH 6.2). The solution was mixed with the activity assay buffer (1 : 1 ratio, total V : 400 μl) 
and NAD+ (20 μl, 2 mM stock solution) was added.  
The reaction medium was then incubated and shaken (30 °C, 1200 rpm). After the desired 
reaction time (1h), the suspension was centrifuged (16'100 g, 1 min) and  the supernatant 
(70 μl) was collected for UV-Vis analysis on a TECAN plate reader (absorbance spectrum 
240 – 360 nm). 
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C.4.5 BRADFORD ASSAY 
A bovine serum albumin standard curve was prepared in buffer (see reference [C5]). 5X 
Bradford blue reagent (50 µl) was added to a sample or albumin solution (200 µl), mixed 
and incubated for 5 min at room temperature. The sample was pipetted into a 96-well plate 
and the absorbance was determined at 595 nm by a spectrophotometer (Synergy™ H1 
Hybride reader from BioTek). 
C.4.6 SCANNING ELECTRON MICROSCOPY AND PARTICLE SIZE MEASUREMENT 
Each sample (2 μl) was spread on freshly cleaved mica sheets, dried at room temperature 
and sputter-coated with a gold–platinum alloy (15 s, 10 mA, SC7620 Sputter coater). 
Micrographs were acquired using the InLens mode with an accelerating voltage of 20 kV. 
Particle sizes were measured using the acquired micrographs with the Olympus Analysis® 
software package. About 100 measurements were recorded per type of nanoparticles. The 
protective layer thickness was determined by comparing their diameter with the diameter of 
unprotected native Stöber SNPs. 
Table C1 Particle size measurement analysis 
 st dev st error 
 
size (nm) diameter increase (nm) ±  
layer 
thickness
SNP native 241 - 9.12 0.91 nm 
Cp*Ir(biot-p-
L)Cl]ꞏS112A@prot-SNP 264 23 10.08 1.00 12 
Cp*Ir(biot-p-
L)Cl]ꞏS112K@prot-SNP 266 25 11.05 1.10 13 
Cp*Ir(biot-p-L)Cl]ꞏS112A-
K121A@prot-SNP 264 23 9.47 0.94 13 
C.4.7 ICP-MS DETERMINATION OF THE TOTAL IR CONTENT 
Each type of lyophilized nanoparticles (1 mg) was incubated with NaOH solution (0.5 M, 
95°C, 5 min) until complete dissolution.[C6] Samples were neutralized using HNO3 solution 
(65 %, semiconductor grade, Sigma Aldrich) and diluted using Milli-Q water (final HNO3 
concentration 3 %). Analysis was performed on a 7500cx ICP-MS system (Agilent, Basel, 
Switzerland) using standard operational settings as described elsewhere.[C7] Quantification 
was perfomed via multi-element standards (Sigma-Aldrich) in matrix-matched calibration 
solutions containing the same amount of NaOH / HNO3 as the samples. Rh was used as 
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internal standard to account for residual matrix effects. The octopole was pressurized (4.5 
mL ꞏ min−1 helium) to remove polyatomic interferences. 
C5. CATALYSIS 
C.5.1 TYPICAL CATALYSIS PROCEDURE IN BUFFER 
 
Figure C10- Typical catalysis reaction 
Protected nanoparticles (1 mg) were resuspended in MOPS / formate buffer (50 μl, 1.2 M 
MOPS, 3 M sodium formate, pH 7) and Mili-Q water (48 μl) in an HPLC vial, equipped 
with a stirring bar. The reaction was initiated by addition of the substrate stock solution (2 
μl, 1 M stock solution) and the resulting mixture was shaken for 48 hours or 7 days at room 
temperature (final volume: 100 μl). 
The reaction was quenched by centrifugation of the reaction mixture (30 s, 3'220 g). The 
supernatant was collected and the nanoparticle pellet was washed with Mili-Q water (3 x). 
The joined water phases were basified by addition of NaOH solution (50 µl, 20 % stock 
solution), extracted with DCM (2 x 0.5 ml), dried over Na2SO4 and analyzed by the means 
of normal phase HPLC. 
C.5.2 TYPICAL CATALYSIS PROCEDURE IN CELLULAR DEBRIS 
 
Figure C11- Catalysis in the presence of cellular debris 
Protected nanoparticles (1 mg) were resuspended in MOPS / formate buffer (50 μl, 1.2 M 
MOPS, 3 M sodium formate, pH 7) and cellular debris containing solution (48 μl) in an 
HPLC vial, equipped with a stirring bar. The reaction was initiated by addition of the 
substrate stock solution (2.5 μl, 400 mM stock solution) and the resulting mixture was shaken 
for 48 hours at room temperature (final volume: 100 μl). 
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The reaction was quenched by centrifugation of the reaction mixture (30 s, 3'220 g). The 
supernatant was collected and the nanoparticle pellet was washed with Mili-Q water (5 x). 
The joined water phases were basified by addition of NaOH solution (50 µl, 20 % stock 
solution), extracted with DCM (2 x 0.5 ml), dried over Na2SO4 and analyzed by the means 
of normal phase HPLC. 
Table C2 Asymmetric imine reduction yielding salsolidine 2a using Cp*Ir(biot-p-
L)Cl]ꞏSav@prot-SNP in the presence of E. coli cell lysate. 
Entry SNP ee (%)a,b Conv. (%)b TON
1 [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav@prot-SNP 25 1 78 
2 [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav@prot-SNP -20 1 171 
3 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav@prot-SNP 31 1 131 
 [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav free enzyme 4 0 0 0 
5 [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav free enzyme 0 0 0 
6 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav free enzyme 0 0 0 
7 [Cp*Ir(biot-p-L)Cl] 0 0 0 
Reactions performed in a reaction buffer using 1 mg of SNPs of free enzyme with the 
corresponding Ir concentration in 100 µl reaction mixture with 20 mM substrate concentration 
at RT for 48 h; [a]Enantiomeric excess and conversion was determined by HPLC analysis on 
a Chiracel-IC column. [b]Positive ee values correspond to (R)-2a; negative ee values 
correspond to (S)-2a. 
C.5.3 HPLC MEASUREMENTS  
Each reaction mixture was analyzed by HPLC using a Chiralpak IC column (5 μm, 4.6 mm 
ꞏ 25 mm) using dichloromethane containing diethylamine (0.06 %) and  isopropanol (0.5 %) 
as an eluent , flow of 1 ml/min; detection at λ=280 nm, 25 °C. 
TR 8.5 min ((S)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline); 9.8 min (6,7-
dimethoxy-1-methyl-3,4-dihydroisoquinoline); 14.6 min ((R)- 6,7-dimethoxy-1-methyl-
1,2,3,4-tetrahydroisoquinoline; referred to as salsolidine). Yields were calculated using a 
response factor of 1.95, as determined elsewhere.[C8]  
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C.5.4 EVOLUTION OF ENANTIOSELECTIVITY OVER TIME 
 Figure C12- Reaction set up for the time-point assay 
SNPs (1 mg) were resuspended in MOPS / formate buffer (50 μl) and Mili-Q water (48 μl) 
in an HPLC vial, equipped with a stirring bar. The reaction was initiated by addition of the 
substrate stock solution (2 μl, 1 M stock solution) and the resulting mixture was shaken for 
0.5 to 96 h at RT (final volume: 100 μl). The reaction was quenched by centrifugation of the 
reaction mixture. The supernatant was collected and the nanoparticle pellet was washed with 
MQ water (3 x). The joined water phases were basified by addition of NaOH solution (50 
µl, 20 % stock solution), extracted with DCM (2 x 0.5 ml), dried over Na2SO4 and analyzed 
by the means of normal phase HPLC. 
Table C3: Salsolidine precursor reduction using [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav SNPs 
entry Reaction time (h)a ee (%)b,c Conv. (%)c TON 
1 0,5 87 1.2 91 
2 1 86 4.6 357 
3 3 87 6.1 477 
4 5 86 9.8 764 
5 24 84 22.2 1723 
6 48 83 30.7 2384 
7 72 81 34.3 2662 
8 96 78 41.5 3222 
[a]Reactions performed in a reaction buffer using 1 mg of SNPs in 100 µl reaction mixture with 20 
mM substrate concentration, [b] Enantiomeric excess and conversion was determined by HPLC 
analysis.[c] Positive ee values correspond to (R)-2a; negative ee values correspond to (S)-2a. 
C.5.5 NAD+ REDUCTION MEASUREMENTS 
SNPs (1 mg) or free enzymes were resuspended in MES buffer (120 μl, 10 mM, pH 6.2). 
The solution was mixed with the activity assay buffer (1 : 1 ratio, total V : 245 μl) and NAD+ 
(5 μl, 10 mM) was added. The reaction medium was then incubated at 30 °C and shaken 
(1200 rpm). After the desired reaction time, the suspension was centrifuged (16'100 g, 1 min) 
and  the supernatant (200 μl) was collected for UV-Vis analysis (λ= 340 nm). The NADH 
quantification was calculated using ε = 6220 M-1cm-1. 
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Table C4 NADH regeneration catalyzed by protected [Cp*Ir(biot-p-L)Cl]ꞏSav@prot-SNP or [Cp*Ir(biot-p-L)Cl]ꞏSav as purified proteins. 
 
 NADH Concentration (uM) TON 
 nanoparticles free enzymes nanoparticles free enzymes 
t 
(h) 
Cp*Ir(biot-p-
L)Cl]ꞏS112A@
prot-SNP 
Cp*Ir(biot-p-
L)Cl]ꞏS112K@
prot-SNP 
Cp*Ir(biot-p-
L)Cl]ꞏS112A-
K121A@prot-
SNP 
Cp*Ir(biot-
p-
L)Cl]ꞏS112A 
Cp*Ir(
biot-p-
L)Cl]ꞏ
S112K 
Cp*Ir(bio
t-p-
L)Cl]ꞏS11
2A-K121A 
Cp*Ir(biot-p-
L)Cl]ꞏS112A
@prot-SNP 
Cp*Ir(biot-p-
L)Cl]ꞏS112K@
prot-SNP 
Cp*Ir(biot-p-
L)Cl]ꞏS112A-
K121A@prot-
SNP 
Cp*Ir(biot-
p-
L)Cl]ꞏS112A 
Cp*Ir(biot
-p-
L)Cl]ꞏS112
K 
Cp*Ir(biot
-p-
L)Cl]ꞏS112
A-K121A 
0 0 0 0 0 0 0 0 0 0 0 0 0 
0.1 9.3 9.3 12.7 3.6 2.8 4.1 714 1557 1687 278 459 544 
0.2 14.8 9.0 13.1 4.6 5.1 10.7 1137 1498 1749 354 856 1430 
0.3 15.3 12.8 17.3 5.3 6.7 11.6 1176 2127 2306 410 1120 1551 
0.5 15.3 14.7 22.5 8.6 7.8 16.3 1177 2448 2994 659 1301 2170 
0.8 16.0 16.1 25.4 13.9 12.4 22.7 1235 2681 3392 1068 2067 3025 
1 16.8 17.8 26.4 16.7 15.9 29.7 1292 2971 3520 1288 2644 3961 
2 18.6 18.5 32.4 29.0 29.1 48.7 1431 3076 4322 2231 4853 6489 
3 37.4 27.8 36.5 38.4 39.0 65.0 2878 4628 4867 2951 6495 8662 
4 38.9 28.1 39.1 48.4 44.9 76.9 2993 4683 5218 3723 7488 10247 
5 45.4 29.3 42.8 59.8 52.2 84.4 3495 4882 5707 4601 8707 11252 
6 49.9 35.8 49.3 68.1 58.2 91.2 3836 5965 6569 5235 9697 12162 
7 59.0 40.6 65.0 74.4 61.1 96.9 4539 6764 8672 5725 10184 12915 
8 68.0 47.2 65.5 88.2 70.0 99.3 5232 7874 8734 6783 11671 13236 
9 77.0 50.2 74.3 93.4 70.6 106.0 5926 8361 9908 7182 11764 14129 
10 83.5 55.3 79.3 100.8 73.8 106.7 6426 9221 10576 7752 12294 14233 
11 92.0 57.7 92.3 103.4 74.6 109.0 7080 9619 12309 7958 12427 14528 
12 127.6 112.5 115.3 114.2 76.2 112.2 9818 18750 15374 8787 12695 14956 
24 128.8 119.2 127.3 122.1 101.1 115.7 9910 19860 16975 9390 16845 15431 
36 134.8 123.3 135.1 130.3 105.7 118.0 10367 20554 18016 10023 17623 15739 
48 137.6 146.2 138.8 131.0 106.1 120.8 10583 24366 18508 10073 17682 16109 
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 Figure C13- NADH regeneration catalyzed by a) protected [Cp*Ir(biot-p-L)Cl]ꞏSav@prot-SNP and 
b) [Cp*Ir(biot-p-L)Cl]ꞏSav as purified proteins over time as determined by absorption at λ= 340 nm. 
Mutant S112A is shown as full circles, S112K as empty squares and S112A-K121A as triangles. 
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APPENDIX D 
Supporting information for Dalton Trans., 2018, 47, 10837-10841. 
D.1. General information 
All commercially available chemicals were purchased from commercial suppliers (Acros 
Organics, Alfa Aesar, AnaSpec, AppliChem, Fluka, Merck, NEB, Sigma-Aldrich) and used 
without purification. Solvents for HPLC measurements were purchased from Baker and 
Biosolve. Horse spleen apoferritin (HsAf) was purchased from Sigma Aldrich and subjected 
to gel filtration prior to use.  
Size exclusion chromatography was performed on an Äktaprime Plus chromatography 
system, using a HiLoad 16/60 Superex 200 pg column from GE Healthcare. 
Dynamic light scattering (DLS) was performed using a Malvern Instruments Zetasizer Nano 
ZS Dynamic Light Scattering Instrument. 
Mili-Q water (resistivity ≥ 18 MΩ cm-1) was produced with a Millipore Synergy purification 
system. Streptavidin (Sav) mutants were produced, purified and characterized as previously 
described. [D1]  
Analyses of the catalytic runs were performed on an Agilent 1100 normal phase HPLC with 
an analytical Chiralpack IC column (250 ꞏ 4.6 mm, 5 μm). ICP-MS analysis was performed 
on a 7500cx ICP-MS system (Agilent, Basel, Switzerland). 191Ir was used for quantification, 
193Ir for verification of the results. 
D.2 STOCK SOLUTIONS AND BUFFERS 
MOPS/formate buffer: 3-(N-morpholino)propanesulfonic acid and sodium formate were 
dissolved in Milli-Q water to a concentration of 6M (formate) and 1.2 M (MOPS). The pH 
was adjusted to 8 by addition of NaOH. 
Tris-HCl buffer: Tris base and NaCl were dissolved in Milli-Q water to a concentration of 
50 mM (Tris) and 100 mM (NaCl). The pH of the solution was adjusted to 8 by the addition 
of 37% HCl. 
Catalyst 3 stock solution: [Cp*Ir(biot-p-L)Cl)] was dissolved in DMF to a final 
concentration of 500 mM. For a detailed synthesis procedure, see reference. [D2] 
Substrate stock solutions:  
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 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 1a was dissolved in Mili-Q water 
(2 ml) to a final concentration of 1 M. 
 1-phenyl-3,4-dihydroisoquinoline 1c (synthesis procedure see reference [3]) was 
dissolved in degassed DMSO (2 ml) to a final concentration of 400 mM. 
D.3 SAV PREINCUBATION AND LYOPHILISATION 
In a typical experiment, purified Sav mutant (25 mg , approx. 3,8 x 10-7 mol) was dissolved 
in Milli-Q water. The average number of free binding sites per purified Sav tetramer was 
determined with a biotin-4-fluorescein assay, as described elsewhere [4]. The corresponding 
amount of [Cp*Ir(biot-p-L)Cl] ligand stock solution was added to produce protein with 
binding sites half filled with the iridium cofactor (ratio of Ir : free binding sites 1 : 2). 
Samples were incubated (37 °C, 2 h), frozen (-80°C) and lyophilised to dryness. 
D.4 APOFERRITIN ENCAPSULATION 
The apoferritin sample purified my gel filtration was subjected to the re-assembly process. 
The protein solution was diluted to a concentration of 30 mg / ml and the pH of the solution 
was decreased below 2 using 37% HCl. The resulting solution was incubated for 20 minutes 
at 600 rpm at RT followed by the addition of a lyophilized ATHase. The pH of the resulting 
solution was increased to 8 using 10 M NaOH solution. After incubation for 2 hours at RT, 
iminobiotin-sepharose beads were added and the solution was incubated for further 1h at 
rapid shaking (800 rpm). After binding the non-encapsulated Sav to beads, the solution was 
centrifuged (5300 g, 15 min), the supernatant was filtered and subjected to another 2 rounds 
of immobilization. The resulting cargo-containing ferritin samples were further purified by 
size-exclusion chromatography. 
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D.5 SIZE-EXCLUSION CHROMATOGRAPHY 
In order to confirm the guest loading, Sav S112A-K121A was incubated with biotin-4-
fluorescein and encapsulated in HsAf. The purified samples were subjected to SEC 
monitored at λ=280 and 495 nm (Figure D1). 
 Figure D1. Size exclusion chromatogram of B4FꞏS112A-K121A Sav@ferritin in  50 mM Tris-HCl, 
100 mM NaCl, pH8. Column: HiLoad 16/60 Superdex 200 pg. 
 
ATHases bearing mutations S112A, S112K and S112A-K121A were encapsulated and 
purified following the same procedure. The fractions corresponding to the ferritin signal 
(elution volume around 60 mL, Figure D2) were pooled, concentrated using a Amicon Ultra 
-15 centrifugal filter unit with a 30 kDa cut-off (Merck Millipore) and stored at 4°C prior to 
analysis by ICP-MS and catalysis. 
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 Figure D2. Size exclusion chromatogram of [CP*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav@ferritin in  
50 mM Tris-HCl, 100 mM NaCl, pH8. Column: HiLoad 16/60 Superdex 200 pg. 
D.6 DYNAMIC LIGHT SCATTERING MEASUREMENTS (DLS) 
Dynamic light scattering (DLS) measurements of the combined fractions containing the 
assembled ferritin were performed on a Malvern Instruments Zetasizer Nano ZS Dynamic 
Light Scattering Instrument. Sample measurements were performed with purified ferritin 
samples at an approx. concentration of 0.1 mg/ml in 50 mM Tris-HCl, 100 mM NaCl, pH 8 
using a low-volume quartz cuvette. All solutions were filtered through a 0.2 μm filter to 
prevent further aggregation. 
Table D1. Average size of apoferritin and ferritin samples containing ATHase cargo  
entry Sample Diameter PDI 
1 Apoferritin 13.43 0.052 
2 [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A Sav@ferritin 15.71 0.488 
3 [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav@ferritin 17.66 0.658 
4 [Cp*Ir(biot-p-L)Cl]ꞏS112K Sav@ferritin 14.44 0.783 
PDI = polydispersity index 
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D.7 ELECTROPHORESIS 
D.7.1 SDS-PAGE 
 
The pooled samples from SEC purification were concentrated using a Amicon Ultra -15 
centifugal filter unit with a 30 kDa cut-off (Merck Millipore) and the protein concentration 
was determined by Nanodrop2000 (ThermoFisher)  using ε280 nm= 4.8x105 M-1cm-1). The gel 
analysis was performed according to a published procedure [D7] using hand-casted 10% 
acrylamide gels, followed by B4F detection under UV and staining with Coomassie Briliant 
Blue. The stacking layer (6% final acrylamide concentration) was prepared at pH 6.8.  
20 μl of each sample type (diluted so the final amount pf loaded protein would be 2 μg per 
lane) was combined with a 6x loading buffer and either heated to 90°C foe 10 min prior to 
loading or directly loaded. The gel was ran at 200 V until for approx. 1.5 hours. After B4F 
visualization the gels were stained with Coomassie Brilliant blue R-250 dye in MeOH and 
acetic acid, followed by de-staining.[D5]  
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Figure D3. SDS-PAGE gel under UV (B4F visualization) and Vis (coomassie staining). + indicates 
heating during sample preparation, - indicates semi-native conditions (absence of heating) Lane 1: 
ladder; 2: Sav WT (control); 3: apoferritin; 4: reassembled apoferritin; 5: [Cp*Ir(biot-p-
L)Cl]ꞏS112A-K121A Sav@ferritin; 6: [Cp*Ir(biot-p-L)Cl]ꞏS112A Sav@ferritin; 7: [Cp*Ir(biot-p-
L)Cl]ꞏS112K Sav@ferritin 
D.7.2 NATIVE PAGE 
The pooled samples from SEC purification were concentrated using a Amicon Ultra -15 
centifugal filter unit with a 30 kDa cut-off (Merck Millipore) and the protein concentration 
was determined by Nanodrop2000 (ThermoFisher)  using ε280 nm= 4.8x105 M-1cm-1). The gel 
analysis was performed according to a published procedure [D7] using hand-casted 10% 
native acrylamide gels, followed by B4F detection under UV and staining with Coomassie 
Briliant Blue. The stacking layer (6% final acrylamide concentration, no SDS added) was 
prepared at pH 6.8.  
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20 μl of each sample type (diluted so the final amount pf loaded protein would be 2 μg per 
lane) was combined with a 6x loading buffer (without DTT or mercaptoethanol) and directly 
loaded. The gel was ran at 200 V until for approx. 1.5 hours. After B4F visualization, the 
gels were stained with Coomassie Brilliant Blue R-250 dye in MeOH and acetic acid, 
followed by de-staining.  
 Figure D4. Native-PAGE gel under Vis (Coomassie staining) and UV (B4F visualization). Lane 1: 
ladder; 2: apoferritin sample; 3: Sav S112A-K121A; 4: [Cp*Ir(biot-p-L)Cl]ꞏS112A-K121A 
Sav@ferritin; 5: apoferritin + Sav S112A-K121A.  
D.8 ICP-MS DETERMINATION OF THE TOTAL IR CONTENT 
Fractions from SEC containing the ferritin species were combined and the sample (10 µl) 
was incubated with concentrated HNO3 solution (65 %, semiconductor grade, Sigma 
Aldrich) at 95°C for 30 min. The resulting samples were diluted to end concentration of 3 % 
HNO3 using Milli-Q water. Analysis was performed on a 7500cx ICP-MS system (Agilent, 
Basel, Switzerland) using standard operational settings as described elsewhere[D6]. 
Quantification was perfomed via multi-element standards (Sigma-Aldrich) in matrix-
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matched calibration solutions containing the same amount of HNO3 as the samples. Rh was 
used as internal standard to account for residual matrix effects. The octopole was pressurized 
(4.5 mL ꞏ min−1 helium) to remove polyatomic interferences. 
D.9 CATALYSIS 
 
Scheme D1. Catalysis set up 
In a typical catalysis procedure, the cofactor, an ATHase or ATHase@ferritin solution (45 
µl) were dissolved in MOPS / formate buffer (50 μl, 1.2 M MOPS, 6 M sodium formate, pH 
8) in a HPLC vial. The reaction was initiated by addition of a substrate stock solution (5 μl, 
end concentration 20 mM). The vials were sealed and the reaction mixtures were shaken at 
600 rpm in a Thermoshaker at 37°C (final volume 100 μl). 
Each reaction mixture was diluted with Milli-Q water (400 μl) and basified using NaOH 
solution (20 %, 50 μl). The resulting mixture was extracted with dichloromethane (2 x, 1 
ml), the combined organic fractions were collected in a PP tube containing anhydrous 
sodium sulfate, and centrifuged (18800 x g, 5 min). The supernatant was analyzed by HPLC. 
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D.10 HPLC MEASUREMENTS 
Catalysis results for substrate 1a were analyzed using a Chiralpak IC column (5 μm, 4.6 mm 
ꞏ 25 mm) and dichloromethane containing diethylamine (0.06 %) and  isopropanol (0.5 %) 
as an eluent (1 ml / min flow; λ=280 nm, 25 °C).  
TR 8.5 min ((S)- 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline), 9.8 min (6,7-
dimethoxy-1-methyl-3,4-dihydroisoquinoline), 14.6 min ((R)- 6,7-dimethoxy-1-methyl-
1,2,3,4-tetrahydroisoquinoline). Yields were calculated using a response factor of 1.95, as 
determined elsewhere.[D8] 
Screening with substrate 1c was analyzed using a Chiralpak IC column (5 μm, 4.6 mm ꞏ 25 
mm) and hexane containing diethylamine (0.06 %) and isopropanol (3 %) as an eluent (1 ml 
/ min flow; λ=265 nm, 25 °C). TR 7.6 min ((S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline, 10.5 
min ((R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline), and 16 min (1-phenyl-3,4-
dihydroisoquinoline). Yields were calculated using a response factor of 13.613 as determined 
elsewhere.[D9] 
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